Molecular Studies on the Interaction of Leptin With Its Receptor by Mistrik, Pavel
M olecular stu d ies on th e  in teraction  o f  
lep tin  w ith  its receptor
A dissertation submitted to the University of Glasgow for the degree of Doctor of
Philosophy
Pavel Mistrik





INFORMATION TO ALL USERS 
The quality of this rep roduc t ion  is d e p e n d e n t  u p o n  the quality of the copy  subm itted .
In the unlikely e v e n t  that the a u th o r  did not send a c o m p le te  m anuscrip t 
and there are missing p a g e s ,  these will be n o te d .  Also, if m ateria l had to be rem o v e d ,
a n o te  will in d ica te  the de le tion .
uest
ProQ uest 13818945
Published by ProQuest LLC(2018). C opyright of the Dissertation is held by the Author.
All rights reserved.
This work is p ro tec ted  a g a in s t  unau tho rized  copying under Title 17, United States C o d e
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 4 8 1 0 6 -  1346
GLASGOW ,
Un iv e r s i  t y  I
l2.iU-G>n
Preface
The research reported within this thesis is my own work, except where other­




Leptin is a hormonal protein involved in energy homeostasis, acting to inhibit 
food intake, stim ulate energy expenditure and influence insulin secretion, lipo- 
lysis and sugar transport. Its action is m ediated by a specific receptor whose 
activation is highly controversial. As a member of the cytokine receptor super­
family, it has been predicted to be activated by ligand-induced dimerization. 
However, recent evidence has suggested that this receptor exists as a dimer in 
both ligand-free and ligand-bound states.
The aim of this project was to determine the kinetics and stoichiometry 
of leptin receptor interaction with its ligand, using a variety of biophysical 
techniques, namely BiaCore and microcalorimetry. To achieve this, it was 
necessary to express the leptin receptor. Because the receptor cDNA was 
not available at the start of this project, the initial goal was to obtain the 
cDNA encoding the extracellular domain of the receptor by RT-PCR. The 
open reading frame consisting of 839 a.a. encoded by 2517 nucleotides was 
generated by several molecular approaches, as the mRNA is a rare species.
To generate large amounts of the receptor required for microcalorimetry, 
Baculovirus expression system for the leptin receptor production was devel­
oped. At the same tim e BiaCore analysis of the interaction was performed 
since it requires small amounts of protein, and commercially available protein 
could be used.
BiaCore was used to measure the thermodynamics of the interaction. Hu­
man or mouse receptor chimeras comprising two receptor extracellular domains 
fused to the Fc region of IgGi were captured on to the sensor via Protein G. 
The kinetics and stoichiometry of interactions with human, mouse or ra t lep­
tin were measured. This data dem onstrated a high affinity interaction. The 
K jj was 0.2 ±  0.1 nM, with ka =  (1.9 ±  0.4) xlO 6 M- 1s- 1  and k^ =  (4.6 ±
0.9) xlO - 4  s- 1  for human leptin with its cognate receptor. The observed stoi­
chiometry was 1 :1 . Little difference was observed for different species of leptin. 
Thus, leptin forms a very stable 1:1 complex with its receptor. This obser­
vation indicates tha t the leptin receptor oligomerization state is not altered 
during its interaction with a ligand. This contradicts the common paradigm  
of cytokine receptor activation.
A truncated version of the leptin molecule with deleted glutam ine at posi­
tion 28 was also expressed in E. coli. Its affinity for human and mouse leptin 
receptor chimeras was analysed by BiaCore, which revealed a 10-fold decrease 
in affinity, indicating a possible involvement of Q28 in binding.
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In trod u ction
1.1 L eptin  and slim ness
Leptin is derived from the Greek word lepton which means thin. The choice of 
name indicates why this protein a ttracted  such a high level of attention in 1994 
when it was isolated [1], Obesity is a severe problem in developed societies 
where heart disease, hypertension and diabetes are the most common causes 
of death. In some countries, this problem has attained alarming proportions. 
In the USA, 30% of the inhabitants are obese, with the highest occurrence 
among black American women, of whom 50 % have a body mass index (BMI, 
weight kg/height m 2) exceeding 30 (a criteria for obesity) [2 ]. Such a large 
group represents a very attractive market for the pharm aceutical industry in 
the search for suitable molecular candidates for treatm ent of obesity.
The existence of a molecule such as leptin tha t controls feeding behaviour 
was forecast in 1953, when the lipostasis theory was formulated [3]. According 
to this theory, body weight is controlled by a peripheral signal produced in 
proportion to the amount of adipose tissue in the body. This signal molecule 
informs the brain about energy stored in adipose tissue. High levels lead to 
a suppression of appetite. This phenomenon forms a basis for intervention in 
the treatm ent of obesity. An appropriate drug could decrease brain demands 
for energy stored in the body and thereby suppress appetite.
The lipostasis theory as a concept is difficult to resist. The only problem 
was th a t no molecule had been identified. Thus, in 1994 the isolation of a new 
protein, leptin, generated great enthusiasm; in particular as it was reported to 
be expressed exclusively in adipose tissue and to interact with brain centres 
involved in the control of feeding behaviour [1].
Since 1994, leptin has a ttracted  a large number of investigators who have
1
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Figure 1 .1 : Sequence alignment of human, mouse and rat leptin (ob) proteins.
explored its many features. Human, mouse and rat leptin have been charac­
terised, and the protein from these three species is highly conserved in primary 
sequence (Fig. 1 .1 ). This concentrated effort has resulted in a very rapid ac­
cumulation of a huge body of knowledge. However, many parts of it are still 
very controversial.
1.2 Leptin - the cytokine
The interest in leptin has been fuelled from the beginning by the fact that it 
met the two conditions required by the lipostasis theory. Leptin was thought 
to be expressed in the adipose tissue in proportion to the am ount of tissue [4, 5] 
and to activate the feeding control centres in the brain [6 ]. However, it has 
been shown more recently tha t leptin is expressed not only in the adipose 
tissue but also in the stomach [7] and placenta [8 ]. This suggests th a t the 
physiological role of leptin is not fully described in terms of a negative feedback 
for control of body weight and body composition. It rather indicates that 
leptin is involved in a much more complex network of interactions, including 
genetic, environmental, behavioural and social factors.
This suspicion has been further confirmed by solving the crystal structure 
of a leptin homologue, leptin-ElOO [10], which represents wild-type human 
leptin with a single amino-acicl substitution of Glu for Trp at position 100 to 
enhance crystalli sation.
The leptin-ElOO crystal structure (Fig. 1.2) consists of four antiparallel 
o-helices (A, B, C and D), connected by two long crossover links (AB and 
CD ) and one short loop (BC), arranged in a left-hand twisted helical bundle 
(Fig. 1.2). The CD loop contains a short distorted helical segment E, which is 
packed almost perpendicularly (87°) against the four helical bundle. The first 
part of the AB loop, residues Thr27 to Gly38, is not visible in the structure
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Figure 1.2: The crystal structure of leptin-ElOO. Leptin-ElOO consists of four 
antiparallel a-helices (A, B, C and D), connected by two long crossover links 
(AB and CD) and one short loop (BC), arranged in a left-hand twisted helical 
bundle. The CD loop contains a. short distorted helical segment E, which is 
packed almost perpendicularly against the four helical bundle (87°). The first 
part of the AB loop, residues Thr27 to Gly38, is not visible in the structure 
because of high flexibility in this region.Derived from PDB file using Swiss- 
PdbViewer [9] and Pov-Ray software.
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Figure 1.3: A hydrophobic cylindrical core of leptin-100. It is formed by the 
most conserved residues of the four a  helices tha t face each other (in black). 
They are residues Val 60 and He 64 in the BD bundle, Met 63 in the C- 
term inal end of helix B and Val 124 and Ala 125 in the N terminus of helix D. 
This lipophilic surface is buried by Leu 104, Leu 107, Leu 110, Leu 114 and 
Val 113 of helix E in the CD loop, which serves as a hydrophobic cap. The 
hydrophobic core is parallel to the helical bundle axis. Derived from PDB file 
using Swiss-PdbViewer [9] and Pov-Ray software.
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because of high flexibility in this region. The hGH and hG H /hG H R complex 
structures show extensive conformational changes upon receptor binding in 
this region: from a coil in the free-ligand structure to a helix in the receptor 
complex. It is possible th a t leptin, in the receptor-bound form, may also 
assume an ordered conformation in this region.
A significant feature of the structure is a large hydrophobic cylindrical 
core parallel to the helical bundle axis (Fig 1.3). This is formed by the most 
conserved residues of the four a  helices tha t face each other comprising residues 
Val 60, lie 64 in the BD bundle, Met 63 in the C-terminal end of helix B and 
Val 124 and Ala 125 in the N terminus of helix D. This lipophilic surface is 
buried by Leu 104, Leu 107, Leu 110, Leu 114 and Val 113 of helix E in the 
CD loop. The E helix serves as a hydrophobic cap.
The intrahelical angles and features of the long crossover loops in the leptin- 
E100 structure are similar to those found in the crystal structures of the long- 
chain helical cytokines , which include Granulocyte Colony-Stimulating Fac­
tor (G-CSF) [11], Leukemia Inhibitory factor (LIF) [12], Ciliary Neurotropic 
Factor (CNTF) [13] and human Growth hormone (hGH) [14]. Despite the ab­
sence of any sequence similarity between leptin-ElOO and these molecules, the 
solved structures have striking structural similarities. The four-helical bundle 
of leptin-ElOO superimposes on LIF (85 Ca  atoms) with an r.m.s. deviation 
of 2.50 A, on G-CSF ( 1 0 1  C a  atoms) (2.37 A), and on hGH (85 C a  atoms) 
(1.95 A).
The fact th a t leptin-ElOO protein bears structural similarity to the long- 
chain helical cytokine family is very surprising. Cytokines are a group of 
soluble secreted factors which are involved in communication between cells of 
the immune system. In particular, they control haematopoiesis, the process 
of blood-cell production. Haematopoiesis comprises a complex sequence of 
events including blood-cell proliferation, differentiation and m aturation. Func­
tions of molecules structurally most closely related to leptin are summarised 
in Table 1.1. They have nothing in common with the control of appetite.
The characterisation of leptin as a cytokine has been strengthened by 
the finding tha t leptin activates the JAK-STAT signalling pathway, which is 
viewed as an integral and widespread mediator of cytokine signal transduction 
within the immune system [15].
The cytokine-related structure of leptin raised the possibility of a cytokine 
role for this molecule. There is some evidence to support this. It has been 
shown in mice tha t leptin possesses an endogenous protective activity against
C H A PT ER 1. IN TR O DU C TIO N  6
Table 1.1: Molecules structurally related to leptin and their function
G -C S F  released from activated monocytes, macrophages, and neutrophils 
as well as from stromal cells, fibroblast and endothelial cells; 
primarily involved in the proliferation and differentiation of 
haematopoietic progenitor cells of the neutrophil/granulocyte linage
inhibits many myeloid leukaemia cells, inhibits migration of PMN 
leucocytes, regulates early haematopoietic cells, activates acute phase 
protein synthesis, inhibits proliferation and adipogenesis of 
endothelial cells
a neurotrophin located predominantly in peripheral nerve tissue; it 
might be involved in the maintenance and regulation of neurons
synthesised in the pituitary gland; it acts upon every 
tissue of the body, exerting powerful effects on growth 
and metabolism
the toxicity of Tumour Necrosis Factor (TNF) [16]. TNF is a cytokine with 
potent antitum our activity. Its effects are largely mediated by a complex 
network of cytokines, hormones, and low-molecular weight mediators induced 
by TNF. The finding that leptin, which is also induced by TN F [17, 18], 
possesses endogenous protective activity against TN F may mean th a t leptin 
has immunomodulatory and anti-inflammatory effects.
It has also been dem onstrated tha t leptin has a stim ulatory effect on the 
proliferation of cells of tracheal (lung) epithelial tissue [19]. This raises the pos­
sibility tha t leptin may be involved in the peripheral regulation of respiratory 
functions in humans.
These structural and functional observations together create a picture of 
leptin acting as a cytokine. However, the precise details are unclear. It is 
therefore surprising tha t leptin was originally isolated as a molecule acting 
inside the brain. Leptin must cross the blood-brain barrier to access the central 
nervous system. A receptor for leptin was identified from the choroid plexus 
and it is thought tha t this receptor may play a role in transporting leptin into 












Table 1.2: Behaviour factors regulating the concentration of circulating leptin 
in humans and animals.
1.3 R egu lation  o f circulating lep tin
Leptin was originally cloned as a molecule whose plasma level in circulation 
is proportional to the amount of adipose tissue [1]. However, there are sev­
eral other factors tha t regulate leptin levels in plasma. First of all is gender. 
Second, and jinore interesting one, is caloric intake (references in [20]). It was 
observed tha 'f both caloric restriction and excess caloric intake affect the level 
of circulating leptin. Thus, leptin is controlled by both adipose tissue mass 
and caloric intake.
An im portant aspect of this regulation is a fundamental difference between 
humans and rodents. The increase in leptin observed in humans occurs only 
after chronic increase in caloric intake (references in [20]). In humans, unlike 
rodents, leptin levels do not change acutely following normal meal consump­
tion. This may indicate tha t leptin does not act as a satiety signal in humansf[[) 
its proposed role in rodents.
An additional factor which alters the circulating level of leptin is energy 
expenditure. Here again significant differences between humans and rodents 
were observed (references in [20]). In rats, a significant reduction in leptin 
mRNA levels was observed immediately after acute exercise. In contrast, there 
was no effect on leptin levels immediately following exercise in m an,(^able 1 .2 . ^
As discussed above, serum leptin concentrations can change with alter­
ations in the amount of adipose tissue, caloric intake and energy expenditure. 
Changes in serum leptin concentration can result from alteration in produc­
tion, hormone clearance or both. Leptin has been shown to have a half life of 
approximately 1 .6  h in the circulation of both normal lean and obese humans 
and lean rats and is prim arily removed by the kidney [20]. Nothing is known 
about clearance in dynamic states such as fasting.
Circulating leptin concentrations appear to be directly proportional to the 
amount of leptin mRNA in the adipose tissue. The amount of leptin mRNA in 
adipocytes from obese individuals is greater than th a t in adipocytes from lean 
subjects (references in [20]). The size of the adipocyte appears to be a m ajor
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determ inant of leptin mRNA expression, liable 1.3.) However, it is not known 
whether it is stretching of the cell wall, the increase in stored triglyceride or the 
presence of a particular intracellular m etabolite tha t determines the amounts 
of leptin mRNA.
Several hormones tha t interfere with leptin action have been identified. The 
most extensively studied is insulin. In humans, a significant correlation be­
tween fasting insulin, leptin and leptin mRNA is observed, (Table 1.4j However, 
the leptin response to insulin is much slower than tha t observed in rodents. In 
humans, insulin does not have an acute effect but a chronic effect exists.
Thiazolidinediones are a new class of anti-diabetic drugs tha t improve in­
sulin sensitivity in both humans and animals. Treatm ent of rodents with 
thiazolidinediones results in significant reduction in leptin mRNA and circu­
lating leptin which is associated with weight gain [20]. In humans, treatm ent 
with these compounds did not have any measurable effect,(Table 1.5  ^ Thia­
zolidinediones seem to mediate their effect on leptin mRNA via the adipose 
tissue-specific transcription factor Pj/f5AR7  (peroxisome proliferator-activated 
receptor), although the specific consensus sequence for PIPARq has not yet 
been identified on the leptin gene promoter.
Glucocorticoids have the opposite effect, (Table 1.67 Their adm inistration 
results in a significant increase in leptin mRNA in rodents [20].
Various other factors have been tested for effects on leptin mRNA in iso­
lated rodent adipocytes, (Table 1.77 17/5-estradiol stim ulated leptin mRNA, 
but testosterone was without effect (references in [20]). In vivo adm inistration 
of endotoxin (LPS), tum or necrosis factor, or interleukin -1  resulted in an in­
crease in epididymal fat leptin mRNA in hamsters (references in [20]). Both 
leptin mRNA and leptin were reduced by exposure to cold, an effect believed 
to be m ediated by the sym pathetic system (references in [2 0 ]).
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Factor Species
adipocytes size 4Vt JIM both
weight loss/gain m b o th /r
fasting ji both
refeeding fj both
overfeeding (no weight gain) t rats
Table 1.3: The size of the adipocyte is a m ajor determ inant of leptin mRNA 
expression. Leptin mRNA decreases with weight loss in both humans and 
rodents and increases with weight gain in rodents. In humans and animals 
fasting results in a substantial fall in leptin mRNA th a t can be reversed upon 
refeeding. Overfeeding has been dem onstrated to increase leptin mRNA in the 




2 -day infusion t
hyperinsulinemia t
H um ans
5-hr hyperinsul. euglycemia -




human adipocytes j' after 48-72 hr
Table 1.4: Regulatory effects of insulin on leptin mRNA expression.
Thiazolidinediones
R o d en ts
AD-5075 67% 4- (weight gain) Zucker fatty  rats
I  (weight gain) dbj db mice
H um ans
troglitazone no effect ( 40-50% J, insulin, no weight gain)
In V itro
troglitazone 40% I  (no weight gain, insulin effect blocked) hum an adipocytes
BRL49653 (weight gain) rat adipocytes
Table 1.5: Regulatory effects of thiazolidinediones on leptin mRNA expression.
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Glucocorticoids
R ats
hydrocortisone 1 - 1 0 0  {xg/g  body wt ft (no weight gain)
dexamethasone 3.7 n g/g  body wt 2.2-fold f  after 24 hr
Iso la ted  a d ip ocy tes
dexamethasone (1 0 - 7 M ) 4~8-fold f  after 10 hr
hydrocortisone 350% f  after 24 hr
dexamethasone 350% t  after 24 hr
Table 1.6: Regulatory effects of glucocorticoids on leptin mRNA expression.
O ther factors
R oden t ad ip ocytes
17/3-estradiol t
testosteron -
h(m ) leptin (1 0 0 /ug/ml) -  after 24 hr
H am sters
endotoxin (LPS; 1-100 fxg/g body wt) t
TN F (17 /xg/g body wt) t
IL-1  (1  fxg/g body wt) t
E xposure to  cold 4
Table 1.7: Several other factors were found to m odulate leptin mRNA expres­
sion.
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1.4 L eptin  and energy balance
The ability of organisms to m aintain the stability of their internal environment 
is a challenging area for understanding. An interesting aspect of homeostasis 
is the subconscious nature of the regulation of these processes.
1.4 .1  A d a p tiv e  th erm ogen esis
In this approach, internalised energy (food) is either stored or consumed in 
physical activity or transformed to heat. This applied version of the first law of 
therm odynam ic provides a useful clue for our examination of energy balance. 
A component of this balance is heat production, also referred to as adaptive 
thermogenesis, and represents heat produced in response to environmental 
tem perature or diet. It serves the purpose of protecting us from cold exposure 
or regulating energy balance after changes in diet. The other two components, 
food intake and amount of physical activity, can be regulated by conscious 
processes.
Factor in fluencing adaptive th erm ogen esis
Adaptive thermogenesis can be induced in two ways. These are either cold 
or diet. Cold-induced adaptive thermogenesis protects us from stress follow­
ing exposure to environmental tem peratures tha t differ substantially from the 
physiological tem perature. Humans, as opposed to rodents, have a broad 
therm o-neutral zone with relatively small changes in metabolic rate occurring 
over relatively wide tem perature changes. This should raise concerns over 
the use of rodents as models for obesity because it suggests th a t we react to 
tem perature challenge in differently from rodents.
Diet is also a potent regulator of adaptive thermogenesis. Starvation can 
decrease the resting metabolic rate by as much as 40 % (references at [21]). 
Similarly, food restriction sufficient to m aintain a 10 % reduction in body 
weight is associated with decreased energy expenditure. The adaptive value 
of decreasing energy expenditure when food intake is lim ited is obvious. How­
ever, this response is counter-productive for weight control by dieting and 
contributes to the poor long-term efficacy of this treatm ent for obesity. Feed­
ing, on the other hand, increases energy expenditure, having both acute and 
chronic effects on metabolic rate. Feeding acutely increases metabolic rate 
by 25 - 40 % in humans and rodents; a phenomenon referred to as the ther­
mic effect of food. Long-term overfeeding also increases energy expenditure.
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The consequence of increased energy expenditure with overfeeding is relative 
protection against the development of obesity. Of interest, this protective 
adaptation is influenced by genetic background, and abnormal responses could 
contribute to the development of obesity.
Diet-induced thermogenesis is particularly apparent during ingestion of 
diets tha t are low in protein. Food serves two im portant functions: provision 
of calories to meet energy demands and provision of amino acids to m aintain 
protein synthesis. If the diet is low in protein, then the food intake must 
be increased to sustain protein biosynthesis. This would lead to obesity if 
the organism lacked the capacity to waste excess calories. Indeed, metabolic 
efficiency, or the ability to store ingested calories, is decreased by as much as 
40 % when rodents are fed low-protein diets.
R ole o f m itoch on dria
A m ajor site of adaptive thermogenesis in rodents is brown adipose tissue. The 
role of brown adipose tissue in man is controversial. Humans may represent 
an exception as we do not have large, distinct depots of brown adipose tissue. 
Thus, results obtained from mouse or rat experiments may not be tha t relevant 
to humans. The tissue responsible for adaptive thermogenesis may not be clear 
in man, but the cellular com partm ent has been defined as mitochondria. In 
mitochondria, metabolism is part of a complex reaction chain, jFig. 1.4.
i r
M etabolism leads to the production of NADH and FADH2, which in tu rn  
donate electrons to the electron-transport chain. As electrons move down 
through the electron-transport chain, protons are pumped out of the m itochon­
drial inner membrane, thereby creating an electrochemical potential gradient. 
Protons re-enter the mitochondrial m atrix  through Fo/F i — ATP synthase; a 
reaction th a t is linked tightly to the synthesis of ATP from ADP. This syn­
thesised ATP is the intracellular energy source.
The pathway is normally tightly coupled. The only way to generate more 
heat is through the conversion of energy normally used in cellular work. This 
can be achieved by uncoupling the reaction chain. One established site of un­
coupling is the leakage of protons back across the mitochondrial inner mem­
brane; thus, bypassing ATP synthase and converting energy stored within the 
proton motive force directly to heat. M itochondrial proton leaks are a bio­
physical property of proteolipid bilayers juxtaposed between a strong proton 
motive force. They are also catalysed by specific inner-membrane proteins 
such as the uncoupling proteins U CP-1 , UCP - 2  and UCP-3. This is an inter-
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Figure 1.4: Energy production in mitochondria.M etabolism leads to the pro­
duction of NADH and FADH2, which in turn  donate electrons to the electron 
transport chain. As electrons move down through the electron transport chain, 
protons are pumped out of the mitochondrial inner membrane, thereby creat­
ing an electrochemical potential gradient. Protons re-enter the mitochondrial 
m atrix through Fo/Fi — ATP synthase; a reaction th a t is linked tightly to 
the synthesis of ATP from ADP. Synthesised ATP is the intracellular energy 
source.
esting way in which thermogenesis can be adapted to environmental or diet 
demands.
Leptin is involved in the control of energy balance in mammals. Energy 
balance comprises the m aintenance of a constant inner environment (tem pera­
ture), the processing of internalised energy to forms more suitable for storage 
and finally the expenditure of redundant energy, mainly by thermogenesis. En­
ergy balance has this interesting aspect tha t we are conscious of some aspects, 
while unaware of others. The most striking example of a conscious aspect of 
energy balance is appetite. Thermogenesis and fat metabolism, on the other 
hand, are examples of subconscious processes contributing to energy balance.
Energy balance is a complex task which can be described only in terms 
of the whole organism. Therefore, when studying the role of leptin in energy 
balance, one can not focus on leptin action in a single region in our body but 
must consider all organs as a possible target for leptin action.
1.4.2 Leptin  in teractions w ith  C N S
Functional analysis of the brain performed some six decades ago [22] first 
dem onstrated tha t the hypothalamus is the m ajor centre controlling food in­
take and body weight, Fig. 1.5. The ‘satiety1 and ‘hunger’ centres were defined 
in the ventromedial hypothalamic nucleus (VMN) and the lateral hypothala-
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Figure 1.5: Diagrams of rat brain, showing m ajor hypothalamic regions impli­
cated in adiposity signalling and regulation of food intake. The small figure 
at the top is a longitudinal view of a rat brain, with olfactory bulb at the 
anterior end on the left and the caudal hindbrain on the right. Cross-sections 
of the brain at two levels (indicated by vertical lines) are shown at the left and 
right. First-order neurons responding to adiposity signals are located in the 
arcuate  nucleus (ARC) and project anteriorly to the paraventricular nucleus 
(PVN) as well as the perifornicular area (PFA) adjacent to the fornix (FX) and 
the lateral hypothalamic area (LHA). O ther regions implicated in regulating 
food intake include the ventromedial nucleus (VMN) and dorsomedial nucleus 
(DMN). The figure taken from [23].
mic area (LHA), respectively. These areas were identified by experim ents in 
which electrical stimulation of the VMN suppressed food intake and bilateral 
lesions of the VMN induced hyperphagia, and obesity. Conversely, s tim ulation 
or lesioning of the LHA induced the opposite set of responses.
From the physiological perspective, the ‘satiety centre’ monitors the s tatus 
of stored energy. It initiates actions aimed to limit stored energy. It suppresses 
food intake, stimulates heat production (thermogenesis), alters hormone (es­
pecially insulin) secretion and partitions energy stores away from fat. The 
‘hunger centre' evokes a distinct set of adaptive responses, including d im in­
ished reproductive capacity and lower thyroid hormone levels, to conserve 
energy for survival.
An investigation of specific neuronal subpopulations which could be in­
volved in energy homeostasis revealed a more subtle nature  of these hypotha­
lamic ‘centres’. Visualised by immunocytochemical studies and in situ hy­
bridisation, these ‘centres’ were found to form not compact centres bu t ra ther  
discrete neuronal pathways th a t  generate integrated responses.
Leptin seems to interact with both of these centres by acting on specific
CH A P T E R  1. INTR O DU CTIO N 15
molecules resident in the hypothalamus. These leptin molecular targets have 
attracted  great attention in the recent past. As a result, several distinct hy­
pothalam ic pathways were identified as candidate mediators of leptin action 
in the CNS. The molecules can be divided into two groups according to their 
effect on energy intake. Energy intake is promoted by orexigenic molecules 
while anorexigenic ones do the opposite, Table 1.8.
N eu ro p ep tid e  Y
A prominent appetite-stim ulating molecule is Neuropeptide Y (NPY). NPY is 
expressed in the arcuate nucleus of the lateral hypothalamus and is downregu- 
lated by leptin (reviewed in [24]). Furthermore, injection of NPY centrally 
evokes virtually all of the features of leptin deficiency, including hyperphagia, 
decreased thermogenesis by brown adipose tissue (BAT), and hyperinsuline- 
mic insulin resistance. Repetitive injection results in obesity. However, NPY 
knocked out through targeted gene disruption did not alter the satiety effects 
of leptin. Thus, other targets of leptin must exist within the brain.
M elan ocortin s
A ttractive candidates for suppression of food intake are melanocortins (re­
viewed in [23]). Corticotropin-releasing hormone (CRH), a-m elanocyte-stim u­
lating hormone (a-M SH), thyrotropin-releasing hormone (TRH), cocaine- and 
amphetamine-regulated transcript (CART) and interleukin-\(3 are among a 
growing list of peptides tha t promote negative energy balance. Neuronal syn­
thesis of these peptides increases in response to increased adiposity. Among 
these, the melanocortin system stands out as being remarkable both for its 
complexity and its importance to energy homeostasis.
Melanocortins are peptides tha t are cleaved from the pro-opiomelanocortin 
(POMC) precursor molecule. They act by binding to members of a family of 
melanocortin receptors. Of particular importance are the MC3- and MC4- 
receptors which are expressed primarily in the brain. A possible involvement 
of these receptors in the control of energy homeostasis emerged after the discov­
ery tha t a synthetic agonist of these receptors suppresses food intake, whereas 
a synthetic antagonist has the opposite effect. Mice lacking the MC4 recep­
tor (owing to gene targeting) are hyperphagic and very obese indicating tha t 
tonic signalling by MC4 receptors limits food intake and body fat mass. Mice 
heterozygous for the deleted MC4 allele also become obese, although less so 
than homozygous knockouts. Lack of a full complement of central MC4 recep-
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Table 1.8: Neuropeptides implicated in the control of energy homeostasis. An 
asterisk designates documented, coordinated effects on both food intake and 
energy expenditure tha t promote a change in energy stores; arrows designate 
direction of effect exerted by one or both of the adiposity signals, leptin and 
insulin.
C H AP T E R 1. INTRODUCTION 17
tors, therefore, predisposes to hyperphagia and pathological weight gain. This 
finding has since been extended to humans with MC4-receptor m utations.
Another antagonist of MC3 and MC4 receptors is a product of the Agrp 
gene. Agouti Gene Related Peptide (AGRP) is expressed in the hypothalamus. 
Its production, like tha t of NPY and POM C, is localised to the arcuate nucleus, 
and is upregulated by fasting and by leptin deficiency. D ata with AGRP 
indicates tha t antagonism of CNS melanocortin receptors is im portant in body- 
weight regulation. Consistent with its role as an anabolic signalling molecule, 
AGRP causes hyperphagia when administered intracerebroventricularly (i.c.v.) 
or expressed transgenically, and the increase of food intake following a single 
i.c.v. injection of AGRP is sustained for up to a week.
Further evidence for the involvement of the melanocortin receptors in the 
control of energy balance came from studies of Agouti (Ay/a ) mice, an auto­
somal dominant model of genetic obesity characterised by a yellow coat colour 
and an obese phenotype. Cloning of the Agouti gene identified the Agouti 
function as an antagonist of cutaneous M CI receptors tha t are normally ex­
pressed by hair follicles. Increased cutaneous agouti protein reduces MCI 
signalling and thereby lightens the coat colour. Agouti mice, however, express 
agouti in tissues throughout the body and consequently develop both a yellow 
coat colour and obesity. Therefore, Agouti mice obesity is a result of ectopic 
agouti production in the brain, which blocks the MC4 receptors.
Although NPY is described as the most potent orexigenic molecule (tha t is, 
a molecule tha t stimulates increased energy intake) when the feeding response 
is measured over a few hours, its effects are short-lived in comparison to those 
of AGRP. AGRP must therefore be considered as the most robust orexigenic 
molecule if potency is measured as the cumulative increment of energy intake 
after a single i.c.v. injection. The mechanism underlying the extraordinary 
duration of action of AGRP remains a fascinating area for further investigation.
T ransduction o f ad ip osity  signals in to  a neuronal response
The prim ary site of action of leptin in th e  hypothalamus is the arcuate nucleus 
(reviewed in [23]). The arcuate nucleus is an elongate (‘arc-like’) collection of 
neuronal cell bodies occupying approximately one half of the length of the 
hypothalamus. It is situated adjacent to  the floor of the th ird ventricle. NPY 
and AGRP are co-localised in arcuate nucleus neurons while POMC and CART
are co-localised in a distinct, but adjacent, subset of arcuate nucleus neurons,
f . r\ .
jug. 1.6.' This suggests tha t the arcuate nucleus transduces information related
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Figure 1.6: N P Y /A G R P  and P O M C /C A R T  neurons in the arcuate nucleus. 
Populations of first-order N P Y /A G R P  and P O M C /C A R T  neurons in the ar­
cuate nucleus (ARC) are regulated by leptin and project to the paraventricular 
nucleus (PVN ) and to the lateral hypothalam ic area (LHA) and perifornicular 
area (PFA), which are locations of second-order hypothalamic neuropeptide 
neurons involved in the regulation of food intake and energy homeostasis. The 
figure taken from [23].
to signalling by leptin into a neuronal response.
This hypothesis is supported by the anorexic response to local microin­
jection of leptin into this area, and the inability of i.c.v. leptin to reduce 
food intake after the arcuate nucleus has been destroyed. The m ajority  of 
both N P Y /A G R P  and P O M C /C A R T  neurons have been found to co-express 
leptin receptors and both types of neurons are regulated by leptin, bu t in 
an opposing manner, as judged by changes in neuropeptide gene expression. 
Thus, N P Y /A G R P  neurons are inhibited by leptin, and consequently are ac­
tivated in conditions where leptin levels are low, Fig. 1.7. Although less well 
studied, a deficiency of insulin also seems to activate these neurons, and insulin 
receptors are also highly concentrated  in the arcuate nucleus.
Conversely, conditions characterised by reduced insulin or leptin inhibit 
POM C and CART expression in th e  arcuate  nucleus, and adm inistration of 
these hormones can prevent or a t ten u a te  these neuropeptide responses. More­
over, involuntary overfeeding in rats, which potently inhibits spontaneous food 
intake once body weight has increased by more than  5 %, elicits a threefold
CH AP TE R 1. INTRODUCTION 19
+ NPYMgRP 
expression
f  r#-Y 
release
t  food intake
P-jsfav^ritnculaf
nucleus
|  «-M8Hexpression 
and release
a-MSH
% o f « -MSN 
to melanoosftin 
receptor*
 ^Activity o f msfesnocortirt 
anoreocia pathways
t  Food intake
|  KPY/AgRP mpm&nim
|A gR P






jiSPP t  a-MSH binding arid acflvaHc 
innifcxtjoo of 0 f mefanocottin receptors
|  Food intake
pathways
' Anorexia
Figure 1.7: Role of arcuate nucleus neurons in adiposity signalling, a, Activity 
of leptin/insulin-sensitive adiposity signalling pathways in hypothalam us un­
der conditions of leptin/insulin  deficiency, b, Increased action of lep tin /insulin  
in arcuate nucleus inhibits the N P Y /A G R P  anabolic pathway and stim ulates 
the POM C catabolic pathway, resulting in reduced food intake and anorexia. 
The figure taken from [23].
increase of POM C messenger RNA levels in the arcuate  nucleus. The dem on­
stration th a t  anorexia induced either by leptin or by involuntary overfeeding 
is reversed by central adm inistration of a melanocortin-receptor antagonist 
(at a low dose tha t has no effect on food intake in control animals) indicates 
th a t  melanocortin signalling is a mediator of the anorexic response induced by 
increased adiposity signalling to the brain.
Taken together, these findings indicate tha t the arcuate nucleus is a m ajor 
site for transducing afferent input from circulating leptin and insulin into a 
neuronal response.
M o d el fo r s ec o n d -o rd e r n e u ro n a l s ig n a llin g  p a th w ay s
Leptin activity is transduced from the arcuate nucleus to the ‘hunger’ centre 
through second-order neurons (reviewed in [23]). These are neurons innervated 
by the arcuate  nucleus tha t form an integrated signalling system with an ele­
ment of redundancy in which variety neurotransm itters  appear to m ediate  the
/
same response, Fig. 1.8. It includes the paraventricular nucleus (PVN), zona
neuion
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Figure 1.8: Diagram showing locations of candidate second-order neurons in­
volved in the hypothalamic response to leptin adiposity signalling. Neuronal 
axons containing NPY and a-MSH from the arcuate nucleus (ARC) innervates 
the PVN, LHA and PFA (adjacent to the fornix). Candidate second-order neu­
rons include those that express TRH, CRH and oxytocin (OXY) in the PVN 
(which cause anorexia), and neurons tha t express orexins and MCH in the 
PFA arid LHA (which increase feeding). The figure taken from [23].
incerta, perifornical area (PFA) and lateral hypothalamic area (LHA).
Signalling in these regions is conducted through a network of intrinsic 
neurons. For PVN several candidates are known, which reduce food intake 
and body weight when administered centrally. These include corticotropin- 
releasing hormone (CRH), which causes anorexia and also activates the sym­
pathetic nervous system in addition to its role as a major regulator of the 
hypothalam ic-pituitary-adrenal axis; thyrotropin-releasing hormone (TRH), 
which reduces food intake in addition to stim ulating the thyroid axis; and 
oxytocin (OXY), which reduces food intake in addition to regulating uterine 
function. The engagement of these molecules in the control of energy balance 
is in good agreement with observations tha t stimulation of the PVN inhibits 
food intake and bilateral PVN lesions cause a hyperphagic obesity syndrome.
The involvement of neurones of LHA/PFA as the second-order media­
tors is based on physiological properties of another neuropeptide, Melanin- 
Concentrating Hormone (MCH), which is expressed in this brain area. MCH 
synthesis is elevated by both energy restriction and leptin deficiency and MCH-
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knockout mice have reduced food intake and are excessively lean. MCH exerts 
its effect through its specific receptor, a G-protein-coupled receptor which is 
coupled to the Gi subunit of the plasma membrane G-protein assembly. By 
activating Gi, binding of MCH to its receptor inhibits formation of cyclic AMP 
and consequently reduces signalling by protein kinase A (PKA). This effect 
is opposite to tha t m ediated by activation of receptors th a t exert anorexic 
effects, such as MC4 or CRH receptors, which are coupled to G s and conse­
quently increase cAMP and PKA signalling.
Two additional peptides are expressed exclusively in the LHA, zona incerta 
and PFA. These peptides, termed ‘hypocretins 1 and 2’ or ‘orexins A and B ’ 
by the two groups [25, 26] tha t simultaneously discovered them , increase food 
intake and cause generalised behavioural arousal when adm inistered centrally. 
Targeted deletion of the hypocretin/orexin gene in mice induces narcolepsy, a 
disorder characterised by the sudden onset of sleep at times when it would not 
ordinarily occur. This finding indicates that reduced hypocretin/orexin sig­
nalling may contribute to the onset and maintenance of sleep, in addition to its 
potential role in the control of food intake. Integration of MCH and hypocre­
tin/orexin neurons into a model of the hypothalamic pathways controlling 
energy homeostasis predicts tha t they should be inhibited by melanocortin or 
CART input, and stim ulated by NPY signalling, from neurons of the arcuate 
nucleus.
L eptin  and p otassiu m  channels
Although the exact m anner of leptin effectors in the hypothalamus is still to be 
clarified, the end-point of this pathway has already been identified. The final 
target of leptin signalling in the hypothalamus appears to be the ATP-sensitive 
potassium ( K a t p )  channel [27]. This hypothesis is based on the finding th a t 
leptin hyperpolarises glucose-receptive hypothalamic neurons of lean Sprague- 
Dawley and Zucker rats, model system for functional leptin signalling, but is 
ineffective on neurons of obese Zucker ( fa / fa )  rats, a system with nonfunctional 
leptin signalling. This hyperpolarisation is due to the activation of a potassium  
current, and single-channel recordings have directly dem onstrated th a t leptin 
activates the K a t p  channel.
1.4 .3  P eriph eral action s o f  lep tin
Recent studies have dem onstrated im portant peripheral actions of leptin in 
humans, including modulation of insulin action on liver cells [28], suppression
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of insulin secretion by pancreatic /?-cells [29], stimulation of hematopoietic 
stem  cells [30, 31], and inhibition of estradiol secretion by the ovaries [32]. 
Leptin also increases sym pathetic nerve activity (SNA) to the kidney and 
hindlimb in lean Sprague-Dawley rats [33].
L eptin  and S y m p ath etic  N erve A ctivation
Leptin also affects energy expenditure as it increases thermogenesis in brown 
adipose tissue. Thermogenesis activity of the brown adipose tissue is controlled 
by the autonomic nervous system.
The autonomic nerve system (ANS) represents the efferent (motor) path­
way tha t links specific effectors such as blood vessels, the heart, the gut etc. 
with specific areas of the brain concerned with the regulation of these internal 
organs. The ANS coordinates the operation of the internal organs to support 
the activity of the body as a whole. The autonomic nervous system is divided 
into the sym pathetic division, which broadly acts to prepare the body for 
activity (increases heart rate, metabolism etc.) and to the parasym pathetic 
division, which tends to promote restorative functions (digestion, slowing heart 
rate).
The efferent fibres of the autonomic nerve system do not directly link the 
CNS with target organs. The sym pathetic ANS fibres pass from the CNS 
to autonomic ganglia which are located outside the CNS. These efferents are 
known as preganglionic fibres. The ganglia are connected with the effector 
organs by postganglionic fibres.
Recent experiments in lean Sprague-Dawley rats [33] indicated th a t leptin 
increases activity of the sym pathetic nervous system. Because the ANS is un­
der control of the CNS (the hypothalamus), it is possible th a t leptin performs 
this effect through its action in the CNS. On the other hand, leptin receptors 
were recently identified in many peripheral tissues and it could be possible tha t 
leptin increases activity of the ANS directly via specific receptors expressed in 
autonomic ganglia in addition to the CNS.
This hypothesis was recently supported by the detection of leptin receptor 
immunoreactivity in human sym pathetic prevertebral ganglia [34]. Preverte- 
bral ganglia regulate gastrointestinal function by affecting motility, absorption 
and secretion of the gastrointestinal tract. Leptin receptor im m unoreactivity 
was also localised to the celiac and superior mesenteric ganglia (mouse and 
rat origin). All these findings suggest tha t leptin may m odulate gastrointesti­
nal function and responses to food ingestion and digestion through receptors
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present in prevertebral ganglia in addition to the effect of leptin at the level 
of the central nervous system.
One puzzling feature of these studies is the cellular localisation of the re­
ceptor, which was identified in the cytoplasm and not on the cell surface [34]. 
This raises the question of the nature and role of this receptor. Does it rep­
resent a population of recycled receptors or a pool of receptors waiting to be 
exported to the plasma membrane? Can the leptin receptor possess a func­
tional intracellular role? How could leptin activate it?
Leptin increases the activity of the ANS fibres innervating the brown adi­
pose tissue (BAT). Because BAT is the thermogenic organ, leptin enhances 
energy expenditure. This leptin effect is likely to be mediated via a central ner­
vous system receptor because BAT sympatho-activation was not clearly related 
to plasma concentrations of leptin [33]. However, sym pathetic nerve activation 
of BAT is also increased in obese Zucker rats, though non-significantly [33]. 
Zucker rats lack intact leptin receptor in the hypothalamus. This may suggest 
th a t the effect of leptin on the sym pathetic innervation to BAT is partially 
independent of CNS and tha t leptin could act directly through receptors in 
the autonomic nervous system.
A u to -M o d e  o f L eptin  A ction
F in d in g s/th a t the leptin receptor (Ob-R) is expressed in white and brown 
adipocytes (WAT, BAT) [35] as well as in many other tissues, opened a possi­
bility tha t leptin may exert its weight-reducing action not only through an en­
docrine, hypothalam ic mode of action, but also through an auto- or paracrine 
pathway.
This possibility has been investigated recently [36] and results from this 
study dem onstrated tha t leptin has direct effects on BAT and WAT at a 
metabolic and molecular level. This conclusion was supported by several in­
dependent lines of evidence: (a) peripheral, but not central, adm inistration 
of leptin increased the insulin-stimulated utilisation of glucose in BAT when 
compared with pair-fed control rats; (b) leptin at concentrations as low as 0 .1  
nM stim ulated basal lipolysis in white fat pads ex vivo in a time- and dose- 
dependent manner, and this effect was absent in fat pads from obese fa /fa  rats 
which are known to be deficient in functional OB-R; (c) leptin induced the ex­
pression of malic enzyme and lipoprotein lipase in prim ary cultures of brown 
adipocytes; (d) BAT, WAT, and primary adipocyte cultures all express OB- 
Rb mRNA (section 1.5); and (e) treatm ent of brown and white adipocytes
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with leptin in vivo or in vitro induced the nuclear translocation of STATs, 
compatible with the currently known mechanism of action of leptin through 
the OB-R.
Taken together, these results suggested that physiological levels of leptin 
had a direct and specific effect on the metabolism and gene expression of 
brown and white adipocytes which is likely to be m ediated through an auto- 
or paracrine pathway.
L eptin  and A drenal G land
Leptin also increases sym pathetic nerve activity (SNA) to the adrenal gland, 
as dem onstrated in lean Sprague-Dawley rats [33]. The adrenal glands are 
paired organs, each one lying above the kidney, enclosed in a fibrous capsule 
and surrounded by fat. Each adrenal gland is, in effect, structurally and func­
tionally divided into two endocrine glands. The inner adrenal medulla derives 
from ectodermal cells of the embryonic neural crest and secretes the cathe- 
cholamines, epinephrine and norepinephrine, in response to activation of its 
sym pathetic nerve supply. It thereby acts as an autonomic ganglion of the 
sym pathetic nervous system. The outer adrenal cortex, which encapsulates 
the m edulla and forms the bulk of the gland, is derived from embryonic meso­
derm and secretes a number of steroid hormones. Unlike the adrenal medulla, 
the secretions of the adrenal cortex are controlled hormonally. The adrenal 
medulla is involved in energy metabolism through epinephrine regulation. The 
adrenal cortex affects many other body functions through cortisol and aldos­
terone production.
The effect of leptin on sympatho-activation of the adrenal gland raises 
again a question of a direct action of leptin on the ANS through a specific 
receptor. Leptin receptor expression in the human adrenal gland has been 
dem onstrated [37]. At the mRNA level, the long form of the leptin receptor 
(section 1.5) was detected in both adrenocortical and adrenomedullary tis­
sues. Furtherm ore, isoforms, previously characterised in human fetal liver, 
were observed in normal human adrenal cell cultures and adrenal tissues. At 
the protein level, the full length Ob-R (section 1.5) was detected by immunos- 
taining in all three zones of the cortex but only a weak signal was detected in 
the adrenal medulla [37].
Leptin acts on adrenal cortex functions. Leptin adm inistered in concen­
trations th a t are equivalent to the in vivo range led to a mild, but significant, 
inhibition of adrenal steroidogenesis [37]. This effect was most significant on
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aldosterone. A strong inhibition required concentrations higher than  those 
normally found in plasma. However, the adrenal gland is naturally embodied 
in the adipose tissue and thus, high local leptin  concentrations may be innate 
in this organ.
The inhibition effect of leptin has been proposed to act through this hor­
mone, m odulating the expression of steroid hormones. This was proposed 
following the finding th a t leptin adm inistration led to a 50 % decrease in 
ACTH-stim ulated cytochrome P450 mRNA expression [37]. This suggested 
th a t the inhibitory effect may be through action on the expression of steroid 
enzymes.
These data  suggest tha t leptin decreases glucocorticoid production. This 
may have an indirect connection to energy control because glucocorticoids 
produce the biochemical features of visceral fat syndrome, including obesity, 
insulin resistance, dyslipidemia, and hypertension.
A decrease in mineralocorticoid (aldosterone) secretion also leads to a fall in 
blood pressure, indicating that leptin may have a counter-regulatory function 
in hypertension.
On the other hand, leptin does not have any direct effect on human adrenal 
catecholamine production. This diminishes a potential direct effect of leptin 
in energy m etabolism through epinephrine regulation. This is in contrast to 
other mammals (rat and mice) where the adrenal medulla expresses abundant 
leptin receptor [37]. This difference can contribute to different leptin effects 
observed in these species.
\  p o  - j 1 'C
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S W E I E A Q A F F I L S D Q H P N I I S P H L T F S E
G L D E L L K L E G N F P E E N N D K K S I Y Y L G
V T 5 I K K R E S G V L L T D K S R V S C P F P A P C
L F T D I R V L Q D S C S H F V E N N I N L G T S S K
K T F A S  Y M P Q F Q T C S T Q T H K I M E N K M
C D L T V *
V TV *
D I S F H E V F I F R *
G M C T V L F M D *
Table 1.9: The intracellular domain of the mouse leptin receptor splicing vari­
ants. The consensus box 1 and box 2 motifs are indicated. * stands for the 
term inal codon.
1.5 L eptin  receptor
1.5 .1  R ecep to r  sp lic ing  variants
The leptin receptor (Ob-R) was originally cloned from the mouse choroid 
plexus [38]. Its DNA sequence suggests tha t Ob-R is a single membrane- 
spanning receptor consisting of extracellular, transm em brane and intracellular 
domains,/Fig. 1.9.%vj
Further investigation in the mouse hypothalamus [39] revealed m ultiple 
splice variants of the leptin receptor gene [39]. Four variants are identical until 
the lysine residue at position 889, which is within the predicted cytoplasmic 
tail. Thus, they have identical extracellular and transm em brane domains but 
different cytoplasmic portions, Table 1.9. These four variants are designed: 
Ob-Ra, Ob-Rb, Ob-Rc and Ob-Rd. A fifth splice variant, Ob-Re, predicts a 
different amino-acid sequence after His 796, and may encode a soluble receptor, 
(Fig. 1.9.)
Ob-Ra corresponds to the Ob-R cloned originally from mouse choroid 
plexus cDNA library [38]. Ob-Rb is the ’’long” form of the receptor and 
has been classified as a mouse homologue for human Ob-R, because the C ter­
minus of Ob-Rb is 78% identical to the human receptor1. Ob-Rc and Ob-Rd
1The human sequence was cloned from the fetal total cDNA library [38].
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T issue O b-R a O b-R b
Heart low very low
Hypothalamus low high
Choroid Plexus low very low
Spleen low very low
Lung high very low
Liver low very low
Sk. Muscle low very low
Kidney high very low
Testes low very low
W hite Fat not tested very low
Brown Fat not tested very low
Pancreas Islet not tested none
Pancreas not tested none
Table 1.10: An expression level of the leptin receptor splicing variants in dif­
ferent mouse tissues.
are suspected to represent nonfunctional variants [40].
The Ob-Ra and Ob-Rb splice variants differ in the nature of their cyto­
plasmic tails. The Ob-Rb variant is able to signal through the activation of 
the JAK/STAT signalling pathway whereas Ob-Ra is not.
A functional difference between Ob-Ra and Ob-Ra became obvious when 
a single point m utation in the Ob-R gene was identified in the db/db  mice 
(C57BL/KsJ strain) [39, 41]. This m utation leads to a replacement of Ob-Rb 
by Ob-Ra. This can account for the db/db  phenotype which is characterised 
by a resistance to leptin.
The leptin receptor has been localised not only in the mouse hypothala­
mus [38, 42] and choroid plexus but also in several other tissues, Table 1.10. 
High levels of Ob-R expression were detected in lung and kidney. Lower levels 
were detected in heart, spleen, liver, skeletal muscle and testes [35, 38, 40]. The 
m ajority of Ob-R in these tissues is the short form, Ob-Ra. Ob-Rb is present 
in these tissues but in much smaller amounts. Ob-Rc, Ob-Rd and Ob-Re were 
not identified. Ob-Rb has also been detected at low levels in white and brown 
fat, but not in pancreatic islets or whole pancreas [40]. The significance of the 
Ob-R tissue distribution is not clear and a role of individual receptor splice 
variants is still speculative.
It is useful to introduce an alternative classification of the receptor splice 
variants according to their cytoplasmic tail. The splice variants Ob-Ra, Ob-Rc 
and Ob-Rd then represent different versions of the short form of the receptor
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OB-Rb OB-Ra OB-Re
E xtr ace l lu la r
d o m a i n
] In t race l lu la r
d o m a i n
Figure 1.9: The leptin receptor splicing variants: OB-Rb and OB-Ra are the 
long and short forms of the leptin receptor, while Ob-Re is likely to represent 
the soluble form of the receptor.
(Ob-Rs) while the Ob-Rb is receptor long form (Ob-Rl)2. The cytoplasmic 
region of the short forms (Ob-Rs) only comprises about 30 aa. The long form 
v __ has a cytoplasmic tail of 336 amino acids, ta b le  1 .9'. II us differencey
has been predicted to account for the dist inct signaling capability of the splice 
variants. The intracellular domain of the Ob-Rl contains a consensus box 
1 motif, JAK tyrosine kinase binding site [43] as well as the box 2 m otif 
which is the binding sequence for the STAT3 transcription factor, a .JAK 
substrate [44, 45]. Therefore, Ob-Rl can activate the JAK-STAT intracellular 
signalling pathway. Ob-Rs with just the box 1 m otif lack this activity.
1.5.2 C ytokine receptor superfam ily
Sequence analysis of the shared extracellular region of all Ob-R forms revealed 
several motifs tha t are common for the cytokine receptor superfamily. T h e s e  
are the Trp-Ser-X-Trp-Ser m otif (where X is a nonconserved amino acid) and 
four conserved Cys residues in its extracellular domain [46]. Together with the 
presence of a typical uBox 1; Box 2” m otif in Ob-Rl, this suggests tha t the 
Ob-R may be a member of the cytokine receptor superfamily.
This proposal has been supported by the solution of the crystal structure
1 T h e  splice varian t O b -R b  is from now on referred to  also as Ob-Rl.
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of leptin, the receptor ligand [1 ]. It has revealed tha t leptin shares structural 
features common for cytokines (molecules which ensure the communication 
between different organs in our body). Thus, the classification of leptin as a 
cytokine supports the concept tha t the leptin receptor is a cytokine receptor.
Although Ob-R is now accepted as a cytokine receptor family member, 
the homology between its prim ary sequence and other family members is rela­
tively low. The most closely related protein: the gpl30 protein (the signal- 
transducing component of the interleukin - 6  (IL-6 ) receptor) has only 21% ho­
mology with the Ob-R. The other ”closely” related proteins are: the granu­
locyte colony-stimulating factor (G-CSF) receptor, the leukaemia inhibitory 
factor (LIF) receptor (a  chain) and the growth hormone (GH) receptor.
1 .5 .3  C anonical extracellu lar dom ain
The extracellular domain of cytokine receptors, which plays a crucial role in 
the interaction with the ligand, is relatively well characterised. Sequence anal­
ysis [47] has revealed several conserved motifs and the canonical extracellular 
domain has been formulated (Fig. 1.10). According to this analysis the ex tra­
cellular region of many cytokine receptors consists of an immunoglobulin-like 
domain in its N terminus followed by a cytokine-binding homology region 
(CHR) which contains the ligand binding site and two or three copies of fi- 
bronectin Ill-like domains. However, a small number of the cytokine receptors 
contain not one but two copies of the CHR. This is the case for the LIFR 
a  chain, the IL-5R (I chain and also the Ob-R. The cytokine receptor ex­
tracellular domain subdivision predicted from the sequence analysis [47] has 
been confirmed by the solution of the crystal structure of several members of 
this family: namely, the growth hormone receptor (GHR; [14]), the prolactin 
receptor (PRLR; [48]), the erythropoietin receptor (EPOR; [49]), and the 
interferon- 7  receptor (IFN7 -R; [50]). These studies have also shown th a t the 
CHR alone contains two fibronectin Ill-like domains (N and C). Its amino- 
term inal domain (N) is characterised by four conserved cysteine residues while 
the carboxy-terminal domain (C) contains the signature m otif Trp-Ser-X-Ser 
motif, which is now recognised as the distinguishing feature for this family of 
receptors.
1 .5 .4  C anonical in tracellu lar dom ain
The first of the cytokine receptor conserved motifs localised in their intracel­
lular domain is a Box 1 motif. Both the short and long forms of the leptin
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im m unog lobu ! in -l ike  dom ain
cytokine-binding homology region
cytokine-binding hom ology region
fibronectin III like domain
fibronectin III like domain
Figure 1 .1 0 : Canonical motifs in the Ob-R extracellular domain. An im­
munoglobulin like domain is followed by two copies of the cytokine-binding 
homology region (CHR) and two copies of fibronectin Ill-like domains.
receptor possess the Box 1 motif, which is usually located within the first 20 
cytoplasmic residues. The Box 2 motif, a less conservative motif, is usually 
found in the first 50-00 amino acids of the cytoplasmic domain. This Box 2 
motif is only present in Ob-Rl, the long form of the receptor. M utational 
analysis of these conserved regions in several receptors suggests tha t t hese two 
domains are both required for the activation of JAK-STAT signalling path­
way [51, 52, 44]. The absence of the Box 2 m otif in the cytoplasmic domain 
of the Ob-Rs suggests that the short form of receptor activates a different 
pathway (if any).
1.6 R eceptor activation
The topic of my project is the activation of the leptin receptor by interaction 
with its ligand. Cytokine receptors have been shown to function as dimers and 
this dimerisation is induced by the ligand [53]. The sequence similarities ol 
leptin/leptin receptor with the cytokine/cytokine receptor family presupposes 
tha t a similar activation process may hold for leptin activation. However, this 
presumption may be misleading and inaccurate.
The current model of the common cytokine receptor activation [53] sup-





Figure 1 .1 1 : The proposed mechanism of leptin receptor activation based on 
GH-GHR interactions. A ligand free receptor exists in a monomeric form. The 
ligand binding induces its dimerization.
poses tha t the ligand-free receptor is expressed on the cell surface in a mono­
meric form and tha t the ligand induces the receptor di/oligomerisation, 'Fig. 1 .1 1 ) 
The number and character of molecules involved in receptor activation dif­
fer between the family members. For example, the growth hormone receptor 
(GHR) undergoes a simple homodimerisation in the presence of the ligand [14], 
while the activated interleukin- 6  receptor (IL-6 R) complex contains (apart 
from IL-6 ) the monomeric IL-6 R together with two gpl30 molecules [54].
A weak point of the model presented is tha t it is based mainly on theoretical 
analysis and is backed only by a weak experimental confirmation. The main 
piece of evidence is the crystal structure of a complex of growth hormone and 
its receptor [14], which indicates tha t the receptor is dimerised in the presence 
of the ligand, but there is no evidence that ligand-free receptor is expressed 
on the cell surface as monomer.
1.6.1 J A K /S T A T  signalling pathw ay
An activated cytokine receptor is able to initiate the intracellular signalling cas­
cade. The membrane receptors signal normally via the phosphorylation of spe-
C H A P T E R  1. IN TRODUCTION 32
cific tyrosine residues of the target molecules. However, cytokine receptors lack 
intrinsic tyrosine kinase activity. These receptors engage receptor-associated 
JAK kinases [38]. JAKs are rapidly activated and tyrosine phosphorylated, 
after ligand binding to a particular receptor. JAK activation is followed by 
tyrosine phosphorylation of receptor subunits and additional signaling inter­
mediates, including cytosolic proteins known as STATs. Phosphorylation of 
STATs results in their homo- or hetero-dimerization via reciprocal phospho- 
tyrosine SH2 domain interactions [55]. These transcription factors then trans­
locate to the nucleus using the importing a / (3 localisation pathway [56]; in the 
nucleus, they bind to cognate response elements adjacent to target genes and 
activate downstream gene transcription [57]. This general scheme, Fig 1.12, 
is now recognised to serve as a high-speed connection between many cytokine 
receptors and their downstream biological responses.
One can try  to deduce the potential effects of leptin receptor activation 
by determ ining the JAK and STAT molecules engaged by leptin receptor. 
The leptin receptor in vitro employs Jak2, STAT-1 , STAT-3 and STAT-5b 
components [59]. The in vivo role of these molecules has been investigated 
using gene disruption studies.
Targeted disruption of Jak2 gene results in an embryonic lethal pheno- 
type [58]. This implies tha t leptin receptor signalling through Jak2 could be 
critical in early developmental processes. Disruption of STAT-1 gene leads to 
marked unresponsiveness to interferon (IN F)-a or 7  and increased sensitivity 
to microbial pathogens [60, 61]. Thus, leptin may play a role in antimicrobial 
defence. A nonfunctional STAT-3 gene results in the same phenotype observed 
when Jak2 was disrupted: i.e. it is embryonic lethal [62]. This phenotype is 
likely to be attribu ted  to the pleiotropic action of STAT-3 in early develop­
ment. Targeted disruption of STAT-5 results in very limited immunological 
defects.
From these disruption studies, one would conclude tha t leptin receptor 
signalling is im portant for the early development of an organism and antim i­
crobial defence. However, this is a very different role from the one originally 
proposed for leptin: control of feeding behaviour through an interaction with 
the central nervous system. This discrepancy raises several questions. Does 
leptin in neuronal cells utilise the JAK/STAT signalling pathway previously 
characterised for cells of the immune system? If not, does leptin activate 
other signalling pathways in the CNS? W hat role would leptin signalling via 
the JAK /STA T pathway have in tha t case?














Figure 1.12: The basic JAK /STA T signal transduction paradigm. Receptor- 
associated JAKs remain quiescent until (a) ligand-induced receptor mul- 
tim erisation promotes their activation, apparently through a trans­
autophosphorylation mechanism, (b) Subsequent phosphorylation of select 
tyrosines within one or both receptor cytoplasmic tails provides attachm ent 
sites for latent cytoplasmic STAT factors via specific SH2  phosphotyrosine 
interactions, (c) It is believed tha t the juxtaposition of STAT factors in a spe­
cific configuration adjacent to activated JAKs within the receptor complex fa­
cilitates their tyrosine phosphorylation, (d) Phosphorylated STAT monomers 
subsequently associate as dimers via reciprocal SH2 phosphotyrosine in ter­
actions, and are then able to translocate into the nucleus to bind sequence- 
specific DNA response elements and promote transcription of target genes. 
Reprinted from [58]
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The hypothesis tha t the leptin receptor uses the JAK/STAT pathway in 
neuronal cells in vivo was investigated in rats [63]. The STAT-3 protein was 
found to be localised in the Ob-R-containing neurons in ra t hypothalamus by 
means of indirect immunofluorescence histochemistry. STAT-3 protein was 
also identified in the paraventricular nucleus (parvocellular part), periventric­
ular nucleus, arcuate nucleus and in the lateral hypothalamic area.
In this same study, direct double-labelling showed the presence of STAT-3 
immunoreactivity in Neuropeptide Y (NPY)-containing neurons of the ven­
trom edial part of the arcuate nucleus and in pro-opiomelanocortin (POMC)- 
containing neurons of the ventrolateral part of the arcuate nucleus.
These results provide an anatomical basis for leptin action mediated by 
STAT3 in Ob-R containing NPY and POMC neurons of the arcuate nucleus, 
as well as by Ob-R containing neurons of the parvocellular, paraventricular 
nucleus and lateral hypothalamic area.
The ability of leptin to activate STAT-3 in the hypothalamus of rats in 
vivo was confirmed by immunoblotting analysis of STAT-3 phosphorylation 
[64], when STAT-3 was found to be phosphorylated after leptin injection.
By contrast, leptin did not increase the phosphorylation of Jak2, or STAT-1 
and -5 despite abundant expression of these signaling molecules in the hypotha­
lamus. It remains unclear how signaling is propagated downstream from the 
leptin receptor to STAT-3, but this may involve novel signaling intermediates.
1 .6 .2  C on stru ction  o f  recep tor  ch im eras
The first a ttem pts to determine the order of multim erisation of the Ob-R 
aggregation have already been undertaken. It has been shown so far tha t 
the Ob-R activation does not require gpl30 protein [59], IL-2 R7  or IL-3 R/? 
signal transduction components [65] because it can signal in hepatom a cells 
(which do not express 11-2 R 7  or IL-3 R(3 components) in the presence of the 
neutralising antibodies to the gpl30. These results suggested tha t the Ob-R 
may undergo homodimerisation during its activation.
This hypothesis has been investigated through several experimental ap­
proaches. In one of them , the chimeras between the leptin receptor and 
the granulocyte-colony stim ulating factor receptor (G-CSFR) have been con­
structed [6 6 ]. The G-CSFR is a m ember of the cytokine receptor superfamily 
predicted to undergo homodimerisation [67]. Thus, the replacement of one 
of the G-CSFR domains (intracellular or extracellular ones) with the Ob-R 
analogue should dem onstrate whether the Ob-R undergoes the same process,
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OB-R G-CSFR
OBR/ G-CSFR chimera G-CSFR/OBR chimera
Figure 1.13: The O BR/G -CSFR and the G-CSFR/O BR chimeras. The 
O BR/G -CSFR chimera consists of the extracellular and transm em brane do­
mains of the mouse Ob-R and the intracellular domain of the human G-CSFR. 
The G -CSFR/O BR chimera consists of the human G-CSFR extracellular do­
main and the human Ob-R transm em brane and intracellular domains.
(Fig- 1.13.^
To verify the ability of leptin to activate the leptin receptor via homod­
imerisation, the chimera (OBR/G-CSFR) consisting of the extracellular and 
transm em brane domains of the mouse Ob-R and the intracellular domain of 
the human G-CSFR, has been constructed, Fig. 1.13) If leptin binding to the 
Ob-R extracellular domain causes dimerization the chimera will activate sig­
nalling because the intracellular domain of G-CSFR is only active in dimeric 
form. The results showed that incubation of the chimera with leptin resulted in 
the signal activation. This finding suggested tha t leptin induces dimerization 
of the chimera.
The role of dimerization of the Ob-R intracellular domain in m ediating 
receptor activation has been investigated through the construction of the con­
verse chimera, namely G -CSFR/OBR chimera, which consists of the hum an 
G-CSFR extracellular domain and the hum an Ob-R transm em brane and in­
tracellular domains. Incubation of the chimera with G-CSF resulted again in 
the signal activation, implying tha t the Ob-R intracellular domain mimics the 
G-CSFR one (i.e. that it is dimerised in an activated receptor).
A combination of these results leads to the conclusion th a t leptin is able to







N O  INTRACELLULAR SIGNAL
Figure 1.14: The Ob-R signalling is cancelled by the overexpression of a signal- 
deficient homodimerising partner.
induce the receptor dimerization and tha t its dimerised intracellular domain 
activates the signalling pathway.
1 .6 .3  O rder o f  o ligom erisation
The possibility tha t the order of the receptor oligomerisation is higher than 2 
(the Ob-R acts as a trim er or tetram er etc.) has been further investigated [6 6 ]. 
This experiment was based on a presumption tha t if the Ob-R only undergoes 
dimerization, then signalling should be negated by the overexpression of a 
homodimerising partner tha t is signalling deficient (Fig. 1.14). This effect has 
been observed for the receptor tyrosine kinase family [6 8 , 69].
A truncated form of the Ob-R containing only 6 a.a. of the intracellular 
domain (OBRD8 6 8 ) was employed as the signalling-defective component. It 
was used in increasing amounts (relative to the full-length OBR) to investigate 
whether overexpression of OBRD 8 6 8  was able to cancel wild-type receptor 
signalling. However, the results have shown that even a large excess of the 
truncated receptor is unable to diminish the signalling. The conclusion (based 
on the above presumption) is th a t the Ob-R does not act as a dimer but in a 
higher order oligomerisation form.
Similar effects have been observed for the interleukin-10 (IL-10) recep­
tor [70]. The model of the IL-10R activation suggests tha t more than two
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IL-10R molecules are involved in the receptor activation but tha t the ju x ta ­
position of only two intracellular domains is sufficient for a signal activation. 
This mechanism would also fit the data obtained for the Ob-R.
However, the observed failure of truncated Ob-R to diminish the activity
of signalling cascade/ can be explained in a different way. W ild-type leptin 
Ir'" / receptor may be unable to form homodimer/when co-expressed with the trun-h-
cated receptor because the truncated receptor would prevent physical contact 
between wild-type leptin receptor molecules.
Nevertheless, the method employed, co-expression of wild-type and trun ­
cated Ob-R forms on the cell surface, with subsequent measurement of the 
response to the ligand binding, is not able to distinguish between these two 
possibilities.
1 .6 .4  R ecep to r  d im erization
The problem of receptor oligomerisation has been investigated further w ith the 
employment of another technique: namely, chemical cross-linking [71]. This 
has been used to compare the efficiency of ligand binding between the receptor 
long form (the wild-type version) and its short form (the truncated one).
Chemical cross-linking of leptin to the Ob-Rl has identified a homodimer 
and homo-oligomer complexes of the Ob-R. In contrast, chemical crosslinking
of leptin to the short form of receptor has not revealed any complex formation.
/ \
No interaction between leptin and the Ob-Rs has been proved even in the 
presence of the Ob-Rl form [71]. These results indicated tha t the incapability 
of the Ob-Rs form to diminish the signalling of Ob-Rl form discussed above 
is not due to the formation of a^/oligomeric complex between Ob-Rs and Ob- 
Rl [66], but rather tha t the overexpression of the Ob-Rs form does not come 
into physical contact with the Ob-Rl molecules.
The role of the Ob-R extracellular domain alone in the formation of the 
receptor oligomeric complex has also been studied. An aggregation state  of 
the soluble Ob-R extracellular domain has been studied using leptin affinity 
and gel filtration chromatography [71]. Surprisingly, it has revealed tha t the 
Ob-R extracellular domain is present in a dimerised form even in the absence 
of leptin. Thus, the wild-type Ob-R may also be present on a cell surface as a 
dimer even before leptin binding. This observation makes the hypothesis th a t 
leptin activates the receptor through its dimerization rather problematic.
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1 .6 .5  E xp erim en ta l design
The cross-linking experiments together with the ligand binding studies repre­
sent very indirect methods for characterisation of the interaction of the leptin 
receptor with its ligand. In the ligand binding experiments, the strength of the 
leptin binding has been deduced from the level of the transcription of a specific 
reporter gene. However, this gene (Luciferase assay) does not represent the 
in vivo leptin signalling target. Therefore, leptin action in its authentic en­
vironm ent may be significantly different. Chemical cross-linking on the other 
hand represents quite a harmful technique. It covalently links proteins which 
are close to each other. The short distance between proteins however does not 
necessarily mean tha t these proteins interact.
D ata obtained using these techniques must therefore be treated with cau­
tion and conclusions made about the receptor activation mechanism should 
be kept open for further modification. The design of less harmful and more 
accurate experimental configuration/is therefore highly desirable. The optim al 
technique should use methods more strictly based on the physical phenomena. 
A ttractive candidates for the determ ination of the number of the involved 
receptor and ligand molecules are analytical techniques, such as BiaCore, m i­
crocalorimetry and analytical centrifugation.
Parallel use of these techniques should provide another useful piece of infor­
mation. BiaCore represents a powerful new technique used mainly for studying 
of reaction kinetics, but it is expected to be useful also for the determ ination 
of reaction stoichiometry. D ata obtained by BiaCore analysis can be directly 
compared with results obtained by microcalorimetry or analytical centrifu­
gation. Such data comparison would provide a very valuable justification of 
BiaCore for the use in the stoichiometrical experiments.
Until recently, the application of these techniques, with the exception of 
BiaCore, has been restricted only to the study of synthetic components because 
natural ones have not been available in sufficient amounts. This problem 
has now been overcome by the development of new highly efficient expression 
systems which today generate adequate quantities of proteins.
The employment of BiaCore, microcalorimetry or analytical centrifugation 
in the analysis of the interaction between leptin receptor and its ligand should 
provide much more accurate results than those from classical biological tech­
niques. A parallel use of more then one technique would furtherm ore minimise 
biases which accompany every single experimental method. Ideally, BiaCore 
would be accompanied by microcalorimetry or analytical centrifugation in the
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characterisation of the leptin-leptin receptor interaction.
1 .6 .6  A im  o f  th e  p roject
The aim of the project was to determine the thermodynamics of the lep tin- 
leptin receptor interaction using a variety of biophysical techniques. To achieve 
this, it was necessary to express the leptin receptor, as the cDNA was not 
available at the s tart of this project. The initial goal was to obtain the cDNA 
encoding the extracellular domain of the receptor by RT-PCR. The open read­
ing frame comprising 839 a.a. encoded by 2517 nucleotides was generated by 
several molecular approaches as the mRNA was a rare species.
Because biophysical techniques require large amounts of protein, different 
expression systems were attem pted. However, BiaCore analysis requires small 
amounts of protein and this method was used to evaluate the leptin-leptin  
receptor interaction.
C hapter 2 
M aterials and M ethods
2.1 M olecu lar b iology
2 .1 .1  G en era l lab oratory  supp lies and p rocedu res
General stock chemicals and equipment were obtained from Sigma Chemical 
Co., Fisons Scientific Equipment or BDH Merck and, when necessary, were of 
analytical, molecular biological, or HPLC grade. Compositions of all solutions 
used are listed in Appendix II when not specified in the text. W ater for general 
laboratory use was single-distilled. Equipment and solutions were sterilised 
by heating to high tem perature (121°C) with high pressure (1.05 bar) for 20 
minutes in an autoclave (Labclave II, Dent and Hellyer).
In addition, general precautions and procedures [72] were followed to min­
imise RNase contam ination in the laboratory. W hen working with solutions 
and equipment used for RNA analysis, gloves were worn at all times to pre­
vent ”finger nucleases” contamination. Sterile, disposable plasticware was used 
wherever possible and plastic disposable pipette tips and microcentrifuge tubes 
were autoclaved prior to use. All glassware and other bakeable equipment, such 
as steel tweezers and foil, were baked at 270°C for at least eight hours to inac­
tivate nucleases. W here possible, separate chemical stocks were designated for 
RNA use only. Solutions for RNA use (with the exception of Tris-containing 
solutions) were treated  overnight with 0.05% diethylpyrocarbonate (DEPC), a 
non-specific inhibitor of ribonuclease, and then autoclaved to destroy any re­
maining DEPC. Dilutions of stock chemicals and enzyme reaction buffers were 
made with D EPC-treated water. Electrophoresis gel rigs, combs and baffles 
dedicated for RNA use were well rinsed with D EPC-treated water, covered 
and stored away from other general laboratory equipment.
40
C H A P T E R  2. M A T E R IA L S  A N D  METHODS 41
2 .1 .2  C ell cu ltu re
M am m alian  cell cu ltu re
Cell culture was performed in laminar-flow tissue-culture hoods (Microflow 
Biological Safety Cabinet, Airflow ServiceCare). Solutions, materials and 
reagents used for cell culture were sterilised either by autoclaving or by fil­
tration through 0.22 f im  filter units (Millex-GV, Millipore).
COS and H E K  cell cu ltures Both cell lines were grown on plastic tis­
sue culture plates. COS cells [73] were grown in Dulbecco’s Modified Eagles 
Medium (DMEM, Gibco BRL) supplemented with 10% calf serum, 2mM glu­
tam ine, 1000 i.u. penicillin and 0.1 m g/m l streptomycin. Human embryo 
kidney (HEK) cells [74] were grown in Dulbecco’s Modified Eagles Medium 
(RPM I, Gibco BRL) supplemented with 10% foetal calf serum, 2mM glu­
tam ine, 1000 i.u. penicillin and 0.1 m g/m l streptomycin. Cells were routinely 
m aintained on 100 mm diameter plates and subcultured every third day. Typ­
ically, 2 - 8  TO5 cells were plated. Cells were routinely passaged up to a 
m aximum of twenty times. Adherent cells were dislodged by a 10 min trea t­
m ent with Trypsin (1:250, Gibco BLR) at 37°C. Cultures were m aintained at 
37°C in a w ater-saturated atmosphere of 95% air and 5% carbon dioxide in 
tissue culture designated incubators (Napco 5410).
C ell quantification  Total cell counts were determined using a haemocy- 
tom eter (Sigma). The cell sample was prepared as follows. 0.5 ml of 0.4% 
Trypan Blue solution (w /v) (SIGMA) was added to a test tube with 0.5 ml of 
cell suspended in phosphate-buffered saline (PBS) and mix thoroughly. The 
solution was allowed to stand for 5 to 15 min W ith the cover-slip in place, 
15 fi 1 of cell solution was transferred to the haemocytometer. Cells in four 
corner squares as well those touching top and left middle line of the perim eter 
of each square were counted. The average number of cells per millilitre was 
calculated to be the average count per square multiplied by both the dilution 
factor (2) and 104.
2 .1 .3  B acteria l cu lture and m anip u lation
All bacterial work was performed at the laboratory bench. Solutions, media, 
glassware and plasticware were sterilised by autoclaving before use. The bench 
was swabbed with ethanol prior to use. A bunsen burner flame m aintained
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aseptic conditions in the area. Tools used, such as m etal loops and glass 
spreading devices, were sterilised by dipping in ethanol and flaming. Bacterial 
cultures were grown at 37° C in an incubator (Napco Model 301).
M ed ia  preparation  E. coli bacteria were grown in Luria-Bertani medium 
(LB, Gibco BRL). Liquid LB medium consisted of 20 g of premixed LB powder 
per litre of distilled water which was then autoclaved. Medium was allowed to 
cool to approximately 50°C before addition of the antibiotic ampicillin (Sigma) 
to 100 /ig/m l. Agar plates were prepared using premixed LB agar powder 
(Gibco BRL). Thirty-two grams of powder were added per litre of distilled 
water and the m ixture was autoclaved which, in addition to sterilisation, dis­
solved the agar. After adding antibiotic, as described above, the liquid was 
poured into sterile, 100mm plastic bacteria'plates; about 33 ml of m edium was 
used per plate. The agar plates were allowed to solidify at room tem perature 
and were then dried, in an inverted position with covers ajar, at 37°C for 30 
minutes. Plates were then either used immediately or stored at 4°C in their 
original plastic storage sleeves for up to one month.
For identification of bacterial colonies transformed with plasmid vector 
containing the beta-galactosidase gene in the polylinker region, agarose plates 
containing besides an appropriate antibiotic also 0.1 mM isopropyl-/TD- thio- 
galactopyranoside (IPTG) and 40 fig/m l of the chromogenic substrate 5-bromo- 
4-chloro-3-indoyl-/?-D-galactopyranoside (X-Gal) were used.
C o m p eten t bacteria  preparation  Bacteria competent to absorb DNA 
were either purchased from Gibco BLR or made unprepared  and transformed 
using calcium chloride. DH5o bacterial strain was streaked onto an LB agar 
plate and allowed to grow overnight at 37°C. The next day, a single colony 
was selected and transferred into 5 ml of TYM medium and allowed to grow at 
37°C with agitation for two to three hours. This culture was then transferred 
to a 250 ml Erlenmeyer flask containing 100 ml TYM media and allowed to 
grow until the absorbance of the suspension was approximately 0.5 OD units 
at 550 nm. The suspension was then snap-cooled in an iced water bath  and 
centrifuged (GS-3 rotor, Sorvall centrifuge) in sterilised polypropylene tubes at 
2600 g for ten minutes at 4°C. The resulting bacterial pellet was resuspended 
in 30 to 40 ml of Tfbl per 100 ml original culture and incubated on ice for 
five minutes. Cells were centrifuged again for eight minutes at 2600 g at 
4°C. The pellet was then resuspended in 4 ml of T fbll per 100 ml original 
culture. One hundred microlitre aliquots of competent cells in polypropylene
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microcentrifuge tubes were snap-frozen in liquid nitrogen and stored at -70°C.
T ransform ation  o f bacteria  w ith  D N A  A 100 fA aliquot of competent 
cells was thawed on ice for each sample of DNA to be transformed. Ten mi­
crolitres of DNA, containing between 10 to 100 ng of DNA, was added to the 
suspension of com petent bacteria and, after gentle mixing, was incubated on 
ice for 15 minutes. The bacteria/DNA m ixture was then ”heat-shocked” by 
incubation at 42°C for 45-50 seconds or at 37°C for 5 minutes. Nine hundred 
microlitres of LB m edia was then added and the m ixture was then incubated 
at 37°C for 15 minutes. A 100 (A aliquot of this m ixture was plated on to LB- 
am picillin /IPTG /X -G al plates. Control transform ation reactions using circu­
lar, non-recombinant plasmid vector were performed alongside experimental 
samples to assess transform ation frequency, which was routinely determined 
to be between 1/103 — 1/104 cells. Reactions eliminating plasmid DNA served 
as negative controls. Recombinant transformants, which have an interrupted 
/Tgalactosidase gene, grew as white colonies while non-recombinant colonies 
were stained blue due to reaction of /3-galactosidase with X-Gal. Recombinant 
bacterial colonies were identified by plasmid ”m inipreparation” , restriction di­
gestion and electrophoresis (see below).
2 .1 .4  N u c le ic  acid  iso la tion
E xtraction  o f to ta l R N A
Total cellular RNA was extracted and isolated using acid phenol extraction 
methocj/[75]. Cells were washed on the culture plate once with 2 ml ice-cold 
phosphate-buffered saline solution (PBS). PBS was removed and 500 fi 1 (for 60 
mm plate) of pre-chilled guanidinium isothiocyanate (GTC) was added. This 
harvest was then transferred to a sterile tube and cells were subsequently kept 
on ice during RNA extraction. Cells were pelleted by centrifugation at 4°C 
for three minutes at 900 g and the resulting pellet was homogenised in the 
guanidinium isothiocyanate solution by thorough vortexing.
This was then acidified by addition of 0.1 volume of 2M sodium acetate, 
pH 4 and then extracted to remove protein with one volume of w ater-saturated 
phenol (R athburn Chemicals Ltd) in the presence of 0.2 volumes of chloro- 
formiisoamyl alcohol (49:1). The solution was vortexed vigorously and after 
15 min incubation on ice the sample was centrifuged at 12,000g for 20 min 
at 4°C. The aqueous phase, containing the RNA, was transferred to another 
tube. Total RNA was precipitated overnight at -20° C by adding one volume
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of 100% ethanol and mixing by inversion. Overnight precipitation ensured 
m axim um  RNA yields.
RNA was pelleted by centrifug^tmg at 4°C for 30 minutes at 8,000 g. After 
decanting the supernatant, the pellet was washed with 1 volume of ice-cold 
75% ethanol. Pellet was resuspended by pipetting. After centrifugation and 
air drying, the final pellet was dissolved in D EPC-treated water. RNA samples 
were routinely stored as 20-50 fd  aqueous solutions at -70°C.
Iso lation  o f p lasm id D N A
P lasm id  ” M in ip reparation” The alkaline lysis method [76] was used for 
DNA miniprep. Individual bacterial colonies were picked from agar plates us­
ing sterile plastic disposable pipette tips, placed (one colony/tube) into 30 ml 
sterile glass test-tubes containing 5 ml of LB/ampicillin and grown overnight 
with constant agitation to saturation at 37°C. Bacteria in 1.5 ml aliquots of 
these cultures were pelleted by centrifugation at 5,000 g for one minute. Su­
pernatant was removed and the bacterial pellet was resuspended in 200 fd  of 
ice-cold, 10 mM EDTA, pH 8.0. Bacteria were lysed by addition of 400 fd  of 
0.2 M NaOH, 1% SDS; protein was precipitated by addition of 225 fd  of 10 
M ammonium acetate. Following gentle mixing by inversion and subsequent 
flicking with the fingertips, tubes were centrifuged for five minutes at room 
tem perature at 8,000 g and the supernatant poured into fresh microcentrifuge 
tubes. DNA was precipitated by adding one volume isopropanol and centrifu­
gation for 10 minutes at 4°C. The resulting pellet was rinsed twice with 90% 
ethanol, air-dried and dissolved in 50-100 fd  TE containing 10 f ig /m l  RNase 
A which had been preboiled to inactivate DNase.
P lasm id  ” M axip rep aration ” Large-scale plasmid preparations were per­
formed using a kit (QIAfilter Plasmid Maxi System, QIAGEN). A single colony 
was picked from a freshly streaked selective plate and a starter culture of 25 
ml LB medium containing the appropriate selective antibiotic was inoculated 
for 8 h at 37°C with vigorous shaking (300 rpm). The starter culture was then 
diluted 1/500 to 1/1000 into selective LB medium. For high-copy plasmids 
100 ml medium were inoculated and grown at 37° C for 12-16 h with vigorous 
shaking (300 rpm) until the culture reached a cell density of approximately 
3-4 x 109. A flask or vessel with a volume of at least 4 times the volume of the 
culture was used. The bacterial cells were harvested by centrifugation at 6000 
x g for 15 min at 4°C. The bacterial pellet was resuspended in 10 ml Buffer P I
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(supplied). For efficient lysis a vessel large enough to allow complete mixing of 
the lysis buffers was used. RNase A has been added to Buffer P I. The bacte­
rial pellet was resuspended completely by vortexing or pipetting up and down 
until no cell clumps remain. 10 ml Buffer P2 (supplied) was added, mixed 
gently but thoroughly by inverting 4-6 times, and incubated at room tem ­
perature for 5 min. The suspension was not vortexed, as this would result in 
shearing of genomic DNA. During the incubation, the QIAfilter Cartridge was 
prepared: The cap was screwed onto the outlet nozzle of the QIAfilter Maxi 
Cartridge. The QIAfilter Cartridge was placed in a convenient tube. 10 ml 
chilled Buffer P3 (supplied) was added to the lysate, and mixed immediately 
but gently by inverting 4-6 times. Immediately after, the lysate was poured 
into the barrel of the QIAfilter Cartridge and incubated at room tem perature 
for 10 min. A QIAGEN-tip 500 was equilibrated by applying 10 ml Buffer 
QBT (supplied). The column was allowed to empty by gravity flow. The cap 
from the QIAfilter outlet nozzle was removed. The plunger was gently inserted 
into the QIAfilter Maxi Cartridge and the cell lysate was filtered into the pre­
viously equilibrated QIAGEN-tip. The cleared lysate was allowed to enter the 
resin by gravity flow. The QIAGEN-tip was washed with 2 x 30 ml Buffer 
QC (supplied). DNA was eluted with 15 ml Buffer QF (supplied). DNA was 
precipitated by adding 10.5 ml (0.7 volumes) room -tem perature isopropanol 
to the eluted DNA. The m ixture was centrifuged immediately at 15,000 x g 
for 30 min at 4°C. The supernatant was decanted carefully. DNA pellet was 
washed with 5 ml of room -tem perature 70% ethanol and centrifuged at 15,000 
x g for 10 min. The supernatant was decanted carefully without disturbing 
the pellet. The pellet was air-dried for 5-10 min, and the DNA was redissolved 
in a suitable volume of buffer (e.g., TE, pH 8.0, or 10 mM Tris-Cl, pH 8.5).
Q uantification  o f nucleic acid
DNA or RNA was quantified spectroscopically using the DU-640B Beckman 
spectrophotom eter. Sample absorption at 260 and 280 nm versus blank was 
measured and concentration determined using a predefined software. Purity  
of DNA/RNA was determined from A260/A 280 ratio which was ideally above 
1.8.
C H A P T E R  2. M A TE R IA L S  AND  METHODS 46
2 .1 .5  N u cle ic  acid m anipu lation
P h en o l/ch loro form  extraction
Protein and /or salts were removed from solutions of DNA by extraction with 
phenol and chloroform [76]. One volume of phenol (equilibrated to pH 7.5 
with 1M Tris, 0.2% /3-mercaptoethanol, 0.1% hydroxyquinoline) was added to 
the DNA solution and vortexed thoroughly. An equal volume of chloroform 
was added to the m ixture to enhance phase separation and the mix was then 
centrifuged at 8,000 g for 5 minutes. The upper aqueous phase containing 
the DNA was removed and care was taken to avoid contam ination with the 
proteinaceous interphase.
E than ol p recip itation  o f nucleic acid
DNA or RNA was precipitated by the addition of NaCl to 0.15 M and the sub­
sequent addition of 2.5 (for DNA) to 3 volumes (for RNA) of ethanol [76]. Pre­
cipitation was allowed to proceed at -20°C for 3-24 hours. When the amount 
or the size of nucleic acid to be precipitated was small, 1 0  fig linear polyacry­
lamide, or 100 /ig glycogen (Boehringer Mannheim) was added to the tube to 
facilitate precipitation; oligonucleotides were precipitated in the presence of 
10 mM MgCh to optimise recovery [76].
2 .1 .6  D N A  m odification
R estr ic tio n  en zym e d igestion
DNA was digested with restriction enzymes using conditions and buffers as 
suggested and supplied (Gibco BRL, Promega, Boehringer M annheim). Typ­
ically, 5-10 units of enzyme were used per microgram of DNA. Incubations 
were carried out for 1 hour at 37° C.
D ep hosp h ory la tion
Shrimp alkaline phosphatase (SAP) (U.S. Biochemicals) was used to remove 
the term inal 5’-phosphate group from DNA. Dephosphorylation was carried 
out for three hours in a reaction volume of 1 0 0  /d containing 1 x buffer, digested 
DNA and 5 units of enzyme. The reaction was term inated by heating to 65° C 
for 10  minutes.
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L igation
T4 DNA ligase (Boehringer Mannheim) was used to catalyse the formation of 
a phosphodiester bond between adjacent 3’-hydroxyl groups and 5’-phosphate 
term ini in DNA [77]. A typical 10 (A reaction containing 2mM ATP, 100-500 
ng DNA, 1 x buffer (Boehringer Mannheim ”L” buffer) and 3 units of enzyme 
was allowed to proceed overnight at 15-25°C. The reaction was term inated by 
heating to 72°C for 5-10 minutes.
2 .1 .7  D N A  agarose gel e lectrop h oresis
One to two percent agarose (SeaKem LE or FMC BioProducts) was prepared 
in 1 x TAE and dissolved by heating in a microwave oven; 0.1 /ug/ml ethidium  
bromide was added to both gel and running buffer to allow visualisation of 
the DNA under illumination with ultraviolet light at 254 nm. Gels were cast 
on m anufactured plates with teflon well combs. Gels were electrophoresed at 
70-100 V in 1 x TAE buffer containing 0.1 /ig/m l ethidium  bromide. Molecu­
lar weight markers (Hind  III /E c o R  I -  digested or Sau3A  I -  digested lam bda 
DNA, H at  III -  digested pBR322) were run alongside the samples. Gels were 
then photographed under ultraviolet illumination at 254 nm using Polaroid 
DS34 Direct Screen Instant camera and Polaroid 667 Land film. If neces­
sary, DNA was extracted from l x  TAE-agarose gels using Gel Extraction Kit 
(QIAGEN).
2 .1 .8  D N A  syn th esis
The cDNA encoding the extracellular domain of the leptin receptor was syn­
thesised by reverse transcription (RT) of mRNA using the cDNA Cycle® kit 
(Invitrogen) and amplification of cDNA using Taq/Pwo Polymerases Mix (Hy- 
baid) or Pfu DNA Polymerase (Stratagene). In the RT step, AMV Reverse 
Transcriptase (Invitrogen) was used, which catalyses the polymerisation of 
DNA using an RNA tem plate in the presence of MnCl2 . The ability of this 
polymerase to reverse transcribe at elevated tem peratures results in increased 
specificity of prim er hybridisation and extension and minimises problems en­
countered with strong RNA secondary structures since these are unstable at 
higher reaction tem peratures. DNA Polymerases used in the PCR step are 
therm ostable enzymes isolated from Thermus thermophilus, which catalyse 
the polymerisation of nucleotides into duplex DNA in the 5’-3’ direction in the 
presence of MgCl2 [78].
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Reactions were performed as outlined by the manufacturer. F irst-strand 
cDNA was synthesised from 8 yg  total RNA in 20 y l  to tal volume with ImM 
M nCl2, 0.2 mM each of dATP, dCTP, dTTP, dGTP, l x  RT buffer (supplied), 
15 pmol of RT (reverse) primer and 4-6 units of polymerase. The reaction was 
carried out in a thin-walled, 0.5 ml microcentrifuge tube at 70°C for 20 m in­
utes. The reverse transcription component of the reaction was then term inated 
by snap-cooling the tube on ice and adding chelate buffer (supplied) which con­
tained EGTA to remove the Mn2+. The reaction conditions within the tube 
were then modified to allow for DNA polymerisation; the reaction volume was 
increased to 100 y l  with DEPC-treated water and MgCl2 to 2.5mM and 15 
pmol of 5’ (upstream , forward) prim er were added. After gentle mixing, 40 y l  
of mineral oil were layered on top of the reaction mix to prevent evaporation 
during amplification. The tube was then subjected to cycled tem perature con­
ditions. After an initial denaturation step at 95°C for five minutes, the reaction 
was allowed to cycle 30 times through a sequence of tem peratures: 1) denatu­
ration of tem plate: 92°C, 1.5 minutes; 2) primer annealing at a tem perature 5 
to 10°C lower than denaturing tem perature (52-60°C), 1 minute; and 3) DNA 
polymerisation: 6 8 °C (Taq/Pwo Mix), 70°C (Pfu), 1 m inute / 1  kb of tem plate. 
A final elongation step at 68(70)°C for 10 minutes was also performed. Ten mi­
crolitre aliquots of the products of the reactions were size-separated by agarose 
gel electrophoresis. Ethidium  bromide-stained DNA products in the gels were 
visualised under ultraviolet irradiation.
2 .1 .9  T ransient tran sfection  (SuperF ect)
The following protocol was used for transfection of adherent mammalian cells 
in 100-mm dishes using SuperFect transfection reagent (QIAGEN). The day 
before transfection, 2  — 8  • 1 0 5 cells (depending on the cell type) were seeded 
per 100-mm dish in 5 ml of appropriate growth medium. The cell number 
seeded should produce 40-80 % confluence on the day of transfection. The 
cells were incubated at 37°C  and 5% C 0 2 in air in an incubator. 10  yg  of 
DNA dissolved in TE, pH 7.4 (minimum DNA concentration: 0.1 y g /y l )  were 
diluted with cell growth medium containing no serum, proteins, or antibiotics 
to a to tal volume of 300 yl. The solution was mixed and 60 y l  of SuperFect 
transfection reagent was added to the DNA solution. The solution was mixed 
by pipetting up and down 5 times, or by vortexing for 10 seconds. The samples 
were incubated for 5-10 min at room tem perature (20-25° C) to allow complex 
formation. While complex formation took place, the growth medium was
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gently aspirated from the dish, and cells were washed once with 4 ml PBS. 
The 3 ml of cell growth medium (containing serum and antibiotics) was added 
to the reaction tube containing the transfection complexes. This was then 
mixed by pipetting up and down twice and was immediately transferred to 
the cells in the 1 0 0 -mm dishes. At this stage serum and antibiotics no longer 
interfere with, but significantly enhance the transfection efficiency of SuperFect 
Reagent. Cells were incubated with the complexes for 2-3 h at 37°C and 5 % 
CO2 . Medium containing the remaining complexes was removed from the 
cells by gentle aspiration, and cells were washed once with 4 ml of PBS. Fresh 
cell growth medium containing serum and antibiotics was added. Cells were 
harvested 24-48 h after transfection.
2 .1 .1 0  T ransient tran sfection  (G en eP O R T E R )
The following protocol was used for transfection of adherent mammalian cells 
in 100-mm dishes using GenePORTER transfection reagent (TSE inc.). The 
day before transfection, the cells were plated on 1 0 0  mm plate so tha t they 
would be 60-90% confluent on the day of transfection3. 8-12 jig of the DNA was 
diluted with serum-free medium 4 to final 500 ml. The GenePORTER solution 
was vortexed. 40-60 fil of the GenePORTER were diluted with serum-free 
medium to final 500 ml. Both the DNA and the GenePORTER solutions were 
mixed well. The diluted DNA was added to the diluted GenePORTER reagent, 
mixed rapidly and incubated at room tem perature for 10-45 minutes. Further 
4 ml of serum-free medium were added to the DNA/GenePORTER mixture. 
The culture medium was aspirated from the cells, the DNA-GenePORTER 
m ixture was carefully added to the cells and incubated at 37°C for 3-5 hours. 
Then 5 ml of medium containing 20% serum was added. The incubation was 
continued overnight under 5-10% CO2 at 37°C. 24 hours post transfection, 
more fresh growth medium was added as needed5. The assay was done 24-72 
hours after the start of transfection depending on the cell type and prom oter 
activity.
3Omitting antibiotics from the media during transfection can increase expression levels. 
This effect is cell-type dependent and usually small.
4Although GenePORTER consistently delivers high transfection efficiencies in a wide 
range of cell types, to obtain maximum efficiency in particular cell lines some optimisation  
may be needed. The two critical variables are the GenePORTER/DNA ratio and the DNA  
quantity. To optimise these two variables, first determine the best GenePORTER/DNA  
ratio by using 3-9 ml of reagent for each 1 mg of DNA. Use a low DNA quantity to optimise 
this parameter. Once the optimal ratio is determined, vary the DNA quantity over the 
suggested range. At this point cell number can also be optimised.
5For some cell types the old media can be replaced with fresh media at this step.
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2 .1 .11  Transient tran sfection  (D E A E -D E X T R A N )
The following protocol was used for transfection of adherent m ammalian cells 
in 100-mm dishes using DEAE-DEXTRAN. 24 hours before transfection, the 
cells were plated on 100-mm plate so tha t they would be 60-90% confluent on 
the day of transfection. The DNA/DEAE-DEXTRAN solution was prepared 
by diluting DNA with 250 ji\ of TE to a final concentration of 0.1-4 /ig /m l and 
adding 200 fA of DEAE-DEXTRAN. The solution was left at room tem pera­
ture for 30 min. Then 5 ml of NU medium was mixed with 5 /A of 100 mM 
chloroquine and warmed to 37° C. Medium was removed from plates and 5 ml 
of warm NU medium was added to cells. Then the DNA/DEAE-DEXTRAN 
solution was added drop by drop. The plates were incubated at 37°C for up 
to 4 hours. NU medium was removed, 5 ml of 10% DMSO/1 xPBS was added 
and cells were incubated for 2 min. Medium was prom ptly removed, cells were 
washed once with lx P B S  and 5 ml of fresh medium was added. Cells were 
incubated overnight and transfer to a new plate, using trypsin, to remove all 
traces of DEAE-DEXTRAN. The assay was done 24-72 hours after the s tart 
of transfection depending on the cell type and promoter activity.
2 .1 .1 2  T ota l p rotein  quantification
The m ethod of Bradford [79] (BioRad Protein Assay Dye Reagent Concen­
tra te) was used to determine total protein concentrations. Bovine serum al­
bumin (BSA, Sigma) was used as standard protein for calibration; calibration 
curves from 1-15 fig BSA were performed alongside all protein determ ination 
experiments. Typically, 5 fA of protein sample were added to plastic, 2  ml 
cuvettes with 0 .8  ml of water. 0 .2  ml of dye reagent concentrate was then 
added and vortexed immediately. After a period of 5 minutes to 1 hour, 
sample absorbance at 595 nm was assessed (DU-67, Beckman) versus reagent 
blank. Blank reagent contained water and dye reagent only. Absorbance val­
ues from the BSA standards were plotted against total protein to obtain a 
standard curve. Linear regression analysis was performed to determine the 
best-fit equation and this line was used to determine protein concentrations 
in the experimental samples which exhibited absorbance readings within the 
linear range of the standard curve.
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2 .1 .1 3  P rep aration  o f  cellu lar m em brane fraction
Cells were grown on a 100 m m  dish. Medium was removed, cells were washed 
with l x  PBS and harvested. Cells were spun at 1000-1200 RPM  for 5 min 
and supernatant was removed. Cells were washed again with 1 x PBS and 
spun at 1000-1200 RPM for 5 min. The cell pellet was placed at — 80° C for 
at least 30 min. After thawing, 500-700 fi 1 of TE was added and cells were 
mechanically homogenised (3 x 20). This was followed by rehomogenisation 
(1 x 20 with 25GA 5/8 0.5 x 16 needle). Homogenised cells were placed in an 
eppendorf tube and spun at 1000-1200 RPM for 5-10 min. Supernatant 1 and 
Sediment 1 were collected. Sediment 1 was resuspended in 500-700 /il TE and 
rehomogenised. It was spun at 1000-1200 RPM for 5-10 min. Supernatant 2 
and Sediment 2 were collected. Supernatant 1 -f Supernatant 2 were then 
spun at 75,000 g for 30 min. The Supernatant and Sediment were collected. 
The Sediment (the membrane fraction) was resuspended in 300-400 fi 1 TE. 
Samples were aliquoted and stored at -80° C.
2 .1 .1 4  S D S -P A G E  analysis  
P reparing SD S-PA G E  gels
Glass plates were assembled according to the m anufacturer’s instructions.The 
appropriate volumes of solutions containing the desired concentration of acry- 
lamide for the resolving gels was prepared, using the values given in Table A .I. 
TEMED was added as the last one. Components were vigorously mixed and 
without delay, the m ixture was swirled rapidly and poured into the gap be­
tween the glass plates. The acrylamide solution was carefully overlaid with 
0.1 % SDS solution (for gels containing <  8  %) or isobutanol (for gels contain­
ing > 10 % acrylamide). After polymerisation was completed (30 minutes), 
the overlay was poured off and the top of the gel was washed several times 
with deionised water to remove any unpolymerised acrylamide. Any rem ain­
ing water was removed with the edge of a paper towel. The stacking gel was 
prepared as follows. In a disposable plastic tube, the appropriate volume of so­
lution containing the desired concentration of acrylamide was prepared, using 
the values given in Table A.2. TEMED was added as the last one. Com­
ponents were vigorously mixed and without delay, the m ixture was swirled 
rapidly and the stacking gel solution was poured directly on to the surface of 
the polymerised resolving gel. A clean Teflon comb was immediately inserted 
into the stacking gel solution, being careful to avoid trapping air bubbles.
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While the stacking gel was polymerising, samples were prepared by heating 
them  to 100°C for three minutes in l x  SDS-gel-loading buffer (BIO RAD) to 
denature the proteins. After polymerisation was completed (30 m inutes), the 
Teflon comb was removed carefully. The gel was mounted in the electrophore­
sis apparatus. Tris-glycine electrophoresis buffer, Table A.3, was added to the 
top and bottom  reservoirs. Up to 100 fA of each of the samples was loaded 
in a predeterm ined order into the bottom  of the wells. The gel unit was run 
overnight at 45-50 V according to acrylamide concentration.
2 .1 .1 5  S ta in ing  S D S-P A G E  gels w ith  B rilliant B lu e
After electrophoresis, proteins were fixed for one hour in a solution of 7 % 
glacial acetic acid in 40 % (v/v) methanol, Table A.4. Four parts of 1 x working 
solution of Brilliant Blue G-Cofloidal Concentrate (SIGMA) were mixed with 
one part of methanol prior to staining. This solution was mixed for 30 seconds 
and the gel was then placed in this staining suspension for 1-2 hours. It was 
followed by destaining with 10% acetic acid in 25 % (v/v) methanol, Table A.5, 
for 60 seconds with shaking. The gel was rinsed with 25 % methanol, and then 
destained in 25 % methanol for up to 24 hours. Gels were stored for several 
months in water containing 2 0  % glycerol.
2 .1 .1 6  P ro te in  transfer
After the protein samples were separated using gel electrophoresis, the resolv­
ing gel was rinsed in the protein transfer buffer. A sheet of Hybond ECL 
membrane was prepared, pre-wetted in distilled water and then equilibrated 
in the protein transfer buffer, Table A.3, for at least 10 min. The protein 
transfer from the gel to the membrane was carried out for 4-5 h (300-250 mA) 
or overnight (40 mA). The membrane was air dried and either stored (between 
sheets of 3MM paper wrapped in SaranWrap at 2 — 8 °C  for up to 3 months) 
or used for Western Blotting.
2 .1 .1 7  W estern  b lo ttin g
To minimise nonspecific binding, the membrane was immersed in 5% (w/v) 
blocking reagent (non-fat dried milk) in TBS-T or PBS-T for one hour at room 
tem perature on an orbital shaker. The membrane was then briefly rinsed using 
two changes of washing buffer (TBS-T or PBS-T). It was then washed once for 
15 min and twice for 5 min at room tem perature (4 ml of buffer per cm2). The
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membrane was then incubated in diluted prim ary antibody for 1 hour at room 
tem perature, followed by a brief rinse using two changes of washing buffer. It 
was then washed once for 15 min and twice for 5 min at room tem perature. 
The membrane was then incubated in diluted secondary antibody for 1 hour 
at room tem perature and washed again. To perform ECL detection, equal 
volumes of detection solution 1 and solution 2  were mixed to give a sufficient 
amount of liquid to cover the membrane (0.125 m l/cm 2). The excess of wash 
buffer was drained from the washed blots and the blots were placed with the 
protein side uppermost on a sheet of SaranWrap spread over the bench. The 
prepared ECL detection reagent was added directly to the side carrying the 
protein and incubated for 1 min. An excess of detection reagent was drained 
off and the blot was placed, protein side down, onto a fresh piece of Saran 
Wrap. The Saran Wrap was folded over the back of the blots to form an 
envelope. The blots were placed, protein side up, in the film cassette. In the 
dark room, a sheet of autoradiography film was put on top of the blots and 
exposed for 1 min. The film was developed. If required, a second exposure 
was performed for an appropriate length of time.
2 .1 .1 8  E. coli exp ression
Screening transform ants for FLAG  fusion proteins
Individual colonies were inoculated into 5 ml LB containing 50 /ig /m l ampi- 
cillin and 0.4 % glucose and incubated overnight at 37°C. Overnight cultures 
were diluted 1:1000 into 5 ml prewarmed LB containing 50 /ig /m l ampicillin 
and 0.4 % glucose in a 125 ml flask to ensure good aeration and incubated with 
shaking at 37°C. At OD6oo of 0 .2 , a volume of 0.5 ml of pre-induction culture 
was removed to a microfuge tube. Cells were pelleted in a microcentrifuge, 
resuspended in 25 ^1 of SDS-PAGE sample buffer (BIO-RAD), heated to 95°C 
for 5 min and stored frozen. IPTG was added to the remaining culture to final 
0.5 mM concentration. At 2 , 4, and 6 hours post-induction, a 0.5 ml aliquot 
of culture was removed. Cells were pelleted in a microcentrifuge, resuspended 
in 25 n  1 of SDS-PAGE sample buffer (BIO-RAD), heated to 95°C for 5 min 
and stored frozen. Protein expression levels were determined by analysis of 
pre- and post-induction samples by SDS-PAGE and Western blot.
A n alysis o f expression  o f FLA G  fusion protein
Individual colonies were inoculated into 5 ml LB containing 50 /ig /m l am pi­
cillin and 0.4 % glucose and incubated overnight at 37°C. Overnight cultures
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were diluted 1:1000 into 5 ml prewarmed LB containing 50 /ig /m l ampicillin 
and 0.4 % glucose in a 125 ml flask to insure good aeration and incubated with 
shaking at 37°C. At ODeoo of 0 .2 , IPTG was added to final 0.5 mM concen­
tration and grown at 37°C for a previously optimised tim e (4 hours). A 0.5 ml 
aliquot of culture was removed. Cells were pelleted in a microcentrifuge, re- 
suspended in 25 jA of SDS-PAGE sample buffer (BIO-RAD), heated to 95°C 
for 5 min and this whole cell sample was stored frozen. The remaining culture 
was divided into two aliquots and each aliquot was centrifuged at 5,000 x g 
for 10 min at 10°C to pellet the cells. The first pellet was used to determ ine 
the presence of the FLAG fusion protein in the periplasm space by the osmotic 
shock procedure. This sample pellet was not frozen to prevent whole-cell lysis. 
The second pellet was used to determine the presence of the FLAG fusion 
protein in the soluble and insoluble fractions of the whole cell extract. The 
pellet was stored frozen until needed.
P erip lasm ic fraction  by osm otic  shock
The unfrozen pellet was warmed to room tem perature and resuspended in 
40 jj, 1 of 0.5 M sucrose, 0.03 M Tris, 1 mM EDTA at a final pH of 8.0 per 
gram of cells. The sample was then centrifuged at 3,500 x g for 10 min at 
10°C for osmotic shock. The supernatant was decanted and the pellet rapidly 
resuspended in 25 m l/g  cell pellet ice-cold, distilled water. The m ixture was 
then centrifuged at 3,500 x g for 10  min at 4°C. Supernatant was collected 
immediately. 50 fA of supernatant were mixed with 50 fi 1 SDS-PAGE sample 
buffer (BIO-RAD) and heated to 95°C for 5 min. The periplasmic fraction 
was stored frozen until ready for electrophoresis.
W h ole  cell extract: soluble and insoluble fractions
The whole cell sample was thawed at room tem perature. 5 ml of Extraction  
Buffer  A, section A.4, was added. The sample was incubated at room tem ­
perature for 5 min or until cells were lysed. 0.5 ml of Extraction Buffer B , 
section A.4, was added and the m ixture was incubated at room tem perature 
for 5 min or until no longer viscous. The m ixture was then centrifuged at 
18,000 x g for 0.5 hour. Supernatant, containing the soluble, whole cell frac­
tion, was collected. 50 /A of supernatant were mixed with 50 jA of SDS-PAGE 
sample buffer (BIO-RAD), heated to 95°C for 5 min and stored frozen. Pellet 
containing insoluble, whole cell m aterial, was resuspended in 5 ml of Extraction  
Buffer A, Sec. A.4. 50 ^1 of supernatant were mixed with 50 fA of SDS-PAGE
CH A P T E R  2. M A T E R IA L S  AND  METHODS 55
sample buffer (BIO-RAD), heated to 95°C for 5 min and stored frozen. 
P rep arative  iso lation  o f FLAG  fusion proteins
FLAG fusion proteins were isolated by the osmotic-shock method. Cells were 
grown according to optimised growth and induction conditions, then harvested 
by centrifugation at 5,000 x g for 10  min at 10°C. Cells were resuspended in 
10 mM Tris-HCl (pH 8.0) diluted from a 0.1 mM stock with room tem pera­
ture distilled water. 40-80 m l/g  cells were used. The m ixture was centrifuged 
at 3,500 x g for 10  min at 1 0 °C. Supernatant was decanted and the pellet 
resuspended in 0.5 M sucrose, 0.03 M Tris-HCl (pH 8.0), 1 mM EDTA at 
room tem perature. 40 m l/g  cells were used. Cells were centrifuged at 3,500 
x g for 1 0  min at 1 0 °C. Supernatant was decanted and the cell pellet rapidly 
resuspended in 25-35 ml ice-cold distilled w ater/gram  of cell pellet. The m ix­
ture was centrifuged at 3,500 x g for 1 0  min at 4°C and supernatant collected 
immediately. An equal volume of 2  x concentrated TBS (pH 7.4) was added 
to the supernatant. CaCl2 was added to a final concentration of 1 mM. The 
m ixture was centrifuged at 25,000 x g for 60 min at 4°C and supernatant 
collected immediately. Supernatant was filtered through W hatm an No 1 filter 
paper and applied to the ANTI-FLAG M2  Affinity Gel.
A ffin ity  purification of FLAG  fusion proteins
P rep aration  o f th e  colum n The empty chromatography column was placed 
on a firm support. The top and bottom  tab were removed and the column 
was rinsed twice with TBS. Buffer was allowed to drain from the column and 
residual TBS was left in the column to aid in packing the anti-FLAG M2 affin­
ity gel in the next step. The vial of anti-FLAG M2 affinity gel was thoroughly 
suspended to make a homogenous slurry of the gel beads. The slurry was 
immediately transferred to the column. The gel bed was allowed to drain and 
the vial was rinsed with TBS. The rinse was added to the column and allowed 
to drain again.
W ashing th e  colum n The gel was washed by loading three sequential 5 ml 
aliquots of 0.1 M Glycine-HCl (pH 3.5), followed by three sequential 5 ml 
aliquots of TBS, avoiding a disturbance of the gel bed while loading. Each 
aliquot was allowed to drain completely before adding the next.
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B in d in g  FLAG  fusion proteins to  th e  colum n The sample was loaded 
onto the column under gravity flow. The column was filled completely several 
times for larger volumes. Depending upon the protein and flow rate, all of the 
antigen may not bind. Multiple passes over the column improved the binding 
efficiency. The column was washed three times with 1 2  ml aliquots of TBS.
E lu tion  o f FLAG  fusion proteins The bound FLAG fusion protein was 
eluted from the column with 6  x 1 ml aliquots of 0.1 M Glycine at pH 3.5 
into vials containing 15 - 25 fA of 1 M Tris base at pH 8.0.
2.2 Surface p lasm on resonance
BiaCore biosensor B I A c o r e ™  2000, CM5 research grade biosensor chips, N- 
hydroxysuccinimide (NHS), ethanolamine-HCl, HBS-EP buffer (10 mM Hepes, 
pH 7.4, 150 mM sodium chloride and 0.005% Tween 20) and N-ethyl-N’-(3- 
diethylaminopropyl)carbodiimide (EDC) were obtained from BiaCore AB (Up­
psala, Sweden). Protein G (IgG Fc Receptor Type III) and anti-hum an Fc 
specific antibody were purchased from Sigma. Recombinant human and mouse 
leptin receptor-Fc chimera as well as recombinant human, mouse and ra t leptin 
were obtained from R & D Systems.
To prepare the biosensor assay, the capturing protein G or anti-hum an Fc 
specific antibody was immobilised onto a research-grade carboxymethyl dex- 
tran  chip (CM5) using the amine-coupling procedure described previously [80]. 
The surface was activated with NHS/EDC for 5 min. Protein G (antibody) 
was injected at a concentration of 200 f ig /m l  in sodium acetate buffer (10 mM, 
pH 4.0) until 2000 resonance units (RUs) of protein were coupled. Remaining 
activated groups were blocked with a 5-min injection of 1 M ethanolamine (pH 
8.5).
For kinetic experiments the recombinant human or mouse leptin receptor- 
Fc chimera was captured onto the protein G (antibody) surface by injecting 
typically a 10 fil of a 50 f ig /m l  solution. After 1800 s equilibrium tim e a 100 fil 
leptin or buffer sample was injected. The leptin concentration was typically 
at 0.1 - 30 nM range. The dissociation phase was then monitored for 400 
s, followed by two 5 fil injections of 10 mM glycine pH 2.0 to regenerate a 
fully active protein G (antibody) surface. All kinetic experiments were done 
at 25°C in a buffer containing 10 mM Hepes, pH 7.4, 150 mM sodium chloride 
and 0.005% Tween 20, at a flow rate of 30 f i l /m in .  In control experiments,
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Protein G (antibody) was used instead of the leptin receptor-Fc chimera to 
evaluate leptin nonspecific binding.
C hapter 3 
R esu lts
3.1 C loning o f th e  extracellu lar dom ain o f th e  
lep tin  receptor
Investigation of the interaction between the leptin receptor (OBR) and its 
ligand was started by the construction of an effective expression system for 
receptor production.
The receptor was originally cloned from the human brain cDNA library [38]. 
However, the cloned cDNA was not initially made available to the scientific 
community. It was, therefore, necessary to construct the receptor from the 
published sequence. The clone encoding the extracellular domain of the recep­
tor was made using human embryo kidney (HEK) cell line instead. The cDNA 
was ligated to an expression vector and this part of the project was finished 
by expression of a recombinant protein.
3.1 .1  Iso la tion  o f  th e  cD N A
The desired cDNA, encoding the extracellular domain of the receptor, was 
generated by means of the reverse transcription polymerase chain reaction 
(RT-PCR). To provide high quality RNA for a synthesis of the first strand 
cDNA in the RT step, HEK cells were grown and total RNA extracted using 
the acid phenol extraction method [76]. The quality of RNA was tested by gel
electrophoresis,^Fig. 3.1. Three intensive bands represent intact 28S and 18S )
ribosomal RNA and 5S transfer RNA. Because these RNA molecules have not 
been degraded by RNAses, messenger RNAs should also be intact and suitable 
for a synthesis of the first strand cDNA. In addition, a background “sm ear” , 
extended over large molecular weights and representing mRNA species, was 
observed. This smear again indicated a lack of degradation.
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Figure 3.1: Total RNA extracted from the HEK cells. Three intensive bands 
correspond to the ribosomal 28s and 18s RNA and transfer 5s RN A.The back­
ground smear represents messenger RNA species of different length.
The next step was to design primers for the synthesis of the cDNA. The 
efficiency of the synthesis of the first-strand (a length of a synthesised product) 
is proportional to the purity of the mRNA used. However, only to ta l RNA 
(not pure mRNA) was available. Thus, it looked very unlikely tha t the whole 
molecule (2.7 kb) could be generated at once. It was therefore decided to 
synthesise its two halves separately and to reconstitute the entire molecule 
afterwards by fragment ligation through a unique internal Xho  1 site located 
in the middle of the cDNA encoding predicted extracellular domain, Eig. 3.2.
Two forward primers were used to generate these fragments. The first one, 
F I ,  should generate the cDNA encoding the first half of the O BR extracellular 
domain. It contains an artificial Hind  III restriction site at the 5 ’ end for 
consequent cloning into an expression vector. The second primer, F2, flanks 
the unique internal Xho  I site, which is located in the middle of the sequence, 
and should generate the cDNA encoding the second half of the extracellular 
domain.
Each of these forward primers was paired with the R3 and R4 reverse 
primers, respectively, Fig. 3.3. The R3 primer comprised the reverse comple­
ment of the sequence downstream of the unique Xho  I site. The R4 prim er 
was the reverse complement of sequence at the 3’ end of extracellular domain 
and contained a B a m H I site to facilitate subcloning. Using these two primer








H indlll Xhol Xhol
Figure 3.2: Two forward primers used in the RT reaction. ^Extracellular do­
main is in white, transm em brane is dotted and intracellular striped.
FI primer F3 primer F2 primer F4 primer
i| 1 "1 1 "1 " 1  n| I
Hind\ 11 Hca\ Hca\ Xho\ Xho\ Hha\ Hha\
-4— < — -4—
R1 primer R3 primer
^  PCR
R2 primer R4 primer
ll 1 "1 1 "I ' " | li| I1
Hind 111 Hca\ Hca\ Xho\ Xho\ Hha\ Hha1 BamH\
Figure 3.3: Forward and reverse primers used in PCR reaction.
pairs, no PC R  products were obtained. This could be a result of the inabil­
ity of Reverse Transcriptase to generate long fragments (1.3 kb) from a rare 
mRNA molecule. Therefore, it was decided to use four forward primers and 
reconstruct the molecule from four fragments (700 bp long),^Fig. 3.4)
In addition to F I and F2 primers two additional forward primers were de­
signed, Table 3.1. F3, containing an internal Rea I site, and F4, containing an 
internal Hha I site. The reverse primers used in sequential PCR reactions were: 
R1 with the Rea I site, R2 with the Hha I site, R3 with the Xho  I site and R4
containing the artificial B a m H I site for a subsequent subcloning,/Fig. 3.3) In
V ' .these experiments, the TAQ/PW O polymerase (Hybaid) with a proof-reading 
activity was used to overcome fidelity problems. This time, products of the 
expected length were generated as revealed by gel electrophoresis, (Fig. 3.5\
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FI prim er F3 prim er F2 prim er F4 prim er
H ind lll Real Xhol H hal
\
RT
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Figure 3.4: Four forward primers used in the RT reaction. 




F3 755 G CAGTG TTCATG A ATGTTGTGA ATG TCTTGTG CC





M 1 2 3 4 5
Figure 3.5: Results of RT-PCR reaction using four primers. Lane M, molecular 
weight marker, Lane /, FI and R1 primers used, Lane 2, F3 and R3 primers 
used, Lane 3, F2 and R2 primers used, Lane 4 , F4 and R4 primers used, Lane 
5, positive control. '





























Figure 3.6: Cloning of PCR products. All four product were cloned to the 
pGEM -T Easy vector. A, The pGEM-T Easy vector used. A single de- 
oxythymidine overhangs in its 3’-ends and multiple cloning sites are depicted. 
B, Resulting construct.
3 .1 .2  C on stru ction  o f  recep tor clone
All four PCR products were ligated to the pGEM-T Easy Vector (Promega) to 
facilitate their subsequent handling. The pGEM-T Easy vector is designed for 
easy ligation of the PCR products with single deoxyadenosine overhang in their 
3’-ends, Fig. 3.6. However, the TAQ/PW O polymerase generates blunt ends. 
Therefore, a post-reaction incubation with the Taq polymerase (Promega) was 
performed to convert the blunt ends to A-tailed ones. By this approach the 
advantage of proof reading was combined with ease of ligation.
The next step in the original plan called here for the digest of the cloned 
PC R  products with appropriate restriction enzymes to ligate them  together. A 
product generated with FI and R1 primers (the “F l+ R l” product) should be 
linked to the “F3+R 3” product (generated with F3 and R3 primers) through 
the shared Rea I site and the “F2+R 2” product (primers F2 and R2 used) to 
the “F4+R 4” product (primers F4 and R4 used) through the shared Hha I site. 
However digests revealed tha t extra restriction sites were present in the pGEM-
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T Easy vector. The vector contains two BspH  I restriction sites. BspH  I is the 
Rea I isojthizomer and hence Rea I also cuts these sites, F i^  3.6) Moreover, 
another 7 copies of the Hha I sites are present in the vector. This means th a t 
a simple digest with Rea I or Hha I can not be used.
To link the “F l+ R l” and “F3+R 3” products together, a m ethod of partial 
digest was used. The partial digest is based on the inability of a restriction 
enzyme in limiting amounts to cut all sites. 5 restriction enzyme samples with 
decreasing concentration were prepared: 1:1,1:3, 1:9,1:27, 1:54. Both 1:27 and 
1:54 dilutions cut the clone only once,(^Fig. 3.7.^The linearised “F l+ R l” and 
“F3+R 3” products were ligated together^Fig. 3.7)
This direct ligation resulted in a m ixture of different constructs. Because 
there are three copies of the Rea I site in each cDNA/pGEM  construct, the 
Rea I partial digest generated three different linear p ieces^ig . 3.7 )^ Random 
ligation of two partial digest products generated 9 different potential con­
structs. The ligation product corresponding to the sequence of the first half of 
the OBR extracellular domain was separated from others by means of PCR. 
By using the F I forward and R3 reverse primers, only the correctly ligated 
product could be amplified, (jj'ig. 3.7.) A band of the appropriate molecular 
length was obtained and this was then ligated to the pcDNA3.1+ vector (In- 
vitrogen)Mhg. 3 .8^The ligation was verified by a restriction digest with Xho  I 
and Hind  IlI,^Fig. 3.9.^
The same strategy, the partial digest, could not be used for the reconstruc­
tion of the second half. The “F 2 + R 2 ” and “F4+R 4” PCR products should 
be ligated through Hha I site. However, the pGEM-T Easy vector contains 
more then 7 copies of the Hha I site. This high copy number made the use of 
partial digest infeasible.
It was therefore decided to ligate the PCR products “F2+R 2” and “F4+R 4” 
directly. Both PCR products were digested with Hha I, purified and ligated 
together, ^Fig.(3.l(jj. The ligation result was again amplified by PCR using the 
forward F2 and reverse R4 primers. The complete second half of the OBR 
extracellular domain was then ligated to the pGEM -T Easy vector, Fig. 3.10A 
To reconstitute the entire extracellular domain, the sequence encoding the 
second half of the receptor extracellular domain was extracted from the pGEM- 
T Easy vector and inserted into the pcDNA 3.1+ vector containing the first 
half of the extracellular domain. This was achieved by parallel digest of both 
plasmids with Xho  I and Apa  I, l+ig. 3.1lj The products were purified and 
ligated together. A restriction digest of the product with Hind  III and Bam H  I
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FI prim er
 1----------1-------- ii -  i - " C-------- 1----------1--
BspHI  BspHI Hi n d l l l  Real  x h o I  BspH[  BspHI
R3 p rim er 
PCR
H in d lll  Xhol
Figure 3.7: The construction of the first half of the receptor extracellular do­
main from the cloned ’’F l + R l ” and ’’F 3 + R 3 ” fragments. A, Three different 
products generated by a plasmid digestion with Rea I in partial digest. B, An 
electrophoresis analysis of digest results. Lane M, molecular weight marker, 
Lanes 1, 2, 3, all three Rea I sites on a single plasmid were cut. Lanes Jh 5, 
only one Rea I site was cut (3.7 kbp). Lanes 6 - 10, same as lanes 1 - 5  but 
the cloned ”F 3 + R 3 ” fragment used. C, Linearised full length fragments were 
ligated together. The desired construct was separated from others in PCR 
reaction using FI and R3 primers. D, An electrophoresis analysis of PCR 
reaction. Lane M, molecular weight marker, Lane 1, the first half of the O b-R 
extracellular domain (residues 1 - 1300).
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pcI)NA3.1 (+/-)
5.4 kb
Figure 3.8: The pcD N A3.1(+) vector.
H i n d  III
L i g a t i o n  p r o d u c t
1300bp
1 . 0  —
Figure 3.9: The ligation of the first half of the OBR extracellular domain to the 
pcD N A 3.1+ vector. A, An illustration of the construct. Restriction sites used 
are depicted. B, An electrophoresis analysis of the ligation result. Lane M, 
molecular weight marker, Lane 1, linearised plasmid digested with Xho  I. Lane  
2, plasmid cut with Xho  I and Hind  III. The insert (1.3 kb, enhanced visibility) 
is released from the vector (5.4 bp). Lane 3, Supercoiled (undigested) plasmid.
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Figure 3.10: The construction of the second half of the receptor extracellular 
domain from the ”F2 +  R2” and the ”F4 +  R4V fragments. A, Both fragments 
were digested with Hha I and subsequently ligated together. B, An analysis 
of a ligation product amplified by PCR. Lane M , molecular weight marker, 
Line 1, PCR amplified fragment (1.3 kb). Lane 2,3 , positive controls. C, The 
second half of the OBR extracellular domain ligated into the pGEM-T Easy 
vector.















Figure 3.11: The reconstruction of the Ob-R extracellular domain. A, Both 
cloned fragments were digested with Xho  I and Apa I. Reaction products were 
then ligated together. B, An electrophoresis analysis of the ligation result. 
Lane M, molecular weight marker, Line 7, the receptor extracellular domain 
(2.6 kbp) released from the pcDNA 3.1(+) vector (5.4 kbp) by a digest with 
Hind  III and B a m H I. Lane 2, undigested plasmid.
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Figure 3.12: Sequence of the 6 xHis-FLAG oligonucleotide.
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Figure 3.13: A schematic cartoon of the 0I3R-H-F plasmid. The sequence 
encoding the extracellular domain of the leptin receptor with a 6 xHIS-TAG 
flag in its C-terminus is cloned between the Hind  III and Not I sites in the 
polvlinker of the pcDNA3.1+ vector. This plasmid was constructed from the 
OBR-GPI plasmid by replacing the GPI sequence with the 6 xHIS-TAG flag.
confirmed that the ligation was successful. Fig. 3.11.
Paradoxically, following successful reconstitution of the extracellular do­
main coding region from the 4 fragments, a repeat a ttem pt to synthesise the 
entire extracellular domain in one run was now successful. This was clone by 
using a freshly prepared sample of total RNA from HEK cells which was used 
as a tem plate in the RT-PCR reaction with the FI and R 1 primers. A product 
of desired length was obtained. This blunt ended PCR product was ligated to 
the pT7 Blue vector from The Perfectly Blunt Cloning Kit (Novagen). The 
pT7 Blue vector was very beneficial for cloning of the product, but this vector 
is not designed for expression, so, it was necessary to transfer the PCR prod­
uct to a mammalian expression vector. The pcDNA3.1-f- vector was chosen 
again and the insert was ligated through the Hind  III and B a m H I sites. This 
new construct, 0bR/pcDNA3.1 +  , encoded the complete open reading frame 
(ORF) of the Ob-R extracellular domain, residues M e l\ -A s p 83y. For easier 
manipulation with the recombinant product, the 6 xHis-FLAG tag, Fig. 3.12,. 
was inserted into its C terminus via Bam H  I and Not I sites, (Fig. 3.13.
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Table 3.2: Primers used in the sequencing of the OBR extracellular 
domain.
Name Start Tm(° C) Length GC content (%)
T7 T7 promoter 53.7 2 0 55.0
SF 1 374 66.5 21 52.3
SF2 896 51.7 2 0 50.0
SF3 1394 51.7 2 0 50.0
SF4 1911 47.9 18 50.0
BGH BGH poly A 50.2 18 55.6
SRI 1980 51.7 2 0 50.0
SR2 1520 47.9 18 50.0
SR3 1 0 2 0 47.9 18 50
SR4 510 47.9 18 50
Table 3.3: M utations in the clone of the Ob-R extracellular domain
Position Residue Amino acid change
504 T T A  ->CTA L-*L
1283 GAA-+GGA E ^ G
1312 TTA-^CTA L-*L
1365 AGT-^AGC S->S
1586 T C T ^ T C C S ^ S
1598 G T C ^ G T T v-*v
3 .1 .3 S ite-specific  m u tagen esis
To sequence both constructs, five forward and five reverse primers were de­
signed to cover the whole region,/ Table 3.2. The sequencing reactions were 
performed externally by the Cambridge Bioscience company. Results were 
compared with the Gene Bank sequence of the receptor, U43168, by means 
of the Gene Jockey software. A preliminary analysis of the first clone, con­
structed from four PCR fragments, revealed tha t extensive use of PC R  during 
its generation introduced several point mutations. However, in the second con­
struct only one change in codoif was identified in the entire sequence. This was 
a change of nucleotide at position 1238 from A to G resulting in a predicted 
change of amino acid from E428 to G. Five other silent m utations were also 
present, ^Table 3.3j. It was thus decided to correct the single m utation in the 
second construct and use this construct for protein expression.
The U.S.E. Mutagenesis kit (Pharm acia Biotech) was used to correct the 
A.1283 Q point m utation. This method of site-specific mutagenesis employs 
the unique site elimination (U.S.E.) procedure [81],^Fig. 3.14. This is based on 
fact that circular plasmid DNA is more efficient in transforming bacteria then
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linear DNA. Here, a two-primer system is utilised to generate site-specific m u­
tations. One primer, designated the target mutagenic primer MP1, introduces 
the desired m utation into a known sequence of the plasmid DNA. A second 
prim er, the SEM selection primer, eliminates a unique non-essential restric­
tion site in the plasmid, which subsequently serves as the basis for selection 
of m utated plasmids. Since both primers anneal to the same strand of the 
denatured double-stranded plasmid, it is possible to synthesise a new strand 
of DNA containing both mutations.
The target mutagenic prim er M P1 was designed so tha t it introduced the 
desired m utation as well as a new unique restriction site BstZ17  I |  Fig. 3.15.^) 
This new restriction site could be used for a rapid analysis of mutagenesis prod­
ucts. The SEM selection prim er was chosen to replace a unique non-essential 
restriction site Pst I with the Sac II site. Pst I is present in the pcDNA3.1 +  
plasmid in two copies. However, it is unique in the ObR-H-F/pcDNA3.1 +  
plasmid because one site, located in the pcDNA3.1+ polylinker, was removed 
during the subcloning of the ObR-H-F insert. The second copy of thePsf I 
site is in the nonutilised Neomycin gene.
The ObR-II-F/pcDNA3.1-|- plasmid contains two B s t Z l l  I sites at posi­
tions 1901 and 5834 bp (the total length of the plasmid is 8024). A successful 
mutagenesis reaction should introduce both a reversal of the m utation G —> A  
and an addition of another BstZ17  I site at the position 2194. M utated and 
parental plasmids should be easily distinguishable in a digest with Not  I6 and 
B s tZ \7  I . The digest of parental plasmid should generate 3 fragments (1675, 
2258, 4096 bp) whereas four fragments of length 334, 1341, 2258 and 4096 bp 
should be produced from m utated plasmid. Thus, an appearance of a 1341 bp 
fragment instead of the 1675 bp fragment in the pattern  of digested products 
is a proof of successful mutation,^Fig 3.16.)
This corrected version of the cDNA encoding the receptor extracellular do­
main was used for generation of several variants, (Table 3.4j In the ObR-GPI 
plasmid, Fig. 3.17, the 6 xHis-FLAG tag was replaced with the GPI anchor [82] 
through Bam H  I and Not I sites. This plasmid encoded a version of the recep­
tor where the extracellular domain is anchored to the membrane through a gly- 
cosyl phosphatidyl inositol anchor (GPI) through post translational processing 
of the nascent protein [82]. Cell surface expressed protein can be cleaved from 
its anchor by the enzyme PIPLC to release Ob-R into the cell supernatant [82]. 
The anchored protein mimics the wild-type receptor which is anchored in the
6In the O bR-H -F/pcDNA3.1+ plasmid there is one copy of N ot  I site at position 3575.
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Figure 3.14: Site-specific mutagenesis, based on the unique site elimination
(U.S.E.) procedure [81]. A two-primer system is utilised to generate site-
specific mutations. One primer, designated the target mutagenic prim er M P 1 , 
introduces the desired m utation into a known sequence of the plasmid DNA. 
A second primer, the SEM selection primer, eliminates a unique non-essential 
restriction site in the plasmid, which subsequently serves as the basis for se­
lection of m utated plasmids. Since both primers anneal to the same strand 
of the denatured double-stranded plasmid, it is possible to synthesise a new 
strand of DNA containing both mutations.
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A.
P st  I 
T A
CCTGAATGA^ CCGCGGjGACGAGGCAG 
S a c  li
B.
GC A GTATAC TG CTG C A AT G A AC AT G A AT G CC
Bst Z M  I
Figure 3.15: Sequence of the U.S.E. primers. A., the SEM selection primer 
replaces a unique non-essential restriction site Pst  I with the Sac II site. B., the 
target mutagenic primer M P 1 designed to introduce the desired m utation(*) 
together with a new B s tZ17 I site.
cell membrane through its transm em brane domain. In the KOZAK plasmid, 
^ ig .  3.18) the flanking region of the Ob-R starting codon was replaced by 
vthe Kozak consensus translation initiation sequence [83], CCAACCATGG, to 
maximise the efficiency of translation. In the KOZ-H-GPI plasmid,, Fig. 3.19, \ 
the 6 xHis-FLAG tag was replaced by 2x6His-GPI sequence. This modifica­
tion should again result in anchoring of the protein into the membrane surface. 
Furthermore, GxHis could be used for purification of a recombinant protein 
after its easy cleavage from the membrane using PIPLC [82].
3 .1 .4  Short form  o f  th e  recep tor
It is im portant to mention tha t at this stage when these several DNA con­
structs were generated we received a clone of the wild-type receptor (the short 
form, [84]) from Dr de Sauvage (Genentech Inc.). In this construct, the OBR 
open reading frame was inserted to the pRK5tkneo vector via/BaraH I site. To 
make the manipulation of the clone easier, it was released from the pRK5tkneo 
vector by a restriction digest with B am H  I and ligated into the pcDNA3.1 +  
vector. A clone in correct orientation relative to plasmid was selected by re­
striction digest with Xba I, (Fig. 3.20y. One Xba I site is in the insert, 6 bp 
downstream from the 5’ Bam H  I. The second one is in the vector, 62 bp down­
stream  from the 3’ B a m H I site. Thus, the digest of the plasmid with Xba I
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Figure 3.16: The analysis of the mutagenic reaction by restriction digest. Plas­
mids were digested with Not I +  B s t Z l l  I. This digest should generate 3 frag­
ments (1675, 2258, 4096 bp) from a parental plasmid or four fragments (334, 
1341, 2258 and 4096 bp) from m utated plasmid. Samples 1 and 3 represent 
mu t at ed p 1 asm ids.
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Table 3.4: Different constructs encoding the extracellular domain of Ob-R
Plasmid Features
OBR-H-F Sequence of extracellular domain of Ob-R
with 6 xHis-FLAG tag in C-terminus
ObR-GPI Sequence of extracellular domain of Ob-R
with a GPI anchor in C-terminus
KOZAK Sequence of extracellular domain of Ob-R
with the Kozak consensus translation 
initiation sequence and 6 xHis-FLAG tag 
in C-terminus
KOZHGPI Sequence of extracellular domain of Ob-R 
with the Kozak consensus translation 
initiation sequence and 6 xHis tag and GPI 
anchor in C-terminus





Figure 3.17: A schematic cartoon of the OBR-GPI plasmid. The sequence 
encoding the extracellular domain of the leptin receptor with a GPI anchor in 
its C-terminus is cloned between the Hind  III and Not I sites in the polylinker 
of the pcDNA3.1+ vector.








Figure 3.18: A schematic cartoon of the KOZAK plasmid. The sequence en­
coding the extracellular domain of the leptin receptor linked in its C-terminus 
to the 6 xHis-FLAG tag is cloned between the Nhe  I and Not  I sites in the 
polylinker of the pcDNA3.1+ vector. In this construct, the flanking region of 
the starting codon was replaced with the Kozak consensus translation initia­







Figure 3.19: A schematic cartoon of the KOZ-H-GPI plasmid. The sequence 
encoding the extracellular domain of the leptin receptor with two copies of 
the 6 xHis tag and GPI anchor in its C-terminus is cloned between the Nhe  I 
and Not I sites in the polylinker of the pcDNA3.1-f- vector. The clone has 
the Kozak consensus translation initiation sequence [83], CCAACCATGG, to 
maximise the efficiency of translation.
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should release 3794 bp fragment (when the clone has correct orientation).
To enhance translation, the consensus Kozak sequence was introduced to 
the clone. This was done by PCR. Here, the forward primer, called FNHEI, 
was used which introduced an Nhe I site and the consensus Kozak sequence at 
the beginning of the sequence. The reverse primer, called H R 1 , introduced the 
B am H  I site at the end of the nucleotides encoding the extracellular domain. 
This construct was sequenced.
Sequencing reactions were carried out by The C.M.H.T, University of Le­
icester. The whole OBR extracellular domain was sequenced using supple­
m entary primers (Table 3.2). The consensus sequence was generated from 
sequencing fragments using Fragment Assembly System (FAS) from GCG pro­
gramme package. The FAS is a series of programs designed to assemble the 
overlapping fragment sequences from a sequencing project. A generation of 
consensus sequence from individual fragments is shown in Fig. 3.21.
The consensus sequence was aligned with the hOBR cDNA (Gene Bank 
accession U43168) using the programme LINEUP from the GCG package. 
Mismatches between the consensus and tem plate sequences were identified at 
following positions: 4, 1956, 1957, 2323, 2367, 2484, where position 1 corre­
sponded to A of the initiation codon, methionine. Because a correct residue 
was present in at least one fragment in all except two positions (4 and 2514), 
it was decided tha t these mismatches are due to incorrect gel reading and tha t 
the analysed and the GeneBank sequences are identical also at these positions. 
The mismatches at positions 4 and 2514 result from the introduction of the 
consensus Kozak sequence (position 4) and an artificial restriction site B a m H I 
(position 2514). Thus, the obtained clone truly encodes the extracellular do­
main of the OBR (the GeneBank sequence U43168).
3.2 E xpression  o f th e  receptor clone
3 .2 .1  M am m alian  exp ression  o f  th e  lep tin  recep tor
After successful cloning, the expression work was started. The plan was to 
express the recombinant protein first in the mammalian expression system, 
COS cells, and then in the Baculovirus (BV) expression system. The ratio­
nale for this is that the m ammalian expression system is easier to setup and 
the recombinant protein should have the same post-translation modifications 
as the authentic protein in the native environment. The disadvantage of the 
mammalian system is the relatively low level of recombinant protein expres-





Figure 3.20: The clone of the short form of the hOb-R. M, molecular weight 
ladder; 1, the plasmid digested with Xba I ; 2, undigested plasmid.
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Figure 3.21: An alignment of sequencing fragments generated by the FAS.
sion. Expression in COS cells should produce enough protein for the BiaCore 
experiments as it requires only micrograms of protein. However, much more 
protein is necessary for microcalorimetry and other biophysical techniques such 
as analytical centrifugation. Typically milligrams of protein are required for 
these, and could be obtained by employing the Baculovirus (BV) expression 
system which results in very high expression levels. Unfortunately, this system 
has one crucial disadvantage over mammalian systems. In the BV system, fast 
production may overwhelm the ability of the cell to modify the protein prod­
uct. Thus, although most of the post-translational modifications occur in the 
BV system, and the sites where these modifications happen are often identical 
to those of the authentic protein in its native cellular environment, the levels 
of glycosylation or phosphorylation are often lower. Thus, comparison of the 
BV and mammalian products in BiaCore experiments would be very useful 
for a validation of the BV system for the Ob-R expression.
The expression work was started with in vitro analysis of translation prod­
ucts generated from constructed plasmids. Their size was evaluated in in vitro 
translation experiments using the TNT Coupled Reticulocyte Lysate System 
(Promega). This system couples in vitro RNA synthesis from T7 RNA poly­
merase promoter with rabbit reticulocyte lysate translation. In this way, the 
T nT  System generates a translation product from any insert ligated to a vec­
tor bearing T7 promoter such as the pcDNA3.1+ vector. Taking advantage of 
the 35 S' incorporation, translation products can be evaluated directly by the 
f a-C’ radiography of the SDS-PAGE results.
The SDS-PAGE analysis of T nT  products from different Ob-R clones7 is 
shown in Fig 3.22. Lane 1 represents the short form of the wild-type receptor; 
lane 2 is ObR-H-F; lane 3 is Kozak-H-GPI; lane 4 is KOZAK; lane 5 is ObR-
7T h e  co n s tru c ted  clones are su m m arised  in T ab le  3.4.
u
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GPI; lane 6  is uncorrected ObR-H-F and lane 7 is Luciferase, positive control. 
A negative control was not included in this particular experiment, but it had 
been performed previously and the results showed that in the absence of DNA 
tem plate, the T nT  system does not generate any detectable protein.
All Ob-R products migrate as 80-100 kDa proteins. This is in agreement 
with the predicted molecular weight of the short form of the Ob-R which 
should be 102.5 kDa as calculated from its prim ary sequence (U50748) using 
the Peptidesort programme from the GCG package. The extracellular domain 
alone (residues 1 - 839) has a predicted size of 96 kDa. Small variation in 
position of bands is due to different C-terminus in these constructs. The sim­
ilar length of the wild-type (896 residues) and recombinant proteins suggests 
th a t the constructed plasmids encode the whole extracellular domain as was 
previously confirmed by sequencing.
The next step was expression of these clones in mammalian system. COS, 
CHO and HEK cells were transfected with target plasmids using DEAE- 
DEXTRAN, Transfectin (Qiagen) and GenePORTER (TSE inc.) transfection 
reagents. Unfortunately, the level of expression was very low in all these sys­
tems. The only product obtained was from COS cells transfected with a clone 
of the wild-type receptor using the GenePORTER reagent,j^Fig. 3.23C This 
product had a size of £sl20 kDa. The difference in size compared to in vitro 
expression is likely due to glycosylation [85].
3 .2 .2  B acu lovirus exp ression  o f  th e  lep tin  recep tor
Because the level of the Ob-R expression in mammalian systems was so low 
it was not possible to make enough protein for BiaCore experiments. It was 
decided, therefore, to switch to Baculovirus expression and concentrate only 
on this system. The Baculovirus expression system is one of the most powerful 
eukaryotic systems available. It is a helper-independent viral system which has 
been used to express heterologous genes from many different sources in insect 
cells. Since the Baculovirus genome is too large to easily insert foreign genes, 
heterologous genes are cloned into a transfer vector. Co-transfection of the 
transfer vector, bearing the gene of interest, and the Autographa californica 
nuclear polyhedrosis virus (AcNPV) DNA into Spodoptera frugiperda (Sf )  cells 
allows recombination between homologous sites, transferring the target gene 
to the viral genome.
It was decided to use the Bac-N-Blue™  system (Invitrogen). This virus 
has a functional lacZ gene and produces blue plaques which are easily purified.
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Figure 3.22: The SDS-PAGE analysis of in vitro translation products from 
different Ob-R clones. Lane 1 represent the wild-type receptor, the short 
form; Lane 2 is ObR-H-F; Lane 3 is Kozak-H-GPI; Lane 4 is KOZAK; Lane 5 
ObR-GPI; Lane 6 is uncorrected ObR-H-F and Lane 7 is Luciferase, a positive 
control.
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Figure 3.23: The SDS-PAGE analyses of the wilcl-type receptor expression in 
different m am m alian systems. HEK, COS, and CHO cells were used. Cell 
lysate samples from transfected (T) and nontransfected (N) cells were com­
pared. The G enePORTER transfection reagent was used in these experi­
ments. Western analysis: Blots were probed with anti-Leptin Receptor an­
tibody (R & D Systems)( 1:1000 dilution) in a combination with the IiR P  
conjugated anti-goat, antibody (Sigma) (1:5000 dilution) and visualised using 
ECL.
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HBM Signa l  6 x H i s  FLAG
Figure 3.24: The Baculovirus transfer vector encoding the Ob-R extracellular 
domain. The original leading sequence was replaced by the honeybee m elit tin  
(IIBM) sequence to facilitate protein secretion to medium. In the C-terminus, 
6xIIis-FLA G  tag was added for easy purification.
Baculovirus infection of S f  cells results in the shut-off of host gene expression 
allowing for a high rate of recombinant mRNA and protein production. Re­
combinant proteins can be produced at high levels reaching 50 % of the total 
insect cell protein.
The pMelBac baculovirus transfer vector (Invitrogen) was chosen for cloning 
of the Ob-R extracellular domain. The pMelBac vector is designed for di­
rect secretion of recombinant protein into the extracellular medium. This 
is achieved by using the honeybee melittin signal sequence which has been 
found to drive high protein expression as well as very efficient secretion to the 
medium [86]. This vector exists in three copies: A, B and C [87]. The version 
B was used because it had the most useful polylinker.
The construction of the Ob-R transfer vector required transfer of the  se­
quence of the Ob-R extracellular domain from the pcDNA3.1-f- vector to the 
pMelBac vector, downstream and in-frame with its starting Met, Fig. 3.24. 
To achieve this, it was decided to introduce a Sac I site directly before As­
paragine at position 23 ( N 23) of the Ob-R sequence. In this way the original 
signal peptide of Ob-R would be replaced by the honeybee m elittin  one. The 
honeybee m elittin sequence is cleaved after protein secretion. Because the 
residues 1-22 of Ob-R are cleaved after transport of the authentic  protein to 
the cell membrane, the BY recombinant protein should have a very similar N- 
term inal sequence with its authentic counterpart. The only difference would 
be due to a introduction of the Sac I site. However, this would introduce a 
minim um  number of new residues because the Sac I site is the second site in 
the pMelBac multiple cloning site. The first one, the B a m H I site, could not 
be used because it is also present in the clone.
The pcDNA3.1+ and pMelBac polylinkers do not share a restriction site 
downstream of the Ob-R insert, which could be used as a second site for clone 
transfer. However, Sal I and Xho  I restriction enzymes produce com patible
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ends. There is a Sal I site in the pMelBac polylinker which lies at the extrem e 
3’ end of the linker. There is an Xho  I site present in the pcDNA3.1 +  polylinker 
and this site lies 3’ to the Not  I site which was used as a second site for insertion 
of the Ob-R clone to the vector. The only disadvantage of the Xho  I site is 
th a t a second site exists in the Ob-R clone as there is also an internal X ho  I 
site in the Ob-R sequence. Thus, Xho  I can be used only in a partial digest 
of the 0bR/pcDNA3.1-|- plasmid.
The procedure for the construction of the ObR/pM elBac plasmid is de­
picted in Fig.3.25. It was started with a modification of the N-terminus of 
the clone for its in-frame insertion to the pMelBac vector. The Sac I site was 
introduced in front of the N 23 by PCR. New primers were designed. The for­
ward prim er introduces the Sac I site in front of the N 23. The reverse prim er 
contains the unique EcoR I site, some 800bp downstream of the methionine 
s tart codon.
The Pfu  Polymerase (Stratagene) was used in the PC R  reaction. This 
is a proofreading DNA polymerase, isolated from Pyrococcus furiosus , which 
exhibits the lowest error rate of any therm ostable DNA polymerases com­
mercially available. The polymerase is supplied with two buffers, Native and 
Native Plus. The Native Plus buffer produces higher product yields for certain 
amplificationj^while m aintaining high fidelity. Both buffers were tested.
This variation in reaction conditions was further multiplied by varying the 
dNTP concentration. Because high dNTP concentration leads to the greatest 
product yield while specificity and fidelity is highest at low dNTP concentra­
tions, both high (1 mM) and low (0.4 mM) concentrations were used. The 
results of the PCR reaction are shown in Fig. 3.26.
From the intensity of the bands it is clear that the yield of product did 
not significantly differ in the various reaction conditions. Because the highest 
fidelity should be obtained for low dNTP concentration, the product No. 1 
was used for subsequent ligation to the pMelBac vector. The purified PC R  
product as well as the vector were digested with the Sac I and EcoR I and 
ligated together. The ligation product was analysed by restriction digest. 
Because there is no common buffer in which Sac I and EcoR I enzymes work 
effectively, other enzymes were used instead: B am H  I , in front of the Sac I, 
and Hind  III following EcoR  I in the pMelBac polylinker^Fig 3.27 \
To reconstruct the entire extracellular domain of the receptor, the second 
part of the clone from the O bR/pcDNA3.1+ (sequence tha t lies 3’ to EcoR I 
site) was released and inserted into the newly created plasmid,(Fig. 3.25 )^ To
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Sac I Eco RI
pMelBac
Sal I
H  h - h -
Sac I Eco RI
pMelBac
BamH I
I !l ~ A
Sac I Bam HI Not I
pMelBac
Figure 3.25: Cartoon representing a protocol for a construction of Baculovirus 
transfer vector encoding the Ob-R extracellular domain. A, A generation of 
the first part of the clone. The PCR product was ligated to the pMelBac 
vector through Sac I and EcoR I sites; B, The second part was released by a 
partial digest of a plasmid with Xho  I followed by a digest with EcoR I. The 
product was inserted to the plasmid generated in step A.
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M 1 2 3 4 5
1.0 -
0 .5 -
Figure 3.26: PCR of the first part of the clone done to introduce the Sac I site 
a t N 23 of Ob-R. M, molecular weight ladder; 1; Native Buffer, 0.4 mM dN TP; 
2; Native Buffer, 1.0 mM dN TP; Plus Buffer, 0.4 mM dN TP; Plus Buffer, 1.0 
m M  dN TP; 5, positive control
5 .0 -
1.0 -  
0 .5 -
Figure 3.27: The restriction digest analysis of a ligation of the first half of the  
Ob-R clone to the pMelBac vector. M, molecular weight ladder, 1, undigested 
plasmid; 2, plasmid digested with Hind  III and Bam H  1 .
M 1 2
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0 . 5 -
Figure 3.28: The partia l digest of the 0bR /pcD N A 3.1  +  with Xho  I. A serial 
dilution of the enzyme was used in 1. - 5. reactions. The digest was performed 
for 15 m in at 37°. Reaction products were then digested with EcoR I. Because 
Xho  I cuts the plasmid at 2211 arid 3582 positions and EcoR I at 1834 position, 
when only the second Xho  I site is cut in the partial digest, the subsequent 
digest with EcoR  I should release a 1748 bp product. This product is obtained 
in reaction 2. The total Xho  I digest released a 1371 bp product.
do this the appropriate fragment between the EcoR I and the second Xho  I site 
in the O bR /pcD N A 3.1+  plasmid was obtained by first performing a partia l 
Xho  I digest of the ObR/pcDNA3.1 +  plasmid. The reaction product was then 
digested with the EcoR  I , Fig. 3.28.
A purified product of appropriate size was ligated to the pMelBac vector 
containing the first part of the extracellular domain, Fig. 3.25. This was 
digested with the EcoR I and Sal I. The Sal I enzyme produces ends compatible 
with Xho  I. Therefore, the fragment of Ob-R released with the EcoR I and 
Xho  1 could be inserted to the plasmid digested with the EcoR  I and Sal I. 
The Sal I site is lost in this process.
The ligcition product was analysed by restriction enzyme digest with several 
different enzymes, Fig. 3.29. The first digest was with B a m H I. Two B a m H I 
sites should be present in the final construct; one in the polylinker in the 
front of the insert (cut position 158) and the second inside the insert (position 
2618). Thus, a digest with the BamW  I should release a fragment of 2460 bp 
as observed in Fig. 3.29a.
The second digest was with EcoR  I and Not I to provide further evidence 
for successful cloning, particularly to show tha t the second of the two original 
Xho  I sites was cut in the partial digest. In the correct construct, the EcoR I




5 _  
3 -  
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2 .0 -  
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Figure 3.29: The restriction digest of the O bR /pM elB ac plasmid. A, The 
B a m H 1 digest. The Bam H  1 site should be present in two copies in the final 
construct. One is in the polylinker in the front of the insert (cut position 158) 
and the second is inside the insert (position 2618). M, molecular weight ladder;
1, a digest with the B a m H I released a 2460bp long fragment; 2, undigested 
plasmid; B, The EcoR I and Not I digest. M, molecular weight ladder; 1, the 
digested plasmid released a insert of correct size: 1742 bp. The EcoR I site 
cut at 929 bp position while the Xho  1 at 2671. 2, undigested plasmid.
site should be cut at 929 bp position while the Xho  I at 2671. The EcoR I 
+  Not I digest should release a fragment of 1742 bp. The digest released this 
fragment, Fig 3.29b. These results suggests th a t  the ligation procedure was 
successful.
The region between the Sac I and EcoR I sites was sequenced. Four se­
quencing reactions with two forward and two reverse primers, which cover this 
region,/JFig. 3.30, were performed by the C.M.I4.T, University of Leicester. /  
The consensus sequence was generated from the obtained sequences using the 
Fragment Assembly System (FAS) from the GCG programme package. The 
derived consensus sequence was compared with the tem plate, designed using 
the SeqEd programme (GCG package) from the Ob-R (U50748) and pMelBac 
sequences, using the Bestfit programm e (GCG package). It revealed 100% 
identity  of the cloned sequence and the template. This result confirmed th a t  
no m utations were introduced by PCR.
The constructed transfer vector was sent to Invitrogen. A recombinant 
baculovirus encoding the Ob-R extracellular domain with the 6xH is-FL A G  
tag in its C terminus was generated by a co-transfection of the transfer vector 
with the Bac-N-Blue7 u DNA into 5/21 cells. Four clones of the ObR-pMelBac
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construct were purified. The DNA purified from a viral stock of each clone 
was analysed by PCR (data not shown). A PCR product of approximately 3.2 
kb, corresponding to 2.8 kb of the insert, and 0.316 kb of the pMelBac vector, 
indicated tha t these are recombinants containing the desired gene.
In Glasgow, the clones were analysed for protein expression by W estern 
Blot (data not shown) and the best one was returned to Invitrogen for the 
generation of a high tite r stock. The high titer stock was completed to a tite r 
of 3.1 xlO 8 pfu/m l.
A tim e course of protein expression was carried out (Invitrogen). The 
250 ml of High Five™ cells used for the tim e course were grown to a density 
of 2 .0 -2 .5 xlO 6 cells/m l in a spinner flask. A 1.5 ml baseline sample, 0 hr, was 
removed. The content of the spinner flask was then infected with the 8.9 ml 
of the high titer stock generated previously. Samples were then taken at 24 
hour intervals up to 96 hours. Each time point sample was separated into cell 
pellet and cell supernatant by centrifugation for 4 min at 2,500 rpm.
Both supernatant and cell pellets were analysed for protein expression 
(Glasgow) by Western Blot. D ata from the analysis of the supernatants indi­
cated, tha t the recombinant protein is expressed and effectively secreted into 
the medium 72 hours post-infection/Fig. 3.3Ij
5 SR 3




4 0 0  8 0 0  1 2 0 0  1 6 0 0
Figure 3.30: Determination of the ObR/pM elBac sequence. The consensus 
sequence was generated from the sequencing results using the Fragment As­
sembly System (FAS) from the GCG programme package.
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Figure 3.31: Time course study of Ob-R expression in High Five™ cells. 1 , 0 hr 
post-infection sample; 2 , 24 hr; 3, 48 hr; 4, 72 hr, 5, 96 hr. In the Western blot 
analysis, anti-leptin receptor antibody (R&D Systems) (1:1,000 dilution) was 
used in a combination with the HRP conjugated anti-goat antibody (SIGMA) 
(1:5,000 dilution) in ECL detection.
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Ob-R ObR - Fc
Figure 3.32: Leptin receptor chimera (ObR-Fc) used in the BiaCore experi­
ments. Idie chimera consists of two extracellular domains of the receptor fused 
to the Fc region of IgG \.  The chimeric receptor used mimics the dimerised 
leptin receptor expressed on the cell surface.
3.3 BiaCore analysis of Ob-ObR interaction
The leptin - leptin receptor interaction was studied using recombinant human, 
mouse and rat leptin and recombinant human and mouse receptor chimeras 
(ObR-Fc). These chimeras consist of two extracellular domains of the recep­
tor fused to the Fc region of I g G The chimeric receptors used mimic the 
dimerised leptin receptor expressed on the cell surface, Fig. 3.32. The possibil­
ity that the leptin receptor exists as a dimer has been proposed recently [71]. 
This contradicts the common model of cytokine receptor activation, in which 
a ligand-free receptor exists as a monomer and its dimerisation is introduced 
by the ligand binding, Fig 1.11.
3.3.1 R eal-tim e B IA  tech n o logy
The interaction between leptin and its receptor was studied using the biosensor 
BIAcore™ 2000 from Pharm acia. BIAcore™ 2000 is a fully autom ated flow­
cell instrument based on the Biomolecular Interaction Analysis (BIA) system. 
This system exploits the optical phenomenon of surface plasmon resonance 
(SPR) to monitor biomolecular interactions, Fig. 3.33.
SPR arises in thin metal films under conditions of total internal reflection.
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Microfluidic cartrid g e
Figure 3.33: BiaCore detection system. The optical system and flow cell in 
the BiaCore analytical instrum ent. The figure taken from the BIAtechnology 
Handbook [88].
The phenomenon produces a sharp dip in the intensity of reflected light at 
a specific angle, the resonance angle. The position of this refractive angle 
depends partly  on the refractive index of the m edium  close to the metal film. 
The refractive index of the m edium  is directly correlated to the concentration 
of dissolved material. Thus, SPR is used in BIA to measure changes in the 
surface layer of solution in contact with the sensor surface. This information is 
then processed to obtain the molecular concentration in the medium close to 
the m etal film. This concentration determines the mass bound to the surface 
and thus formation of the molecular complex in real time.
In real-time monitoring, continuous-flow technology is used to measure 
chip-bound molecular mass during the course of interaction. The experimental- 
geometry of the system is as follows. One interactant is immobilised on the 
sensor surface, which forms one wall of a micro-flow cell. Solution containing 
the other in teractant flows continuously over the sensor surface. As molecules 
from the solution bind to the immobilised interactant, the resonance angle 
changes and a response is registered.
Results from real-time BIA are presented in the form of a sensorgrarn. 
The sensorgrarn is a plot of the resonance-signal change as a function of time, 
Fig. 3.34. The signal change is marked in arbitrary  resonance units (RU). 
Kinetic da ta  are extracted from the rate of the signal change.
The BiaCore has several advantages over other techniques, the most im­
portan t being real-time monitoring and label-free detection. The real-time






Figure 3.34: BiaCore sensorgrarn. During association phase, analyte is exposed 
to the chip and binding is monitored. If the reactions proceed long enough, 
equilibrium may be achieved. W hen the chip is washed with buffer, dissocia­
tion phase , the dissociation of the analyte-ligand complex is monitored. The 
chip can be reused after regeneration with mild acid or base.
monitoring of interaction is the ideal way to obtain kinetic data. The absence 
of a need to label molecules results in minimal interference with the interaction 
being studied. A problem of the interaction alteration due to  the immobilisation 
of one of the interactants onto the chip is routinely eliminated by a coupling 
the interactant on the chip surface via a monoclonal antibody with a binding 
site different from tha t involved in the interaction/Section 3.3.3.\
3 .3 .2  Sensor chip
The m etal film on the sensor chip is essential for generation of an SPR sig­
nal ^3.35  ^ Gold is used in real-tim e BIA because it gives an SPR signal at a 
convenient combination of reflectance angle and light wavelength, and is also 
chemically inert to solvents and solutes typically used in biochemical contexts.
The gold film on the sensor chip is covered with a surface m atrix (cova­
lently attached through an inert linker layer) on which biomolecules may be 
immobilised using well-defined chemistry. The sensor chip, CM5, has a m a­
trix  consisting of carboxym ethylated dextran, which provides an environment 
suitable for studies of biomolecular interactions and enhances the interactant- 
immobilisation capacity of the surface.





Figure 3.35: Sensor chip. The surface of Sensor Chip CM5 consists of three 
layers: glass, a th in  gold film, and a m atrix  layer. The m atrix  is bonded 
to the  gold film through an inert linker layer. The figure taken from the 
BIAtechnology Handbook [88].
3.3 .3  Ligand im m obilisation
In BiaCore experiments one molecule (ligand) is immobilised on the sensor 
surface, while the other (analyte) is injected in continuous flow over the sur­
face. The ligand can be coupled to the surface either directly or indirectly 
by capturing via immobilised antibody. Direct coupling creates a stable sur­
face. However, coupling procedures, such as primary amine coupling [80], can 
introduce heterogeneity in the surface bound molecule.
Alternatively, capturing methods e.g. using monoclonal antibodies [89] or 
nickel chelating surfaces [90, 91] orient molecules on the surface, thus minimis­
ing the effects of surface heterogeneity. Unfortunately, the capture step does 
not always create a stable complex with the first molecule which artificially 
increases the complexity of the binding responses for the second molecule [92].
A capturing assay shown in Fig. 3.36 was used for receptor immobilisation. 
Leptin receptor was captured on the chip surface via one of two molecules: 
Protein G or anti human (Fc specific) antibody, which were covalently linked 
to the  chip surface by amine coupling using reactive esters.
Amine coupling introduces N-hydroxysuccinimide esters into the surface 
m atrix  by modification of the carboxymethyl groups with a m ixture  of N- 
hydroxysuccinimide (NHS) and N-ethyl-N,-(dimethyl-aminopropyl)- carbodi- 
imide (EDC). These esters then react spontaneously with amines and other
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nucleophilic groups on the ligand to form covalent links [80].
The desired amount of the capturing molecule (2000 RU of Protein G or 
7000 RU of anti-hum an antibody) was amino-coupled to all four cells of the 
chip. An im portant feature of the capturing molecule is the stability of its 
binding capacity for ligand over a large number of repeated experiments. For 
each experim ental cycle the ObR-Fc is first captured on the surface via the 
capturing molecule Protein G or anti-human antibody. Leptin is then injected 
over the surface. At the end of the experiment ObR-Fc and leptin are removed 
during surface regeneration. Good regeneration of the surface is im portant 
because residual surface-bound residues after each regeneration would affect 
the subsequent analyte response.
A 1 min pulse of glycine pH 2.0 was used to regenerate the surface. It effec­
tively disrupted interaction between the ObR-Fc and the capturing molecule.
However, repeated use of glycine pH 2.0 might lead to degradation of the 
capturing molecule. We monitored Protein G as well as the anti-hum an an­
tibody degradation by measuring an amount of ObR-Fc bound in repeated 
experim ents^Fig. 3.37, 3.38^ It was clear from the comparison tha t Protein ( ^
G created a much more stable surface than anti-human antibody, so, we used 
Protein G in subsequent experiments.
3 .3 .4  M ass tran sport
We continued with an evaluation of mass transport. Mass transport refers to 
the transport of analyte from bulk solution Objiow to the chip surface Obsurj .
This can be described by the following equation
k k
ObJlow ^  Obsurf +  ObR  ^  Ob : ObR
kd
Mass transport can significantly affect binding if the interaction between 
analyte and ligand is much faster than the transport of analyte from bulk 
solution to the surface. For a given analyte, there are two factors affecting 
mass transport: the flow rate and the concentration of surface binding sites.
The flow rate affects the mass transport rate constant km but has no effect on 
the interaction kinetics. Increasing the flow rate increases km, but this effect 
is relatively low. On the other hand, the concentration of surface binding 
sites affects the absolute interaction rate but has no effect on mass transport.
This is the more im portant param eter because increasing the surface binding 
capacity increases the initial interaction rate, so tha t mass transport is more 
likely to be limiting.
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To minimise mass transport, it is im portant to keep surface binding capac­
ity as low as possible. Immobilisation levels of 50-250 RU are recommended. 
Mass transport can be ignored if the initial binding rate does not increase 
more than  5-10 % when the flow rate is raised from 15 to 75 fi 1/min.
To verify whether or not the leptin-leptin receptor interaction was mass- 
transport limited, a control experiment was carried out. 180 RU of the ObR-Fc 
was immobilised. The flow rate was changed from 15 to 100 fi 1/min and the 
binding rate was monitored for an initial 100 s,(Fig. 3.39.) Because no increase 
was observed, mass transport was treated as not limiting and not considered 
in data  analysis.





S e n so r
Figure 3.36: Schematic of the biosensor capturing assay. The ObR-Fc was 
captured onto the chip surface via protein G, which was covalently bound to 
the dextran m atrix of the chip. In this configuration a homogenous receptor 
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3 .3 .5  E xp erim en ta l design
To measure leptin-leptin receptor interaction, an active surface was created on 
flow cells 2, 3 and 4 by immobilising the receptor chimera (human or mouse). 
The flow cell 1 was used as a control surface to measure leptin nonspecific 
binding. In this case Protein G alone was used instead of ObR-Fc.
In a typical experiment, 50-3000 RU of one of the two receptor chimeras 
was immobilised on flow cells 2 , 3 and 4. After equilibrating for 100 s, leptin 
injection was passed over all four flow cells and leptin binding to active (Fc 
2, 3 and 4) and control (Fc 1 ) surfaces was measured. This procedure was 
repeated several times with different leptin concentrations.
Examples of collected binding data are shown in Fig. 3.40. The higher 
traces show an overlay of six repeated leptin JO. 1 - 30 nM) or buffer alone 
(0 nM) injections on to an active surface (Fc(2),. The lower traces represent 
control experiments in which leptin from the same injection passed over a 
control cell (Fc 1). The rapid rise in signal at the start of each injection is due 
to the difference in bulk refractive index of the injection and running buffer, as 
well as instrum ent noise. It is followed by a slow increase representing leptin 
binding to the chip surface.
Generation of good quality data for kinetic analysis was achieved classi­
cally as follows. To remove contributions of non-specific binding and refractive 
index, the control responses from Fc 1 were subtracted from binding data  ob­
tained from active cells (Fc 2, 3 and 4). Results are shown in Fig. 3.41. A 
minor baseline drift was observed as shown in Fig 3.42A. This was a disadvan­
tage of the capturing method used. Using Protein G to capture the ObR-Fc 
resulted in the correct orientation of the receptor relative to the chip and the 
analyte thereby minimising surface heterogeneity. On the other hand, the com­
plex between the ObR-Fc and the Protein G slowly dissociated. This could be 
corrected by subtraction of a bulk injection (0 nM) from (0.1-30 nM) binding 
data, Fig. 3.42B.
First, the compatibility of flow cells was analysed. For initial chip-activation, 
the predefined BiaCore application wizard, Immobilisation, was used to link 
2000 RU of Protein G covalently on to all four flow cells. The final values of 
1505, 1117, 1593 and 1606 RU on flow cells 1 , 2 , 3, and 4, respectively, were 
obtained. This difference in Protein G levels on different cells raised a question 
of their compatibility. This problem was investigated by injecting the same 
amount of the human ObR-Fc ( 1 2  jA  of 0.5 /ig/m l solution) on each of the 
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Figure 3.39: Mass transport evaluation. The flow rate was changed from 15 to 
1 0 0  i i l / m i n  and the binding rate was monitored for initial 1 0 0  s.
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Cell k j  1 0 6 kd/ 1 0 - 4 X2
2 1.26 4.05 0 .1 1 0
1.53 3.92 0.103
1.47 4.74 0.106
3 1.58 2.78 0.097
1.61 3.56 0.0843
1 .6 8 4.23 0.0864
4 1.42 3.56 0.0931
1.43 4.19 0.0901
1.42 4.37 0.0969
Table 3.5: Flow cells compatibility; k a and kd are the association and dissoci­
ation rate  constants, x 2 describes the closeness of fit.
cessed as described above and fitted to the 1:1 Langmuir model. The derived 
values for &aand kd are summarised in Table 3.5. They clearly dem onstrate 
tha t despite different levels of hObR-Fc immobilised on individual cells, the 
reaction kinetics are very similar.
To obtain binding data for all possible combinations of human and mouse 
ObR-Fc and human, mouse and rat Ob a simple macro for controlling the 
BiaCore instrum ent was w ritten, Appendix C. An execution of this macro 
performed the following tasks in three subsequent repeats. All four cells were 
first regenerated with two injections of a 1 min pulse of glycine pH 2.0. The 
hObR-Fc was then immobilised on Fc 3 (12 y \  of 0.5 ^g /m l , 3 yul/min) and 
the m ObR-Fc on Fc 2 (5 jA of 0.5 ^zg/ml, 3 ^1/min) and Fc 4 (10 fil of 0.5 
/ig/m l, 3 /A /m m ) .  Different injection volumes for mObR-Fc were used to 
compare data from surfaces with different immobilisation levels Ri. After 180 
s of equilibration, a 100 /i\ of Ob was injected (20 (A /m m )  and the binding 
was monitored. Thus, performing one such macro on the BiaCore instrum ent 
generated 3 sets of data for leptin (human, mouse or rat) binding to human 
leptin receptor and 6  sets of data for mouse leptin receptor (one cell used for h 
ObR-Fc and two for mObR-Fc). Performing the described macro three times 
with different leptin molecules generated data for all possible combinations of 
Ob and Ob-R molecules available. This macro with small modifications was 
used in all experiments.
3 .3 .6  D a ta  analysis
Association and dissociation phases of all corrected sensorgrams (0.1 - 30 nM) 
from one data set were simultaneously fitted to a predefined 1 :1  binding model
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from the BIAevaluation 3.1 software. This is a simple model for 1 :1  interaction 
between analyte and immobilised ligand, which is equivalent to the Langmuir 
isotherm  for adsorption to surface. Experim ental data were fitted to the model 
by means of non-linear regression analysis. Equation B.5 was used for fitting 
the association phase of a single sensorgrarn while equation B.7 was exploited 
for fitting of the dissociation phase.
Association and dissociation rate constants ka, kd, and the analyte m axi­
m um  binding capacity R max were determined as fitting param eters. The rate 
constants ka and kd were fitted globally to all six sensorgrams. R max was fitted 
locally for each sensorgrarn. Local fitting of R max was used to reflect possible 
minor differences due to ObR-Fc dissociation from the Protein G complex.
F itted  data are presented in Fig 3.43 - 3.48. The quality of the fitting 
model was assessed from residual plots, which represent a difference between 
theoretical and experimental data for each sensorgrarn. The residual plots for 
all six sensorgrams are present in Fig. 3.49- 3.54. In all cases the difference be­
tween experimental and theoretical data is smaller than 2  RU, which is a level 
of instrum ental noise, indicating tha t the 1 :1  Langmuir model approximates 
kinetic processes on the chip surface very accurately.
To minimise experimental errors, especially those arising from pipetting, 
data were collected for several independently prepared samples. Kinetic data 
obtained are summarised in Tables 3.7 - 3.12. Single lines separate data ob­
tained from different samples.
There was a good overall agreement between data, but some discrepancies 
were also observed, especially for the dissociation rate constant, k^. If one or 
two values did not fit into the numerical range determined by the values from 
a given set, these were considered as a consequence of experimental and data
Ob-R Ob k j  106 kd/ lO" 4 K D/lO~10
M ~ l • s " 1 s ' 1 M
h h 1.9 ± 0.4 4.6 ± 0.9 2 ± 1
h m 1 .1 ± o to 1.3 ± 0 .6 1 .2 ± o 00
h r 2.9 ± 0 .1 to bo ± 0 .2 1 .0 ± o bo
m h 1 .2 ± o CO F5 oo ± 0 .6 6 ± 2
m m 0.7 ± 0 .1 1.4 ± 0 .6 2 ± 1
m r 1 .1 ± 0.3 3.2 ± 0.9 3 ± 1
Table 3.6: Kinetic constants for the Ob-Ob-R interaction. D ata represent the 
average value ±  standard deviation derived from values obtained in repeated 
experiments; ka and kd are the association and dissociation rate constants, Kp  
is the equilibrium dissociation constant.
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processing errors and excluded from a calculation of the average values of k a 
and k d. The dissociation constant, K d , was determined as kd/ k a. Its standard 
deviation S.D.(AT>) (% ) was calculated as S . D . ( K a) -f S . D . ( K d). The kinetic 
constants obtained from this analysis are summarised in Table 3.6.
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• 0 1 nM 
■ 1 nM
• 3 nM 
- 5 nM
• 10 nM 
30 nM
Figure 3.42: Drifting baseline correction. A. A dem onstration of a baseline 
decay due to a dissociation of the complex between ObR-Fc and Protein G.
B. The baseline decay was corrected by subtracting the 0 nM injection.
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Experim ent No. k a/ 106
M ~ l • 5_1
V i o - 4
s - 1
x 2 Cell
1 1.59 5.41 0 .1 0 0 Fc3
2 2.14 6 .2 1 0 .1 1 2 Fc3
3 2.36 5.59 0.114 Fc3
4 1.53 3.92 0.103 Fc2
5 1.61 3.56 0.084 Fc3
6 1.43 4.19 0.090 Fc4
7 2 .1 1 3.92 0.113 Fc2
8 2.32 3.44 0.153 Fc3
9 2.40 5.00 0 .1 2 1 Fc4
Table 3.7: Kinetic constants for hO b-R/hO b interaction determ ined from re­
peated experiments; ka and kd are the association and dissociation rate con­
stants, x 2 describes the closeness of fit and Cell corresponds to the chip flow 
cell used.
Experiment No. k a / 1 0 6
M ' 1 • s " 1
V I O " 4
5 —1
X2 Cell
1 0.95 0.78 0.096 Fc3
2 1.08 0 .8 8 0.087 Fc3
3 1.24 1.81 0.097 Fc3
4 1.18 2.04 0.085 Fc3
5 1.18 1.08 0.088 Fc3
Table 3.8: Kinetic constants for hO b-R/m O b interaction determ ined from re­
peated experiments; ka and kd are the association and dissociation rate con­
stants, x 2 describes the closeness of fit and Cell corresponds to the chip flow 
cell used.
Experiment No. k a / 106
M - 1 ■ s - 1
V I O " 4
s _1
x 2 Cell
1 . 2.62 2.41 0.093 Fc3
2 . 2.75 2 .6 6 0.099 Fc3
3. 3.20 3.01 0.099 Fc3
4 2 .6 8 2.84 0.119 Fc2
5 2.82 3.36 0 .1 1 1 Fc2
6 2.78 3.18 0.118 Fc2
7 2.71 2.91 0.097 Fc 3
8 3.06 2.67 0.087 Fc 3
9 3.41 2.43 0.092 Fc 3
Table 3.9: Kinetic constants for hO b-R/rO b interaction determ ined from re­
peated experiments; ka and kd are the association and dissociation rate con­
stants, x 2 describes the closeness of fit and Cell corresponds to the chip flow 
cell used.
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Experiment No. k a / 1 0 6 kd/ 1 0 " 4 x 2 Cell
M ~ l • s " 1 5,_ 1
1 0 .8 6 7.26 0.114 Fc2
2 0.97 6 .1 0 0.098 Fc3
3 0 .8 8 5.80 0.104 Fc4
4 1.24 7.17 0.136 Fc2
5 1.05 6 .2 1 0.140 Fc3
6 0.92 7.87 0.161 Fc4
7 1.70 6.73 0.126 Fc2
8 1.62 6.78 0.115 Fc3
9 1.43 7.02 0.127 Fc4
Table 3.10: Kinetic constants for m O b-R/hO b interaction determ ined from 
repeated experiments; ka and kd are the association and dissociation ra te  con­
stants, x 2 describes the closeness of fit and Cell corresponds to the chip flow 
cell used.
Experiment No. k a / 106
M ~ l • s ' 1
k d/ 1 0 ~ 4 
1
X2 Cell
1 0.82 2.47 0.098 Fc2
2 0.75 2 .0 2 0.089 Fc3
3 0.95 1.36 0.107 Fc4
4 0.65 0.78 0 .1 2 1 Fc2
5 0.73 1.09 0.097 Fc3
6 0.57 1.74 0 .1 1 2 Fc4
7 0.65 0.43 0.107 Fc2
8 0.54 0.95 0.103 Fc3
9 0.46 1.73 0 .1 2 0 Fc4
Table 3.11: Kinetic constants for m O b-R/m O b interaction determ ined from 
repeated experiments; ka and kd are the association and dissociation ra te  con­
stants, x 2 describes the closeness of fit and Cell corresponds to the chip flow 
cell used.
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Experiment No. K /1Q 6 
M ~ l • s " 1
k d/ 1 0 - 4
s -1
x 2 Cell
1 1.41 4.33 0.113 Fc2
2 1.52 3.17 0 .1 0 2 Fc3
3 1.47 3.33 0.113 Fc4
4 0.98 2.62 0.136 Fc2
5 0.89 1.87 0.133 Fc3
6 0.76 2.06 0.146 Fc2
7 0.79 3.32 0.146 Fc3
8 0.77 4.62 0.151 Fc4
Table 3.12: Kinetic constants for m O b-R/rO b interaction determ ined from 
repeated experiments; ka and kd are the association and dissociation rate  con­
stants, x 2 describes the closeness of fit and Cell corresponds to the chip flow 
cell used.
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Ob-R Ob Stoichiometry 
3000 RU 1300 RU 300 RU
h h 0.49 0.75 1 .1 1
h m 0.52 0.81 1 .1 1
h r - 0.82 1 .1 2
m m 0.81 1 .0 0 1 .0 0
m h 0.77 0.91 0.91
m r - 0.99 1 .0 1
Table 3.13: Stoichiometry of the Ob - Ob-R interaction determined from the 
BiaCore experiments with human and mouse leptin receptor chimera and hu­
man, mouse and rat leptin.
3 .3 .7  S to ich iom etry
The BiaCore instrum ent measures the mass of molecules bound to the sensor 
surface. Thus, the stoichiometry of the surface molecular complex can be 
determined from the following equation
, • , • , R-max ' MWligand . .s to ichiometry = ——— ---------- —  (3.1)
IVl Wanalyte ’ til
where R max, analyte binding capacity, can be extrapolated from experi­
mental data and R[ is given directly from a sensorgram recorded during ligand 
immobilisation.
The stoichiometry of ObR-Fc-Ob interaction was determined using the fol­
lowing values: MWhObR-Fc =  220 kDa, M W mobR-Fc — 160 kDa,  MWh,ob = 
M W mob = M W rob =  16 kDa.  All these numbers refer to monomeric mol­
ecules. Therefore, tha t the derived stoichiometry represents the number of Ob 
molecules bound to a monomeric ObR-Fc molecule. The obtained values for 
different species are summarised in Table 3.13.
Apart from some of the data obtained on a very dense surface (about 3000 
RU receptor immobilised), the observed stoichiometry is around 0.9 i.e. de­
scribing a 1:1 configuration. Thus, one monomeric ObR-Fc molecule interacts 
with one Ob molecule (one dimerised ObR-Fc molecule interacts with two 
Ob molecules). Lower stoichiometry (around 0.5) was observed when large 
amounts of hObR-Fc (3000 RU) were immobilised. This phenomenon is prob­
ably due to steric hindrance on the sensor surface which hinders Ob molecules 
from binding to all presented binding sites.
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30 nM
Figure 3.49: Residual plots for hO b-R/hO b interaction.
Figure 3.50: Residual plots for m O b-R/hO b interaction.
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Figure 3.52: Residual plots for m O b-R/m O b interaction.
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30 nM
Figure 3.53: Residual plots for hO b-R /rO b interaction
0.5 nM
300 nM
Figure 3.54: Residual plots for m O b-R /rO b interaction.
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3.4 B ind ing properties o f a tru n cated  lep tin
3.4 .1  C on stru ction  o f  exp ression  v ec to rs
A clone of human leptin was kindly provided by Dr. Masuzaki [93]. The 
sequence analyses revealed that glutamine 28 (Q28) was deleted from the se­
quence. This is an interesting feature as Q28 is localised in the AB loop tha t 
is predicted to be involved in receptor binding,(Fig 4.1.)
Therefore, it was decided to overexpress this clone, encoding leptin with 
the Q28 deletion, in E. coli and use the recombinant protein for the BiaCore 
analysis and to determine the potential role of Q28 in receptor binding.
The FLAG system (SIGMA) designed for fusion of the FLAG peptide to 
proteins and expression in E. coli was used. The open reading frame (ORF) of 
leptin lacking Q28 (AQ28) was cloned into an amino-terminal FLAG expression 
vector. Two expression vectors were used: pFLAG-MAC and pFLAG-ATS. 
The pFLAG-ATS vector codes for the OmpA signal peptide which allows for 
expression of amino-terminal FLAG fusion protein within periplasm. The 
pFLAG-MAC lacks the coding sequence for the OmpA signal peptide and is 
useful for the expression of Met-amino-terminal FLAG fusion proteins within 
the cytoplasm.
The leptin cDNA was engineered for subcloning to both pFLAG-MAC 
and pFLAG-ATS vectors. Its leading sequence, MeG-Val22, was removed and 
the sequence encoding the processed protein was inserted into the vectors 
in-frame with respect to the ATG translation start codon. PCR was used to 
introduce the relevant restriction sites,' Fig. 3.55 A, Bi The forward and reverse 
primers were designed. The forward primer introduced a Sma  I site in front of 
Pro23 in-frame with respect to the vector ATG translation start codons. The 
reverse primer contained the Bgl II site directly after the stop codon. The 
PCR product was subcloned into the pFLAG-MAC and pFLAG-ATS vectors 
digested with the Sma  I and Bgl II restriction enzymes,^Fig. 3.56 A, B)
The two constructs encoding FLAG-leptin expressed either in the cyto­
plasm (ob-ATS) or periplasm (ob-MAC) were sequenced to check for any mu­
tations introduced by PCR and were found to encode desired proteins.
3.4 .2  Screen ing transform ants for FL A G  fusion  p rotein s
Anti-M 2  monoclonal antibody, which binds to the FLAG tag at any location 
on FLAG fusion protein, was used to screen for the presence of fusion proteins 
encoded by the ob-ATS or ob-MAC plasmids in bacterial transform ants. Pro-








ob -A T S
Figure 3.55: Design of FLAG-leptin fusion proteins. A. The ob-MAC plasmid 
designed for the expression of M et-amino-terminal FLAG fusion leptin within 
the cytoplasm. B. The ob-ATS plasmid designed for the expression of amino- 
terminal FLAG fusion leptin within periplasm.
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A. B.
M 1 2 M 1 2
Figure 3.56: PCR of FLAG-leptin. (A.) The cDNA encoding processed leptin 
protein was amplified by PCR. The forward primer introduced the Sm a  I site 
in front of Pro23 in-frame with respect to the vector ATG translation s ta r t  
codon. The reverse primer contained the Bgl II site directly after the stop 
codon. M, molecular weight ladder; 1, PCR product; 2, positive control. (B.) 
The PCR product was subcloned into the pFLAG-M AC and pFLAG-ATS 
vectors. M, molecular weight ladder; 1, The ob-ATS digested with Sm a  I and 
Bgl II ; 2, undigested plasmid.
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tein expression levels at 0, 2 and 4 hours post-induction were analysed. The 
expression of proteins with expected molecular weight (14 kDa) and specificity 
was confirmed by SDS-PAGE and Western blot, Pig. 3.57 A, B .)
The doublet observed for the ob-ATS corresponds to the processed and non­
processed protein without or with the OmpA signal peptide which is cleaved 
after protein transport to the periplasm. The BAP-ATS plasmid expressing 
the BAP (Bacterial Alkaline Phosphatase) gene as a 49 kDa FLAG fusion 
protein was used as positive control. The pFLAG-ATS plasmid (ATS) was 
used as negative control.
3 .4 .3  A nalysis o f  exp ression  o f  FL A G  fusion  p rotein s
Western blot analysis was used to determine whether the expressed FLAG fu­
sion proteins are found in the periplasm, soluble whole cell fraction or insoluble 
whole cell fraction,^Fig. 3.58.)
The doublet observed for the ob-ATS in the whole cell sample corresponds 
to the processed and non-processed protein without or with the OmpA signal 
peptide which is cleaved after protein transport to the periplasm. The m ajority 
of the processed protein is found in the periplasm, while the unprocessed 
protein is localised in the insoluble fraction. The pFLAG-ATS plasmid (ATS) 
was used as negative control. The results indicate, tha t the transcript from 
the ob-ATS is expressed in the periplasm. The transcription product of the 
ob-MAC vector was not detected in any of the subcellular fractions although 
it was present in the whole cell sample.
3 .4 .4  Im m uno-affin ity purification  o f  F L A G -lep tin
To purify the protein encoded by the ob-ATS plasmid localised in the insoluble 
fraction, it would be necessary to solubilise it with a detergent or chaotropic 
agent prior to affinity purification with the anti-FLAG M2 affinity gel. How­
ever, the protein found in the periplasm fraction could be simply isolated using 
osmotic shock. The isolated ob-ATS protein was then purified using immuno- 
affinity purification with the anti-FLAG M2  affinity gel,(Fig. 3.58 A, B?)
SDS-PAGE analysis, Fig. 3.59 A, indicated, th a t the purified recombinant 
FLAG-leptin protein had no detectable contamination. This protein was used 
in the BiaCore experiments to examine the effect of deletion of the glutam ine 
28 (Q28) on the affinity of binding to the receptor.
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ATS MAC ATS ATS
Figure 3.57: Optimisation of protein expression. The expression levels of the 
ob-ATS, ob-MAC, FLAG-BAP (positive control) and pFLAG-ATS (negative 
control) at 0, 2 and 4 hours post-induction were analysed by Brilliant Blue 
staining of SDS-PAGE (A.) and Western blot (B.). The doublet observed 
for the ob-ATS corresponds to processed and non-processed protein. In the 
Western blot analysis, anti-FLAG M2 antibody (SIGMA) (10 pg /m l)  was used 
in a combination with the HRP conjugated anti-mouse antibody (SIGMA) 
(1:15,000 dilution) in ECL detection.
t = 0 h { = 2 h t = 4 h
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Figure 3.58: Fractionation of FLAG fusion proteins. The fractionation of the 
FLAG fusion proteins to the periplasm, soluble whole cell fraction or insoluble 
whole cell fractions was analysed by Western blot. The doublet observed for 
the ob-ATS in the whole cell sample corresponds to the processed and non- 
processed protein. The processed protein is identified in the periplasm, while 
the unprocessed protein is localised in the insoluble fraction. The pFLAG-ATS 
plasmid (ATS) was used as negative control. In the Western blot analysis, anti- 
FLAG M2 antibody (SIGMA) (10 ^zg/ml) was used in a combination with the 
H RP conjugated anti-mouse antibody (SIGMA) (1:15,000 dilution) in ECL 
detection.
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Figure 3.59: Immuno-affinity purification of FLAG-leptin. The isolated tran ­
script of the ob-ATS plasmid was purified using immuno-affinity purification 
with the anti-FLAG M2 affinity gel. (A.) SDS-PAGE stained with Brilliant 
B1 ue. (B.) Western blot analysis. F, Flow through sample; W Wash sample; 
E l ,  E2, E3, E4 Elution samples. In the Western blot analysis, anti-FLAG M2 
antibody (SIGMA) (10 /ig/ml) was used in a combination with the H RP con­
jugated anti-mouse antibody (SIGMA) (1:15,000 dilution) in ECL detection.
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3.4 .5  B ind ing  analysis
The effect of the Q28 deletion from the leptin sequence on the leptin binding 
to the receptor was evaluated using BiaCore. The capturing assay, described 
in section 3.3.3, was used. D ata were collected for both human and mouse 
leptin receptor chimeras (ObR-Fc). The concentration range of leptin was 0.2 
- 300 nM. Data were processed as described in section 3.3.6 and fitted to a 1:1 
Langmuir binding model, Fig. 3.60-3.61.
The accuracy of the fitting model was assessed by an exam ination of resid­
ual fits, Fig. 3.62-3.63. The difference between experimental and theoretical 
data for both human and mouse chimeras is smaller then 2 RU, which is the 
level of instrum ental noise. This indicates tha t the 1:1 Langmuir model ap­
proximates kinetic processes on the chip surface very accurately.
Derived kinetic constants are summarised in tables 3.14, 3.15. Calculated 
average values of association and dissociation rate constants, and the dissoci­
ation constant for both human and mouse leptin receptor chimeras (ObR-Fc) 
are presented in table 3.16.
Comparison of data  obtained for AQ28 with those for the wild-type leptin, 
table 3.6, indicate th a t deletion of Q28 resulted in a 10-fold increase in Kd for 
both human and mouse receptor chimeras,i^Fig 3 .64^T he main contribution 
to this increase in Kd resulted from a change in the dissociation rate constant. 
The association rate was very similar for leptin wild type and AQ28 molecules.
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Experiment No. k j  1 0 5
M - 1 • s " 1
kd/ 1 0 " 4
<s—1
x 2 Cell
1 . 2.58 9.18 0.113 Fc2
2 . 2.51 6.87 0.140 Fc3
3. 3.15 6.90 0.098 Fc2
4. 3.17 6.85 0.094 Fc3
5. 2.52 7.82 0 .1 2 0 Fc2
6 . 2.99 7.13 0.094 Fc3
Table 3.14: Values of kinetic constants for hO bR /A Q 28 interaction determ ined 
from separate experiments; ka and kd are the association and dissociation ra te  
constants, x 2 describes the closeness of fit and Cell corresponds to the chip 
flow cell used.
Experiment No. k a / 1 0 5
M ~ l • s - 1
k d/ 1 0 -3
s~ l
x 2 Cell
1. 2.73 1.98 0.118 Fc4
2 . 3.75 1.54 0.092 Fc4
3. 5.09 2 .2 2 0 .1 1 0 Fc2
4. 5.17 2.24 0 .1 1 2 Fc4
Table 3.15: Values of kinetic constants for m O bR /A Q 28 interaction deter­
mined from separate experiments; ka and kd are the association and dissocia­
tion rate constants, x 2 describes the closeness of fit and Cell corresponds to 
the chip flow cell used.




h 2.8 ±  0.3 7.1 ±  0.4 2.5 ±  0.4
m 4 ±  1 20 ±  3 5 ±  2
Table 3.16: Kinetic constants for hOb-R/AQ28 and m O b-R/A Q 28 in ter­
actions. D ata represent the average value ±  standard deviation derived from 
values obtained in separate experiments; ka and kd are the association and 
dissociation rate constants, is the equilibrium dissociation constant.
CHAPTER 3. RESULTS  129
























































Figure 3.62: Residual plots for hOb-R/hAQ28 interaction.
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Figure 3.63: Residual plots for m Ob-R/hAQ28 interaction.










4.1 B iaC ore analysis o f lep tin  - lep tin  receptor  
in teraction
The BiaCore instrum ent was used to analyse the leptin - leptin receptor inter­
action, Section 3.3. A chimeric receptor consisting of two receptor extracellular 
domains fused together via Fc region of IgGi (ObR-Fc) was used. This is a 
useful experimental system for studying a recently proposed model of leptin 
receptor activation [71]. According to this model, leptin receptor exists as a 
dimer in both ligand-free and ligand-bound states. This model predicts tha t 
the receptor is activated by a conformation change introduced by leptin bind­
ing.
This model differs from a common model for activation of cytokine recep­
tors. The leptin receptor belongs to the cytokine receptor family according 
to its primary sequence. The model proposed for cytokine receptors requires 
tha t ligand binding activates cytokine receptors by inducing a change in their 
oligomerisation state. The most common mechanism is dimerization of mono­
meric receptor by ligand [53, 94]. However, experimental evidence indicates 
tha t this is not the case for leptin receptor [71].
Here, the leptin - leptin receptor interaction was evaluated using the recep­
tor chimera immobilised on to the BiaCore chip. In the capturing assay used, 
Protein G was covalently linked to the chip surface and employed for receptor 
capture and immobilisation,^Fig. 3.36^ The interaction was evaluated using 
human, mouse and rat leptin in combination with human or mouse chimeric 
receptors.
D ata were collected in parallel experiments from one active (ObR-Fc) and 
one control (Protein G) cell,/Fig. 3.4(\ with leptin injections usually ranging
133
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from 0.1 to 30 nM. Nonspecific binding and a contribution of bulk refractive 
index were corrected for by subtracting data from the control cell from data 
from active one,^Fig. 3.4L) f )
The effect of mass transport was completely eliminated by immobilising 
small amounts of the receptor (100 - 200 RU). The insignificance of mass 
transport was confirmed by analysing the association phase of the interaction.
The flow rate was changed from 15 - 100 /il/m in and leptin binding was moni­
tored,^Fig. 3.39) Because no increase in the initial binding was observed when 
the flow rate was raised from 15 to 75 fi 1/min, mass transport was treated as 
not limiting and was, therefore, not considered in data  analysis.
The only phenomenon which complicated data analysis was a drifting base­
line, jFig. 3 .4 2 ^  a consequence of the capturing assay used. Use of protein 
G facilitated the correct orientation of receptor molecules away from the chip 
surface, thereby minimising the effects of surface heterogeneity. On the other 
hand, the complex between the ObR-Fc and the Protein G slowly dissociated.
The drifting baseline could be treated in two ways. D ata corrected for nonspe­
cific binding and bulk refractive index could be either fitted to the 1 :1  binding 
model with exponentially drifting baseline from BIAevaluation software or the 
drift could be corrected by subtracting a bulk injection (0 nM) from (0.1-30 
nM) binding data. We used the second option, as it also corrected for injection 
artifacts. An example of data corrected for drifting baseline is in Fig. 3.42B.
Corrected data were fitted to the 1 :1  Langmuir binding model. F itted  data 
are presented in Fig 3.43 - 3.48.
Association and dissociation rate constants, kaj kd, and the analyte max­
imum binding capacity, R max, were determined as model fitting parameters.
The rate constants, ka and kd, were fitted globally to all six sensorgrams. R max 
was fitted locally for each sensorgram. Local fitting of R max was used to re­
flect possible minor differences due to ObR-Fc dissociation from the Protein 
G complex.
Values for the association and dissociation rate constants, ka and kd, were 
determined as average values from repeated experiments, Tables 3.7 - 3.12.
Small variations observed may be due to either differences in leptin samples 
used (pipetting error, protein degradation) or instrum ental artefact.
An aspect worth consideration is the possibility of protein degradation.
During an experiment the samples were kept in a rack equilibrated for 25°C.
Because experiments were very time-consuming (normally 20 hour required 
for completion) some degradation could have occurred. This unwanted fea-
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ture could be minimised by employing a cooling system which would keep the 
sample rack at 4°C.  In the meantime, it is im portant to determine kinetic con­
stants from several independent experiments to minimise experim ental bias.
4 .1 .1  D eterm in a tio n  o f  b ind ing s ite
The importance of accurate data becomes obvious when areas of applications 
are considered. The genuine advantage of BiaCore is a direct determ ination 
of the association and dissociation rate constants, ka and k^. A knowledge 
of ka and k^ can be effectively exploited for analysis of molecular binding 
sites [95, 96]. These studies have dem onstrated different roles for charged and 
bulk residues in molecular interactions. Charged residues are im portant in the 
association phase, when the electric charge appears to provide a driving force 
for complex formation. By contrast, bulky uncharged residues are crucial for 
complex stabilisation as they determine the spatial complementarity of in ter­
acting molecules. Thus, the association rate constant, ka, is likely to reflect a 
contribution from an interaction of charged residues while the dissociation rate  
constant, k^, probably reflects a contribution from nonpolar bulk residues.
Thus, the ability of the BiaCore to measure ka and k^ can be exploited 
for effective analysis of suspected binding sites. The BiaCore in combination 
with site-specific mutagenesis can provide information about target residues 
involved in binding or not.
This approach could also be used to some extent in analysis of the leptin - 
leptin receptor interaction. Human, mouse and ra t leptin molecules have very 
high sequence identity (84%),(Fig. 4.11 In mouse and rat amino acid sequences 
there are only six different residues, four of which are chemically similar. The 
human sequence stands apart as it bears 19 additional differences (out of 146). 
Of these, 11 are chemically similar. Thus, the three leptin molecules can be 
considered as naturally occurring m utant variants and used in BiaCore analysis 
to determine a binding site.
According to the leptin crystal structure, Fig. 1.2, [10], leptin has two 
possible receptor binding sites. The first is in the first part of the AB loop, 
Fig 4.1, containing the residues flanked by Thr27 and Gly38. This region is not 
visible in the crystal structure because of its high flexibility. This flexibility 
has also been observed in a similar region of growth hormone (hGH) [14], 
another member of the cytokine family. This region in growth hormone shows 
extensive conformational changes upon receptor binding, changing from a coil 
structure in the free-ligand structure to a helix in the receptor complex. Thus,
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Figure 4.1: Sequence alignment of human, mouse and rat OB proteins. Helices 
A-E, determined by the crystal structure of leptin-ElOO [10], are depicted. 
Residues forming the hydrophobic domain are marked with a circle. Made 
with the Pileup programme from GCG package.
CHAPTER 4. DISCUSSION 137
this leptin region may also represent a coil which would assume an ordered 
conformation after binding the receptor.
The second possible receptor binding site is a large hydrophobic cylindrical 
core parallel to the helical bundle axis, Fig 1.3. It is formed by the most 
conserved residues of the four helices tha t face each other. These are residues 
Val 60, lie 64 in the BD bundle, Met 6 8  in the C-terminal end of helix B and 
Val 124 and Ala 125 in the N terminus of helix D. This lipophilic surface is 
buried by Leu 104, Leu 107, Leu 110, Leu 114 and Val 113 of helix E in the 
CD loop. The E helix serves as a hydrophobic cap.
In the first possible binding site, the AB loop, there are only three conserved 
mutations between the rodent leptins and human leptin. The second possible 
binding site, the hydrophobic core, is much richer in m utations. However, 
these two regions are not exclusive domains of diversity between the three 
molecules. To associate differences in ka and between species, Table 3.6, 
with the location of binding site, it would be necessary to introduce more 
specific mutations in leptin.
The strategy of introducing targeted m utations was initiated by analysis of 
binding properties of a m utated human leptin molecule with deleted glutam ine 
28 (Q28). Glutamine 28 is localised in the first part of the AB loop, residues 
27 to 38, and may be im portant for binding. Its affinity for both human and 
mouse leptin receptor chimeras was analysed by BiaCore. Results showed th a t 
this m utant has a 10-fold lower affinity for both receptors, indicating tha t Q 28 
may be im portant for binding. A change in affinity due to a different folding 
of the m utant can be ruled out because the highly flexible AB loop is unlikely 
to contribute to the formation of the tertiary  structure.
4 .1 .2  K in etics and sto ich iom etry  o f  in teraction
The kinetic data obtained indicate tha t human, mouse and rat Ob bind both 
human and mouse chimeric receptors (ObR-Fc) with high affinity (K/j w 0.2 
nM). The association rate is similar for the different species of leptin to ei­
ther receptor and the differences in affinity results mainly from a variance in 
the dissociation rates. The affinity of human leptin for its cognate receptor 
(K/p =  0 .2 2  ± 0 .1  nM) reflects a very strong ligand binding to dimerised recep­
tor. This value is consistently 50-fold smaller than th a t reported previously 
where the Kd was found to be 9.5 nM [97], using monomeric receptor. To­
gether, these results suggest that receptor dimerization stabilises the complex.
Because the BiaCore instrum ent measures the mass of molecules bound to
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the sensor surface, data can be analysed to determine the stoichiometry of sur­
face molecular complexes. For the leptim leptin receptor interaction, our data, 
summarised in Table 3.13, indicate a 1 :1  interaction, i.e. one monomeric ObR- 
Fc molecule interacts with one Ob molecule (one dimerised ObR-Fc molecule 
interacts with two Ob molecules). The apparent 1:2 stoichiometry (around 
0.5) observed when high amounts of hObR-Fc are immobilised is likely to be 
due to steric restriction on the sensor surface which hinders Ob molecules from 
binding to all presented binding sites. The same reason leads us to interpret 
reactions with measured 0 .8  - 1 .1  stoichiometry as 1 :1  interaction.
The 1:1 stoichiometry of interaction is interesting in many respects. First of 
all, it is in agreement with data obtained from native polyacrylamide gel elec­
trophoresis [71]. Secondly, it suggests tha t leptin triggers receptor activation 
through a change in conformation rather than through oligomerisation of the 
receptor. Thirdly, because dimeric receptor acts as two independent monomers 
in its interaction with ligand, there should be no difference in K d between 
dimeric and monomeric receptor. However, K d obtained for our dimeric hu­
man receptor (K d = 0.2 ± 0 .1  nM), is only about one-fiftieth of tha t reported 
for the monomeric receptor (Kd — 9-5 nM) [97]. This difference is not negli­
gible. It may be due to intrinsic difference of the interaction system or may 
be the consequence of the oligomerisation state of the receptor. It is possible 
that receptor dimerisation induces a particular structural modification of the 
receptor, modifying its ligand recognition sites and hence improving its affin­
ity for the ligand. Both sites would be entirely functional and independent. 
The improved affinity would therefore not be a consequence of ligand bivalent 
binding, as usually observed.
There are several other factors, which could contribute to the differences 
observed. Experimental systems used here and previously [97] are not entirely 
similar. In both cases, a Pharm acia Biosensor BIAcore™ instrum ent was 
used, but recombinant leptin receptor molecules (monomeric and dimeric) were 
immobilised on a sensor chip in different ways. The monomeric receptor was 
immobilised directly on to an NTA (nitrilo-tri-acetic acid) sensor chip via the 
6 xHis epitope localised in its C-terminus. The dimeric receptor was anchored 
on to a CM5 sensor chip via Protein G. Ligand binding experiments were 
performed under identical experimental conditions in HEPES-buffered saline 
at room tem perature.
It must also be considered, that human leptin receptor contains extensive 
glycosylation, approximately 36 % [98]. Recombinant monomeric and dimeric
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receptors discussed above were expressed in Baculovirus (BV) and a mouse 
myeloma cell line, NSO, respectively. Level of post-translation modifications 
in the BV is usually lower than in mammalian cell lines. This implies tha t 
the level of glycosylation in these two proteins may be different and this could 
affect their function.
Another source of differences could be the dimeric receptor itself. It consists 
of two extracellular domains linked together via the Fc portion of IgGi. This 
covalent link could restrict the m utual orientation of monomers, tha t could, 
in turn, affect dimer affinity for ligand. However, the hinge region in the 
Fc portion allows slight relative motion between the monomers, tha t could 
compensate for the restriction raised by the linkage. It is also not clear whether 
the covalent linkage of the receptor extracellular domains leads to a specific 
interaction between the two monomeric molecules, forming a dimer, or holds 
two monomers together but without any specific contact.
Our observation that the dimeric receptor interacts with two molecules 
of leptin supports the idea that the receptor, expressed on the cell surface 
as a dimer, interacts with its ligand in 1:1  stoichiometry, as recently pro­
posed [71]. This opens a question on the geometry of this receptor-ligand 
complex, [Tig. 4.2} As was mentioned above, each leptin molecule has two 
possible receptor binding sites: the AB loop and the hydrophobic cylindrical 
core, [Fig 1.3  ^ Each of the leptin receptor extracellular domains possesses two 
cytokme-biricling homology regions (CHR) as predicted from the prim ary se­
quence, and each represents a possible binding site [47]. The receptor dimer 
could therefore be predicted to possess four ligand binding sites and the two 
leptin molecules could satisfy all four receptor binding sites which could in 
part explain the very high affinity observed for this interaction. However, only 
the second cytokine-binding homology region has been reported to bind the 
ligand [99].
An analysis of the BiaCore data provides additional evidence for this model. 
Two BiaCore models are available: the 1:1 simple model and the 1:1 model 
with a parallel binding to two different sites. The first model was found much 
more appropriate for analysis of the curves. This suggests th a t there is only 
one distinctive binding site on the ObR-Fc chimera.
However, the 1:1 stoichiometry does not restrict the leptin oligomerisa­
tion state. It is possible tha t leptin could act either as a dimer or as two 
independent monomers binding to the dimerised receptor. Thus, two reaction 
mechanisms must be considered. In the first, leptin would have to dimerise
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Figure 4.2: Model of leptin-leptin receptor complex. The leptin molecule has 
two possible receptor binding sites. Each of the leptin receptor extracellu­
lar domains possesses two predicted binding sites. However, only the second 
cytokine-binding homology region has been reported to bind the ligand [99].
before binding to the chimeric receptor, equations 4.1, 4.2. In the second, a 
monomeric leptin molecule would bind to the chimeric receptor first, followed 
by a binding of the second leptin molecule to the Ob:ObR-Fc complex, equa­
tions 4.4, 4.4. These two processes are intrinsically different and characterised 
by different rate constants (k1 and k2). The BiaCore analytical system is not 
fast enough to clearly distinguish between them. However, the 1:1 Langmuir 
model used suggests that the dimerisation of leptin does not occur before 
interaction with chimeric receptor.
KxOb +  Ob £
klzOb2 + ObR -  Fc  £  
or 




Ob +  Ob :  ObR-Fc £
k 2
d‘2
Furthermore, a new role for leptin, which could interfere with its receptor 
binding, has recently been proposed. Leptin has been suggested to act as a 
transporter of free fatty acids (FFA) [100]. We used BiaCore to investigate 
this possibility. The small size of FFA, about 300 daltons, means that the
Ob 2 (4.1)
Ob : O b R -  Fc :Ob  (4.2)
Ob : ObR -  Fc  (4.3)
Ob : ObR -  Fc  : Ob (4.4)
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Figure 4.3: Leptin interaction with free fatty  acids. A competitive approach, 
when the free fatty acid (FFA) competes with the immobilised leptin receptor 
(ObR-Fc) for binding to leptin (Ob), was used to investigate a possible role of 
leptin as a FFA transporter.
interaction between leptin and FFA can not be measured directly, because the 
instrument BiaCore™ 2000 used can not detect molecules smaller than 1 0 .0 0 0  
daltons. Therefore, it was decided to use an alternative competitive approach, 
in which the FFA competes with the immobilised leptin receptor for binding 
to leptin, Fig 4.3.
Arachidonic and oleic acids were used in this experiment. Arachidonic 
acid was found previously to bind leptin [1 0 0 ], while oleic acid did not and 
was used as negative control. The results dem onstrated that arachidonic acid 
does not compete with leptin receptor for binding to  leptin as arachidonic acid 
at concentrations as high as 30 f i M  did not have any effect on 30 nM leptin 
binding to leptin receptor (data not shown).
This observation rules out the possibility that FFA binds to the receptor 
binding site on the leptin molecule. However, it is possible that leptin bears 
an independent binding site for FFA. An ideal candidate would be the leptin 
hydrophobic cylindrical core, Fig. 1.3, as FFA has been found previously to 
bind to the hydrophobic cavity of several proteins like adipocyte lipid-binding 
protein (ALBP) and intestinal fatty acid-binding protein (I-FABP) [101, 102].
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4 .1 .3  M olecu lar com p lex ity
A situation depicted above, when leptin may interact simultaneously with sev­
eral molecules (leptin receptor, free fatty  acids, sugar molecules) indicates a 
potentially complex nature of leptin action in its authentic physiological envi­
ronment. It must be adm itted tha t the inherent enigmatic nature of biological 
systems makes them  very difficult to study, because simultaneous experimen­
tal evaluation of their inner regularities is impossible due to high m ultiplicity 
of such systems. Thus, it is im portant to search for new ways to measure and 
analyse the emerging complexity of biological systems. This task will be very 
valuable in our post-genomic era. Employment of BiaCore in this field is likely 
to prove extremely beneficial as BiaCore data is exactly the sort of information 
needed. An accumulation of accurate kinetic data can provide an information 
pool which could be highly valuable for overcoming experimental difficulties as­
sociated with complex systems. Simultaneous interactions can be successfully 
modelled using powerful computer systems. Software designed for analysis 
of complex biological interactions is a rapidly expanding business. However, 
”Silicon Biology” is in acute need of input data: values of kinetic constants, 
cellular localisation of interacting components etc., which can only be provided 
by experimentalists. The BiaCore together with other analytical techniques, 
such as microcalorimetry and analytical centrifugation, will probably be the 
most valid supply of experimental data for metamorphosis of integral cellular 
mechanisms into the virtual reality of superpowerful computers.
4.2 L eptin  action
4 .2 .1  A ctiv e  b o d y
As described in Chapter 1 , extensive investigations of the molecular control 
of the appetite revealed tha t leptin, one of the key molecules, is involved in a 
very complex framework of molecular interactions. Leptin is engaged in the 
control of food intake, stimulates energy expenditure, acts as a signal to the 
reproductive system, influences insulin secretion, lipolysis and sugar transport, 
possesses immuno-modulatory and anti-inflammatory effects and also inhibits 
bone formation, to mention its functions so far experimentally dem onstrated.
In a classical description of human physiology, these functions are a t­
tributed to different systems, which exert a high degree of autonomy. These 
are the immune, reproductive and digestive systems. Leptin ability to regulate 
and coordinate the activity of such diverse systems implies tha t leptin belongs
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to an arsenal of the endocrine or nervous systems, which coordinate the action 
of different organs. However, this leptin aspiration is difficult to accommodate 
within the current physiological concept.
Leptin is not a classical hormone, because it is not secreted by any of well 
defined endocrine glands, such as the thyroid or p itu itary  gland. Instead, 
leptin is produced in adipose tissue, which serves us as our energy storage 
com partm ent and no ability to coordinate the action of distinct organs is 
attribu ted  to it.
A localisation of the leptin source, recently extended to the placenta and 
stomach, also disqualified leptin from being engaged by the central nervous 
system (CNS). The CNS in its postulated superiority, is not concerned with 
protein molecules produced outside its own domain. However, leptin cancels 
out the autonomy of CNS, as it is able to get across the blood-brain barrier 
and to activate specific centres in the hypothalamus.
Leptin emerges from these considerations as a very mysterious cytokine 
molecule, which possesses the regulatory roles previously a ttribu ted  only to 
the molecules of the endocrine and nervous systems. However, leptin is nei­
ther hormone nor neurotransm itter. This implies th a t the privileged control 
position in the hierarchy of the physiological systems is not occupied exclu­
sively by the endocrine and nervous systems. Furthermore, it indicates that 
our bodies are not passive participants in the control of physiological pro­
cesses, but that they exercise very active interaction with both endocrine and 
nervous systems. Therefore, it may be said tha t rather than  the brain controls 
the body, the body uses the brain to arrange tasks it finds appropriate.
Leptin seems to use several means of body regulation simultaneously. It 
acts through the endocrine and nervous modes of action, as well as through 
auto- or paracrine pathways,(^Section 1.4. Leptin action through the nervous 
system has a very interesting inner structure, characterised by a high degree of 
redundancy,(Fig. 4.^. Leptin acts directly on the hypothalamus,^Sections 1.4.2 
and 1.5^through which it regulates several physiological functions including 
the sym pathetic nerve activity and, therefore, the activity of peripheral or­
gans. At the same time, the leptin receptor expression in the autonomic 
ganglia, localised outside the CNS, Section 1.4.3, implies a possibility tha t 
the hypothalamus is by-passed in the control of an innervation of peripheral 
organs. In some cases, the nervous system is left aside completely, as leptin 
has been shown to act through auto-pathways, as dem onstrated for the adi­
pose tissue, Section 1.4.3] This again indicates a very vital regulation role of





Figure 4.4: Leptin action through the nervous system. Leptin acts directly on 
the hypothalamus, through which it regulates several physiological functions 
including the sym pathetic nerve activity and, therefore, the activity of periph­
eral organs. At the same time, the leptin receptor expression in the autonomic 
ganglia, localised outside the CNS, implies a possibility that the hypothala­
mus is by-passed in t he control of an innervation of peripheral organs. In some 
cases, the nervous system is left aside completely, as leptin has been shown to 
act through auto-pathway, as demonstrated for the adipose tissue.
leptin, supporting an idea that our bodies actively participate in the control 
of physiological processes.
4.2.2 R odent m odels o f  leptin  action
There is one lim itation concerning our knowledge of the action of leptin. Most 
of the investigations have been done in rodents. This fact raises the question of 
the adequacy of rodent models for studying human physiology. W ith respect 
to leptin, several factors must be considered.
First is the role of leptin as a molecular signal term inating food consump­
tion, if any such signal exists. Leptin circulation is regulated in a fundamen­
tally different way in humans and rodents, Section 1.3. Levels of human leptin 
increase only after chronic increase in caloric intake. On the contrary, in ro­
dents leptin levels change acutely following every meal. This may indicate
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that leptin in humans does not act as a satiety signal as it does in rodents.
Another controversial area is the effect of leptin on energy metabolism , 
Section 1.4.3. Leptin does not have any direct effect on human adrenal cathe- 
cholamine production, which diminishes its potential direct effect in energy 
metabolism through epinephrine regulation. This is in contrast to rodents 
where the adrenal medulla expresses abundant leptin receptor, and a direct 
effect of leptin on energy metabolism is likely to occur.
There is also the question of a cold-induced thermogenesis which protects 
us from stress following exposure to environmental tem peratures. Humans, as 
opposed to rodents, have a broad therm o-neutral zone with relatively small 
changes in metabolic rate occurring over relatively wide tem perature changes.
Finally, there is a morphological difference between hum an and rodents, 
which underlies the above discussed variations. In rodents, a m ajor site of 
adaptive thermogenesis, brown adipose tissue, exists. The role of brown adi­
pose tissue in man is controversial. We do not have large, distinct depots 
of brown adipose tissue and therefore, humans may not by able to convert 
superfluous energy to heat by the adaptive thermogenesis.
4 .2 .3  L eptin  and o b esity
An interesting consequence of using a rodent model for studying leptin action 
is the confusion over genetic predisposition for obesity. There is a striking 
difference between humans and rodents, because several genetic disorders have 
been identified for rodents, but none for humans.
At present, three rodent “obese” strains are known. These are the objob  
and db/db mouse and f a / f a  rat. The ob/ob mouse lacks leptin itself [1]. The 
db/db  mouse has a single m utation in the leptin receptor, Section 1.5.1, result­
ing in a change of a functional receptor Ob-Rb to its nonfunctional splicing 
variant Ob-Ra. In the f a / f a  ra t [103], another single point m utation (Gly269 —> 
Pro) inactivate the receptor.
In humans, no such m utation has been so far identified. An exception is a 
family of Kabilian origin with a homozygous m utation in the leptin receptor 
gene which result in their profound obesity [104]. However, it is quite difficult 
to establish a link between this Turkish family and millions of obese people 
in the developed world. Thus, it is most likely th a t the human obesity is not 
associated with any particular genetic disorder. More likely, it results simply 
from a sedentary lifestyle and a high-fat diet.
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4 .2 .4  B od y-b ra in  con cept
Experim ental data available on the physiological role of leptin, Sections 1.2-1.4, 
indicate tha t the molecular basis of the hypothalamus mode of leptin action is 
at present much better understood than leptin signalling in peripheral organs. 
This reflects the fact tha t the hypothalamus is in general considered to  be a 
supreme coordinator of all physiological processes and, therefore, the prim ary 
target in studying their control.
However, the analysis of the intrinsic structure of leptin engagement in 
energy balance suggests, Section 4.2.1, tha t the role of the hypothalam us in 
the control of our energy-storage com partm ent (adipose tissue) is not th a t 
dominant. A part from the hypothalamus, leptin uses several other modes of 
action, including even the auto-regulatory pathway. Thus, we should asked 
ourselves, where is the dominant role of the hypothalamus in the control of 
the adipose tissue derived from. It is tem pting to speculate tha t this idea is not 
deduced from experimental data but from a current “philosophical” concept 
of human beings.
According to this concept, the brain and spinal cord form an independent 
logical unit (Central Nervous System, CNS) which controls the body. The 
body itself does not possess any ability to participate in this control. W ithin 
this tradition human beings are reduced to robots, whose bodily activities are 
explained in mechanical terms and fully controlled by a computer, positioned 
in the robot’s “skull” .
This concept has its origin in Descartes’s m editations at the beginning of 
the 17th century. Descartes describes human beings and, in fact, the whole 
Universe as the three-dimensional world of physics, res extensa, which is ex­
plicable entirely in terms of interacting elementary particles, a ttribu ted  only 
with quantitative properties such as size, shape, velocity etc. This physical 
world is perceived by res cogitas, thinking substance, which is independent 
of any m aterial substance and which is capable of analysing all the physical 
phenomena in m athem atical language.
Formulating his theory, Descartes led the shift from the traditional ’scholas­
tic ’ explanation of things described by their qualities noted by our five senses 
such as colours, tastes, smells, textures and sounds towards a quantitative 
analysis of the interactions between microscopic particles, of which our ordi­
nary world is composed. This shift in thinking catalysed profound changes in 
the way we understand the Universe and formed the ground base for m odern 
science.
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On the other hand, the concept of human being, which he has left for us, is 
rather awkward. Human beings are for Descartes dualistic entities composed 
of mind, res cogitas, and body, res extensa, bearing the attributes defined 
previously. Thus, our body is a three-dimensional sum of inanim ate particles, 
mechanical interaction of which is reflected by the mind. This concept is 
obviously an archetype of our current description of our nature. The only 
feature changed is the corporealisation of our mind, which has been associated 
with the brain.
Descartes himself never managed to explain how mind, the thinking sub­
stance with no contact with physical world, would control our physical body. 
This puzzle has not been solved by any of his followers either. Furthermore, 
Descartes has eventually been shown to have made a logical mistake in deriv­
ing the core of his theory, probably still best known in the quotation: I am 
thinking, therefore I exist ( Cogito ergo sum).
These antagonisms urge us to think about a better scientific description of 
human beings based more strictly on experimental observations rather than 
on disproved concepts from the 17th century. Stimulation for this intellectual 
activity can be derived from the discoveries achieved in expanding interdisci­
plinary research addressing complex biological phenomena. The notion of a 
high degree of cooperation emerging from these studies indicates th a t physio­
logical processes in every living creature, including human individuals, can be 
fully described only within the global context these creatures themselves rep­
resent. Understanding the brain is simply not enough for knowing ourselves. 
This new body of information can be used to redraw a scientific description 
of human beings and cast away a schizophrenic concept of a mechanistic in­
dividual suffering from its intrinsic division between body and brain. Instead, 
human beings can be described as integral individuals, manifesting a deep 
inner organisation, with democratic rather then hierarchic structure.
The satisfaction for a strenuous effort to reveal the molecular interactions, 
leptin is engaged in, does not need to be sought only in lurid economical 
profit. This experimentation itself is an inexhaustible wellspring of profound 
rum ination on our own nature without which we would probably be those 
mechanistic robots from the dawning of the Enlightenment.
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A p p en d ix  A  
Solutions
A .l  G eneral solutions
K C l 4M in distilled water; sterilised by autoclave
N aC l 5M in distilled water; sterilised by autoclave
T E  bu ffer lOmM Tris, ImM EDTA, pH 7.4
LB  M ed iu m  Bacto-Tryptone: Yeast extract: NaCl 2:1:1
IP T G  0.1M stock in distilled water; filter sterilised; stored at -20°C
X -G al 2 % stock in N ’,N’-dimethyl formamide; stored at -20°C
A m p ic illin  100 m g/m l stock in distilled water; filter-sterilised; stored at 
-2 0 °C
lO x P B S
• 3 M NaCl
• 2.7 mM KCl
• 8.3 mM Na2HP04
• 1.5 mM KH2PO 4 , pH 7.0 
T fb l
• 30 mM KOAc
• 250 mM MnCl2
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• 15% Glycerol 
Tfb2
• 10 mM Na-MOPS, pH 7.0
• 275 mM CaCl2
• lOmM KCl
• 15% Glycerol
A .2 Solutions for D N A  work
Buffer P I  (Q IA G E N )
• 50 mM Tris-HCl, pH 8.0
• 10 mM EDTA
• 100 m g/m l RNase A
Buffer P 2 (Q IA G E N ) 0 .2  M NaOH, 1 % SDS 
Buffer P 3  (Q IA G E N ) 3.0 M potassium acetate, pH 5.5
Buffer Q B T  (Q IA G E N )
• 750 mM NaCl
• 50 mM MOPS, pH 7.0
• 15% isopropanol
• 0.15% Triton® X-100
Buffer QC (Q IA G E N )
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• 50 mM M OPS, pH 7.0
• 15% isopropanol 
Buffer QF (Q IA G E N )
• 1.25 mM NaCl
• 50 mM Tris-Cl, pH 8.5
• 15% isopropanol
lOx T4 D N A  Ligase Buffer 100 mM Tris-HCl, pH 7.5, 100 mM MgCH 
50 x TAE, 1 1 242 g Tris base, 57.1 ml glacial acid, 100 ml 0.5 M EDTA 
E th id ium  B rom ide Stock 10 m g/m l in TE; stored away from light 
10 x  R N A  E lectrophoresis Buffer 0 .2  M MOPS, 10 mM EDTA pH 7.0
A .3 Solutions for D eae-D extran  tran sfection
D E A E -D E X T R A N  10 m g/m l in lx P B S  
C hloroquine 100 mM in lx P B S
D M E N  10% NU serum +  additions according to the cell line used 
D M SO  10% DMSO in lx P B S
A .4 Solutions for E ,  c o l i  expression  work
Buffer for osm otic shock
• 500 mM Sucrose
• 30 mM Tris-HCl
• 1 mM EDTA 
E xtraction  Buffer A
• 50 mM Tris-HCl, pH 8.0
• 5 mM EDTA
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• 50 /Ug/ml sodium azide 
E xtraction  B uffer B
• 1.5 M NaCl
• 0.1 M CaCl2
• 0.1 M MgCl2
• 0 .0 2  m g/m l DNAse I
• 0.05 m g/m l ovomucoid protease inhibitor
A .5 Solutions for protein  work
A .5.1 S olu tion s required for W estern  B lo ttin g  
Tris buffered saline (T B S ), pH  7.6
• 0.695 (3.475) g Trizma base
• 3.03 (15.15) g Trizma HC1
• 8 .0  (40) g Sodium Chloride
• Dilute to 1000 (5000) ml with distilled water. Store at 2  — S°C  
P h osp hate buffered saline (P B S ), pH 7.5
• 11.5 g Di-sodium hydrogen orthophosphate, anhydrous
• 2.96 g Sodium di-hydrogen orthophosphate
• 5.84 g Sodium chloride
• Dilute to 1000 ml with distilled water. Adjust pH to 7.5 with hydrochlo­
ric acid. Store at 2 — 8 °C
P B S-T w een  (P B S -T ), T B S -T w een  (T B S -T ) Dilute required volume of 
Tween-20 in PBS (TBS) to give a 0.1% (v/v) solution. Store at 2  — 8 °C
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A .5.2  S o lu tion s required for S D S -P A G E
Table A .l: Solutions for resolving gel
V olum es (m l) per m old  vo lum e o f  
Solution  com p on en ts 15 m l 30 m l 60 m l
6 %
h 2o 7.975 16.050 32.100
30 % acrylamide mix 3.000 6 .0 0 0 1 2 .0 0 0
1.5M Tris (pH 8 .8 ) 3.800 7.500 15.000
20 % SDS 0.075 0.150 0.300
10  % ammonium persulfate 0.150 0.300 0.600
TEMED 0 .0 1 2 0.024 0.048
8 %
h 2o 6.975 14.050 28.100
30 % acrylamide mix 4.000 8 .0 0 0 16.000
1.5M Tris (pH 8 .8 ) 3.800 7.500 15.000
20 % SDS 0.075 0.150 0.300
10  % ammonium persulfate 0.150 0.300 0.600
TEMED 0.009 0.018 0.036
Table A.2: Solutions for preparing 5% stacking gel
V olum es (m l) per m old  vo lum e o f
Solution com pon en ts 4 m l 10 m l 20 m l
h 2o 2.720 6.850 13.700
30 % acrylamide mix 0.670 1.700 3.400
1.0 M Tris (pH 6 .8 ) 0.500 1.250 2.500
20 % SDS 0 .0 2 0 0.050 0 .1 0 0
10  % ammonium persulfate 0.040 0 .1 0 0 0 .2 0 0
TEMED 0.004 0 .0 1 0 0 .0 2 0
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Table A.3: Solutions for 10 x running buffer and transfer buffer
C om pon ents
10 x R unning Buffer ( 1 I  ) 
A m ount ( g )
Transfer B uffer ( 5 I  ) 
A m oun t ( g  )
Tris-base 30.3 15.0
Glycine 144.2 72.0
SDS 1 0 .0 -
Methanol - 1 I
Table A.4: Fixing solution for drying gels
C om ponents V olum e
50% methanol 125 ml
1 0 % glacial acetic acid 25 ml
h 2o 1 0 0  ml
Table A.5: Soaking solution for drying gels
C om ponents V olum e
7% methanol 17.5 ml
1 % glycerol 2.5 ml
1 0 % glacial acetic acid 17.5 ml
h 2o 228.5 ml
A p p en d ix  B  
K inetic  theory
B .l  A ssociation  kinetics
The formation of a surface-bound complex in the BIA flow cell between analyte 
A and surface-bound ligand B can be described by a simple scheme
ka
A  + B  ^  A B
kd
The rate of association d [A B \/d t  is directly proportional to concentrations of 
free analyte [A] and ligand [B] while that for dissociation d[A B ]/d t  is directly 
proportional to the concentration of the complex formed [AB]:
M  =  ka[A)[B] (B .l)
- ^ 1  =  kd[AB\ (B.2)
where k a and kd  are association and dissociation rate constants, respectively. 
During the association phase of the BIA experiment when analyte is passing 
over the surface-bound ligand, association and dissociation processes happen 
simultaneously and the rate of association d[AB]/d t  is
^ l  = ka[ A ] [ B ] - k d[AB] (B.3)
dt
The equation B.3 implies tha t the association of molecular complex depends 
on both k a and k d .
The rate equation B.3 can be rewritten to a more useful form. Considering 
tha t the concentration of unoccupied ligand [B] is the difference between the
total amount of ligand on the surface [£?]o and the amount of complex [AB]:
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[5] =  [B]o -  [AB]
Substituting in the rate equation B.3 for formation of AB:
= K [ A \ m o -  [AB]) -  kd[AB\
If the total amount of ligand [B]0 is expressed in term s of the maximum an­
alyte binding capacity of the surface, all concentration term s can be expressed 
as SPR response in RU, eliminating the need to convert from mass to molar 
concentration:
—  = kaC ( R max - R ) -  kdR  (B.4)
where d R /d t  is the rate of change of the SPR signal, C is the concentration of 
analyte, R max is the maximum analyte binding capacity in RU and R is the 
SPR signal in RU at time t.
Equation B.4 can be solved analytically if C is assumed to be constant, 
which is a valid approximation in real-time BIA experiments. Separating vari­
ables and integrating, equation B.4 gives:
h P RR  =  T (1 -  e- ^ c +kd)t) ( B  5)
r ^ a C  d- k d
This equation gives the response at any time during the association and can 
be used for non-linear regression analysis of single sensorgrams.
B .2 D issociation  kinetics
After the pulse of analyte has passed over the sensor chip surface, the surface- 
bound complex dissociates in a zero-order reaction. Assuming tha t re-association 
of released analyte is negligible, the equation B.3 is reduced to
«  -  -M ^ l
Using SPR response R expressed in Resonance Units (RU) rather than  molar 
concentration, we get
^  =  - k dR  
dt
Thus, the dissociation rate depends only on kd. Separating variables and 
integrating gives
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R t = flo • (B .6 )
or
In - fr  = kd(t - 10) (B.7)
Rt
where R t is the response at tim e t and R q is the response at an arbitrary
starting time to. Equation B.7 can be used for non-linear regression analysis
of the dissociation phase of a single sensorgram. Equations B.7 give




In-—  = l n ( - k dR 0) -  kd(t -  t 0) 
at
Plotting ln (R o /R t)  or ln (dR /d t) against t — tQ gives a straight line with slope 
kd or —kd and can be used for calculating kd .
B .3 Equilibrium  constants
Im portant characteristics of a molecular interaction are equilibrium constants 
K a and K d - They are linked with the rate constants ka and kd by equation
ka[A\[B] = kd[AB) (B .8 )
derived from B.2 for an equilibrium state when association and dissociation 
rates are equal. Equation B .8  can be rearranged to give
ka -  w  D ( 9)
or
kg _  [^-^] _  j r  / o
kd [A}[B} A ( }
where K d [M] and K a [M ~l ] are the dissociation and association equilibrium 
constants. An im portant advantage of BiaCore over other techniques is tha t 
it determines both ka and kd directly while other techniques provide only K d 
(K a )- Thus, BiaCore provides more detailed information about the kinetics 
of the interaction, separating the association and dissociation phases.
A p p en d ix  C 
B iaC ore M acro
A macro designed to obtain binding data for all possible combinations of hu­
man and mouse ObR-Fc and human, mouse and rat Ob.
! hOBR immobilized on Fc3, m ObR on Fc2,4; nothing on F c l,
! h(m ,r)O b injection on F c l,2,3,4; Detection 2-1, 3-1, 4-1 
! Software: BIACORE 3000 Control Software 
! Version: 3.1 
! Configuration: IFC 6
! Remarque : r2f2 =  Glycine pH 2.0 as regeneration buffer







QUICKINJECT R2f2 5 
QUICKINJECT R2f2 5 
!Immobilization of m ObR on Fc2 
FLOW 3 
FLOWPATH 2 
* QUICKINJECT R2A2 5
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-3 RPO IN T -b mObR-0.5ug/ml 
120 RPOINT Level-mObR 
Hmmobilization of hOBR on Fc3 
FLOW 3 
FLOWPATH 3
* QUICKINJECT R2A1 12
-3 RPOINT -b hOBR-0.5ug/mL 
260 RPO IN T Level-hOBR 
Hmmobilization of mOBR on Fc4 
FLOW 3 
FLOWPATH 4
* QUICKINJECT R2A3 10
-3 RPOINT -b m O B R-lug/m L 
260 RPOINT Level-mOBR 





* KINJECT %position 100 900 
-3 RPOINT -b %concentration 





r2 b l hLeptin=0.1nM
r2b2 hL eptin= lnM
r2b3 hLeptin=3nM
r2b4 hLeptin=5nM
A P P E N D IX  C. B IAC O R E M ACRO
r2b5 hLeptin=10nM























APROG algorithm %position %concentration
ENDLOOP
LOOP Ob-Injection-m STEP
APROG algorithm %position %concentration
ENDLOOP
LOOP Ob-Injection-r STEP
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